

NO. _____
A.M. _____ FILED
P.M. _____

LAWRENCE G. WASDEN
ATTORNEY GENERAL
STATE OF IDAHO

BRETT DELANGE, ISB #3628
JANE HOCHBERG, ISB #5465
Deputy Attorneys General
Consumer Protection Unit
Office of the Attorney General
Len B. Jordan Building, Lower Level
650 W. State Street, P. O. Box 83720
Boise, Idaho 83720-0010
Telephone: (208) 334-2424/Facsimile: (208) 334-2830

CHARLES BARNHILL (pro hac vice application pending)
Miner, Barnhill & Galland, PC
44 East Mifflin Street, Suite 803
Madison, WI 53703
Telephone: (608) 255-5200/Facsimile: (608) 255-5380

ROBERT S. LIBMAN (pro hac vice application pending)
Miner, Barnhill & Galland, PC
14 West Erie Street
Chicago, IL 60610
Telephone: (312) 751-1170/Facsimile: (312) 751-0438

P. JEFFREY ARCHIBALD (pro hac vice application pending)
1914 Monroe Street
Madison, WI 53711
Telephone: (608) 661-8855/Facsimile: (608) 661-8855

MICHAEL WINGET-HERNANDEZ (pro hac vice application pending)
Winget-Hernandez, LLC
3112 Windsor Road #228
Austin, TX 78703
Telephone: (512) 474-4095/Facsimile: (512) 697-0080

ATTORNEYS FOR THE STATE OF IDAHO

**IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO, IN AND FOR THE COUNTY OF ADA**

STATE OF IDAHO,) Case No. CV OC 0701847
Plaintiff,)
vs.)
ALPHARMA USPD INC.; ASTRAZENECA)
PHARMACEUTICALS LP; ASTRAZENECA LP;)
COMPLAINT AND DEMAND
FOR JURY TRIAL


BARR LABORATORIES, INC.; CENTOCOR,)
INC.; IVAX CORP.; IVAX PHARMACEUTICALS,)
INC.; JANSSEN PHARMACEUTICAL)
PRODUCTS, LP; JOHNSON & JOHNSON;)
McNEIL-PPC, INC.; MERCK & CO., INC.;)
ORTHO BIOTECH PRODUCTS, LP; ORTHO-)
McNEIL PHARMACEUTICAL, INC.; PAR)
PHARMACEUTICAL COS., INC.; PUREPAC)
PHARMACEUTICAL CO.; SANDOZ, INC., f/k/a)
GENEVA PHARMACEUTICALS, INC.; TEVA)
PHARMACEUTICALS USA, INC.; WATSON)
PHARMA, INC., f/k/a SCHEIN)
PHARMACEUTICALS, INC.; and WATSON)
PHARMACEUTICALS, INC.,)
)
Defendants.)
)
)
)
)
)

The plaintiff, State of Idaho, by Lawrence G. Wasden the Attorney General for the State of Idaho, brings this action on behalf of the State and taxpayers complaining of the above-captioned pharmaceutical manufacturer defendants as follows for their illegal conduct which has resulted in windfall profits at the expense of the State and its taxpayers:

NATURE OF THE ACTION

1. This action is brought on behalf of the State of Idaho, by Lawrence G. Wasden, Idaho Attorney General, pursuant to the Idaho Consumer Protection Act (ICPA), Idaho Code § 48-601 *et seq.* and rules promulgated thereunder.

2. Idaho brings this lawsuit to recover damages and obtain injunctive relief from defendants, who are manufacturers of prescription drugs. As described in this complaint, defendants have taken advantage of the enormously complicated and non-transparent market for prescription drugs to engage in an unlawful scheme to cause the State of Idaho to pay inflated prices for prescription drugs in connection with its Medicaid Program. The scheme involves the

publication by defendants of phony "average wholesale prices" ("AWPs"), which then become the basis for calculating the cost at which "providers" – the physicians and pharmacies who provide these prescription drugs to patients – are reimbursed by the State of Idaho. Defendants reinforce this basic tactic with other deceptive practices described in this complaint, including the use of secret discounts and rebates to providers and the use of various devices to keep secret the prices of their drugs currently available in the marketplace to other purchasers. By engaging in this unlawful scheme, defendants have succeeded in having Idaho's taxpayers finance windfall profits to these providers. Defendants attempt to profit from their scheme by using the lure of these windfall profits competitively to encourage providers to buy more of their drugs instead of competing in the marketplace solely on the basis of legitimate factors such as price and the medicinal value of their drugs.

AUTHORITY

3. The Attorney General of Idaho is authorized and empowered to enforce the ICPA by Idaho Code § 48-606.

PARTIES AND JURISDICTION

4. The Attorney General for the State of Idaho brings this action on behalf of the State of Idaho and its citizens. As described in this complaint, defendants' unlawful scheme has resulted in higher prices for prescription drugs being paid by Idaho under the Medicaid program. The Attorney General has reason to believe that defendants have used and continue to use the methods, acts, and practices set forth in this complaint and which, among other violations, are illegal under the ICPA, and that these proceedings are in the public interest.

5. Defendants are pharmaceutical companies whose fraudulent schemes, including the publication of excessive and inflated prices for prescription drugs as described in this complaint, have caused to be presented to officers and/or employees of the State of Idaho false or

fraudulent claims for payment or approval of certain drugs to get these false or fraudulent claims paid or approved by the State of Idaho Medicaid program, and have resulted in Idaho's taxpayers paying for drugs at inflated prices, as detailed below.

6. At all times material to this civil action, each defendant has transacted business in the State of Idaho by, including but not limited to, selling directly or through wholesalers its drugs, including those identified in this complaint, to purchasers within the State of Idaho.

7. The following two defendants are hereinafter referred to as the Alpharma group:

(i) defendant Alpharma USPD Inc. ("Alpharma USPD") is a Maryland corporation with its principal place of business located in Baltimore, Maryland. Alpharma USPD Inc. manufactures and markets pharmaceutical products under its own name under Labeler Code 00472; and

(ii) defendant Purepac Pharmaceutical Co. ("Purepac") is a Delaware corporation in the business of manufacturing and selling pharmaceuticals. Purepac's principal place of business is 14 Commerce Dr., Suite 301, Cranford, NJ 07016.

Until December 19, 2005, defendants Alpharma USPD Inc. and Purepac were wholly-owned subsidiaries of Alpharma Inc. On that date, Alpharma USPD and Purepac were purchased by Actavis Group HF and became wholly-owned subsidiaries of Actavis Inc., a wholly-owned subsidiary of Actavis Group HF.

8. Defendants AstraZeneca Pharmaceuticals LP and AstraZeneca LP ("AstraZeneca") are related Delaware corporations with their principal place of business at 1800 Concord Pike, Wilmington, DE 19850.

9. Defendant Barr Laboratories, Inc. ("BLI") is a Delaware corporation engaged in the business of manufacturing and selling pharmaceuticals. BLI's principal place of business is located at 400 Chestnut Ridge Road, Woodcliff Lake, NJ 07677. BLI is a subsidiary of Barr Pharmaceuticals, Inc. ("BPI").

10. The following six defendants are hereinafter referred to as the Johnson & Johnson group:

- (i) defendant Johnson & Johnson ("J&J") is a New Jersey corporation engaged in the business of manufacturing and selling pharmaceuticals. J&J's principal place of business is located at One Johnson & Johnson Plaza, New Brunswick, NJ 08933;
- (ii) defendant Janssen Pharmaceutical Products, LP ("Janssen"), a wholly-owned subsidiary of J&J, is a New Jersey limited partnership engaged in the business of manufacturing and selling pharmaceuticals. Janssen's principal place of business is located at 1125 Trenton-Harbourton Rd., Titusville, NJ 08560;
- (iii) defendant Ortho Biotech Products, LP ("Ortho Biotech"), a wholly-owned subsidiary of J&J, is a New Jersey limited partnership engaged in the business of manufacturing and selling pharmaceuticals. Ortho Biotech's principal place of business is located at 700 U.S. Hwy. 202, Raritan, NJ 08869;
- (iv) defendant Ortho-McNeil Pharmaceutical, Inc. ("Ortho-McNeil"), a wholly-owned subsidiary of J&J, is a Delaware corporation engaged in the business of manufacturing and selling pharmaceuticals. Ortho-McNeil's principal place of business is located at 1000 U.S. Rte. 202 S., Raritan, NJ 08869;
- (v) defendant McNeil-PPC, Inc. ("McNeil"), a wholly-owned subsidiary of J&J, is a New Jersey corporation engaged in the business of manufacturing and selling pharmaceuticals. McNeil's principal place of business is located at 7050 Camp Hill Rd., Ft. Washington, PA 19034. McNeil Consumer & Specialty Pharmaceuticals ("McNeil Cons") is a division of McNeil; and
- (vi) defendant Centocor, Inc. is a wholly owned subsidiary of Defendant Johnson & Johnson with its principal place of business at 800/850 Ridgeview Dr., Horsham, PA 19044. The principal drug it markets is Remicade for autoimmune conditions.

11. Defendant Merck & Co., Inc. ("Merck") is a New Jersey corporation engaged in the business of manufacturing and selling pharmaceuticals. Merck's principal place of business is located at One Merck Dr., Whitehouse Station, NJ 08889-0100.

12. Defendant Par Pharmaceutical Cos., Inc. ("Par") is a Delaware corporation with its principal place of business located at One Ram Ridge Rd., Spring Valley, NY 10977. Par is

also being sued for the conduct of its subsidiaries and/or divisions, including but not limited to Par Pharmaceutical, Inc.

13. Defendant Sandoz, Inc. ("Sandoz"), formerly known as Geneva Pharmaceuticals, Inc., is a Delaware corporation engaged in the business of manufacturing and selling pharmaceuticals. Sandoz's principal place of business is located at 506 Carnegie Ctr., Princeton, NJ 08540.

14. The following three defendants are hereinafter referred to as the Teva group:

(i) defendant Teva Pharmaceuticals USA, Inc. ("Teva US") is a Delaware corporation engaged in the business of manufacturing and selling pharmaceuticals. Teva USA's principal place of business is located at 650 Cathill Rd., Sellersville, PA 18960. Teva US is a subsidiary of an Israeli corporation, Teva Pharmaceutical Industries, Ltd. ("Teva Ltd."). Teva USA is also being sued for the conduct of Novopharm USA, Inc., a subsidiary of Novopharm Ltd. Novopharm Ltd. was acquired by Teva Pharmaceutical Industries Ltd. and Novopharm USA, Inc. was subsequently merged into Teva US;

(ii) defendant Ivax Corp. ("Ivax"), which became a wholly-owned subsidiary of Teva Ltd. on January 26, 2006, is a Florida (formerly Delaware) corporation engaged in the business of manufacturing and selling pharmaceuticals. Ivax's principal place of business is located at 4400 Biscayne Blvd., Miami, FL 33137; and

(iii) defendant Ivax Pharmaceuticals Inc. ("Ivax Pharm"), a wholly-owned subsidiary of Ivax, is a Florida corporation engaged in the business of manufacturing and selling pharmaceuticals. Ivax Pharm's principal place of business is located at 4400 Biscayne Blvd., Miami, FL 33137.

15. The following two defendants are hereinafter referred to as the Watson group:

(i) defendant Watson Pharma, Inc., f/k/a Schein Pharmaceuticals, Inc. ("Watson Pharma"), a wholly-owned subsidiary of Watson Pharmaceuticals, Inc. since 2000, is a Delaware corporation engaged in the business of manufacturing and selling pharmaceuticals. Watson Pharma's principal place of business is located at 311 Bonnie Cir., Corona, CA 92880; and

(ii) defendant Watson Pharmaceuticals, Inc. ("Watson") is a Nevada corporation engaged in the business of manufacturing and selling pharmaceuticals. Watson's principal place of business is located at 311 Bonnie Cir., Corona, CA 92880.

16. This Court has jurisdiction over plaintiff's claims as they involve claims arising exclusively under Idaho statutes and authority of the Attorney General to act on behalf of the State of Idaho. The Attorney General has previously given notice in writing to each defendant that these proceedings were contemplated and each defendant had the opportunity to appear before the Attorney General and enter into an assurance of voluntary compliance or consent judgment. None of these defendants has agreed to do so however.

17. Venue is proper in the district court of Ada County, Idaho pursuant to Idaho Code § 48-606(2).

FACTUAL BACKGROUND

A. The market for prescription drugs.

18. The market for prescription drugs is enormously complex and non-transparent. It is composed of over 65,000 separate national drug codes ("NDCs") (there is a separate NDC number for each quantity of each drug manufactured by each defendant). The essential structure of the market is as follows. The drugs are manufactured by pharmaceutical companies such as defendants. Defendants sell the drugs (usually with intermediaries and agents involved in the process) to physicians, hospitals, and pharmacies. These physicians, hospitals, and pharmacies are commonly referred to as "providers." The providers then, in essence, resell the drugs to their patients when the drugs are prescribed for, administered, or dispensed to those patients. Most patients have private or public health insurance coverage. Where a patient has such insurance, the payment that is made for the patient's prescribed drug ultimately will be made, in whole or in large part, by a private insurance company, a self-insured entity, or a government entity (in the case of the Medicare and Medicaid programs). These private insurance companies, self-insured entities, and government entities are commonly known as "payers." More often than not, the payer makes the reimbursement payment directly to the provider, not to the patient.

19. This market structure means that the market for prescription drugs differs in two crucial respects from most markets.

20. First, in most markets, the ultimate consumers of the product determine the demand for a product. This is not the case for prescription drugs. In the prescription drug market, the decision to use a prescription drug is overwhelmingly made not by the consumer of the drug -- the patient -- but by physicians, hospitals in which the patient is treated, home health-care agencies, long-term care facilities, or (with respect to the decision to use generic drugs versus brand-name drugs) pharmacies. Because prescription drugs are dispensed only on a physician's order, the physician has the principal say as to what drug will be chosen for the patient. However, hospitals also have considerable influence over this choice. If a hospital decides to put one drug as opposed to a competing drug on its "formulary" (the list of drugs that the hospital stocks), physicians (particularly residents and attending physicians who are employed by the hospital) likely will choose the drug on the formulary rather than a competing drug. Likewise, although pharmacies do not prescribe drugs, pharmacies can exert important influence over the choice of which drug the patient will purchase if there is a choice between generic versions of the drug the physician has prescribed.

21. A second difference between the prescription drug market and ordinary markets is that in ordinary markets, the ultimate consumer of the product pays for it directly. In the prescription drug market, however, most payments for drugs are made by "payers" through private or public insurance programs.

22. This structure of the prescription drug market produces the following fundamental fact that underlies defendants' unlawful scheme. If a defendant drug manufacturer can cause a "payer" to reimburse the provider for defendant's drug at a higher price than the price the provider paid to buy the drug from the defendant, there will be a "spread" between the two

prices, and that "spread" is retained by the provider as additional profit. The larger the "spread" that can be created for a particular drug, the greater the incentive the provider has to choose, or influence the choice of, that drug rather than a drug of a competing manufacturer.

B. The purpose of the Medicaid program and how it responds to the complexity of the drug market.

23. The purpose of the Idaho Medicaid program is to provide medical assistance to the state's neediest citizens.

24. Idaho, through its Medicaid program, is an enormous purchaser of drugs, purchasing over \$166 million in fiscal year 2005. Although defendants' participation in the Idaho Medicaid program is purely voluntary, all defendants have chosen to participate and sell drugs to Idaho Medicaid participants because of the size of the Idaho Medicaid program. Thus, Idaho may at any given time have to reimburse a provider for any of the drugs of any of the defendants -- a universe of many thousands of drugs.

25. Idaho's task is further complicated in that federal law places limits on what Idaho may pay providers for any particular drug. Specifically, Idaho must not reimburse providers more than "the lower of the -- (1) Estimated acquisition costs plus reasonable dispensing fees established by the agency; or (2) Providers' usual and customary charges to the general public." 42 C.F.R. § 447.331. "Estimated acquisition cost" is defined as "the agency's best estimate of the price generally and currently paid by providers for a drug marketed or sold by a particular manufacturer or labeler in the package size of drug most frequently purchased by providers." 42 C.F.R. § 447.301. Thus, pursuant to federal law, the highest price Idaho can pay for a drug is the provider's cost to acquire that drug.

26. Because defendants have hidden both the prices at which they sell their drugs to wholesalers, and their knowledge about the prices at which wholesalers sell their drugs to

providers (as described in more detail herein), Idaho has no access to the pricing information it needs to estimate accurately the providers' acquisition cost of defendants' drugs. Because neither Idaho nor any other state has sufficient resources to compile complete and accurate lists of defendants' drug prices, entire businesses have grown up to provide pricing information to the states and others. Three of these are of particular importance in this case. They are First DataBank, the Red Book, and Medispan. These compendia purport to supply accurate price information on defendants' drugs through surveys of wholesalers and information obtained from defendants themselves.

27. Idaho, like most other states, has chosen First DataBank as its primary cost source because it supplies up-to-date pricing information in electronic form which can be integrated into Idaho's payment structure. First DataBank purports to supply the states with accurate information about the AWP of all drugs, information it receives from the drug manufacturers themselves. As First DataBank explained AWP to its customers in September, 1991:

Average Wholesale Price (AWP) is perhaps the most misunderstood concept in the pharmaceutical industry. The purpose of this article is to describe what is meant by AWP and to explain some of the underlying concepts involved in the acquisition, determination and maintenance of First DataBank's AWP.

AWP represents an average price which a wholesaler would charge a pharmacy for a particular product. The operative word is average. AWP never means that every purchase of that product will be exactly at that price. There are many factors involved in pricing at the wholesale level which can modify the prices charged even among a group of customers from the same wholesaler. AWP was developed because there had to be some price which all parties could agree upon if machine processing was to be possible.

At First DataBank, all pricing information is received in hard copy from the manufacturers. Catalogs, price updates, and other information reach us by fax, Federal Express, or U.S. mail. In the past two years, fax transmission has streamlined the acquisition of data to a large extent.

28. For virtually the entire time period relevant hereto, First DataBank has represented that its published AWPs reflect actual average wholesale prices consistent with the definition of AWP.

29. Because Idaho, like most states, has no in-house source of comprehensive information about providers' acquisition cost for defendants' drugs, Idaho has relied on the prices defendants reported to First DataBank. Consistent with First DataBank's suggestion that some providers were paying less than AWP, Idaho agreed to pay providers an amount consisting of AWP minus a certain percentage (currently AWP minus 12%). Idaho has also continued to pay a separate dispensing fee to providers to reimburse them for the service provided in dispensing drugs to customers.

30. As a practical matter, Idaho, like with most other states, is dependent on the First DataBank pricing reports for the maintenance of its Medicaid claims processing system. When a pharmacy fills a prescription and dispenses a drug to a Medicaid patient, information on the reimbursement price for that prescription is communicated electronically between Idaho's electronic claim processor, EDS, to the pharmacy provider at the point of sale. The information EDS uses to determine that reimbursement originates from First DataBank, and is downloaded into EDS' database. On a weekly basis, First DataBank electronically sends its updated AWPs for the thousands of NDC-numbered drugs listed in its database to EDS. These prices become the basis for Idaho's reimbursements to providers. There is no other electronic source for this information, besides Medispan which publishes the same prices. Accordingly, Idaho is functionally dependent on the accuracy of the data defendants supply to First DataBank in meeting its obligation to pay providers no more than their actual acquisition cost of defendants' drugs.

C. Defendants' corruption of the government Medicaid assistance programs.

31. Defendants have defeated the intent of the Medicaid program to pay providers no more than their acquisition cost by reporting false and inflated AWPs to First DataBank and/or by reporting prices that they knew, because of the manner of First DataBank's operations, would misrepresent defendants' true wholesale prices. One purpose of this scheme was and is to create the spread between a drug's true wholesale price and the false and inflated AWP published by First DataBank and thereby increase the incentive for providers to choose the drug for their patients, or, at a minimum, to counteract the same tactic used by a competitor.

32. The higher the spread between the AWP and the true wholesale price, the more profit a provider can make. Defendants often market their products by pointing out (explicitly and implicitly) that their drug's spread is larger than the spread of a competing drug.

33. All of the defendants have inflated their drugs' reported AWPs to levels far beyond any real average wholesale price for their drugs. One high-ranking industry executive has described it as the industry practice to do so.

34. In 2004, high-ranking executives of certain pharmaceutical manufacturers, including defendant Barr, testified before Congress that their AWPs do not reflect the actual selling prices of their drugs. At the same meeting when asked why his generic drug manufacturer doesn't lower its AWP on generic drugs, a chief financial officer of one of the manufacturers testified: "The simple answer is that given the system that now exists our customers won't buy from us if we lower our AWP."

35. Attached as Exh. A to this complaint is a list of drugs manufactured by some of the defendants and/or their subsidiaries that the U.S. Department of Justice, after an extensive investigation, found to have inflated AWPs. The U.S. Department of Health and Human Services concluded, with respect to all drugs utilized in the Medicare program that "[a] general

conclusion reached in reviewing the GAO [General Accounting Office] and OIG [Office of Inspector General] data is that there is a level of overstatement in the listed AWP for *all* drugs...." Payment Reform for Part B Drugs, 68 Fed. Reg. 50,431 (August 20, 2003) (emphasis added).

36. Plaintiff has obtained the false prices defendants caused to be published by FirstData Bank. Plaintiff has also obtained data showing the true AWPs of defendants' drugs from two of the largest national drug wholesalers: Cardinal and AmerisourceBergen. Attached as Exh. B to this complaint is a chart containing additional examples of defendants' drugs that have false and inflated AWPs. For each defendant, Exh. B identifies (a) the NDC; (b) the name of the drug; (c) the false AWP published by First DataBank as of the end of each year from 2001 to 2003; (d) the average AWP published by First DataBank for each year from 2001 to 2003; (e) a market price for the NDC for each year from 2001 to 2003; and (f) the spread between the market price and the AWP. The AWPs and market prices are unit prices. The source of the market prices is AmerisourceBergen, one of the three largest wholesalers. The market price is the average price at which AmerisourceBergen sold the NDC numbered drug to the classes of trade that are reimbursed by the Idaho Medicaid program, *i.e.*, retail pharmacies, chain pharmacies, and long-term care facilities. The spread, expressed as a percentage, is calculated as average AWP minus market price. The NDC numbered drugs on Exh. B are those for which the Idaho Medicaid program paid more than \$10,000.00 between 2001 and 2003. Plaintiff has similar data for years prior to 2001 and after 2003, which data will be produced to defendants upon request during discovery. The NDC numbered drugs identified in Exh. B constitute most, but not necessarily all, of the NDC numbered drugs upon which the state is seeking damages. The following provides an example of Exh. B:

Defendant	Drug NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
Alpharma	ACYCLOVIR 228260611	2.170	2.170	0.181	1097%	2.170	2.170	0.455	376%	2.170	2.170	0.159	1262%
Astra-zeneeca	ATACAND 186001631	1.342	1.319	1.097	20%	1.447	1.408	1.138	24%	1.543	1.502	1.190	26%
Barr	AMPHETAMINE 555097202					1.372	1.342	0.886	51%	1.372	1.372	0.882	56%
Ivax	ACYCLOVIR 172426760	2.169	2.169	0.108	1905%	2.169	2.169	0.092	2259%	2.169	2.169	0.096	2150%
Janssen	DURAGESIC 50458003605	42.646	41.751	34.641	21%	50.282	46.167	37.110	24%	54.002	52.066	41.406	26%
Mcneill	HALDOL DECAN 45025414	66.182	64.794	53.565	21%	76.590	71.536	57.079	25%	81.100	78.758	62.339	26%
Merck	CANCIDAS 6382210	360.000	360.000	285.702	26%	376.910	360.046	283.553	27%	388.210	380.037	295.197	29%
Ortho	FLOXIN 62154002	4.338	4.247	3.507	21%	4.973	4.685	3.735	25%	5.316	5.137	4.062	26%
Par	AMILORIDE 49884011701	0.476	0.476	0.311	53%	0.476	0.476	0.302	58%	0.476	0.476	0.295	62%
Sandoz	ALPRAZOLAM 781107705	0.761	0.701	0.015	4480%	0.761	0.761	0.020	3744%	0.844	0.840	0.047	1704%
Teva	ALBUTEROL 93066116	0.065	0.065	0.042	57%	0.065	0.065	0.044	48%	0.065	0.065	0.044	47%
Watson	BACLOFEN 591573001	0.363	0.344	0.036	845%	0.610	0.423	0.042	912%	0.610	0.610	0.198	208%

37. As they have done with their AWPs, defendants have illegally and deceptively misrepresented and inflated the wholesale acquisition cost ("WAC") of their drugs. WAC is the price at which defendants sell their drugs to wholesalers. Defendants have made it appear that any reduction in the purchase price below the listed WAC would result in a loss to the wholesaler and was, hence, unachievable, when in fact defendants secretly discounted the WAC to purchasers other than the Medicaid program through an elaborate charge back system (as described in more detail below).

**DEFENDANTS' EXACERBATION OF THE COMPLEXITIES OF THE
MARKET AND AFFIRMATIVE CONCEALMENT OF THEIR WRONGDOING**

38. Defendants have been able to succeed in their drug pricing scheme for more than a decade by exacerbating the complexities of the huge and complex drug market, and by purposely concealing their pricing scheme from Idaho and other payers, as set forth below.

39. The published wholesale price of any of the thousands of NDC numbered drugs might, and often does, change at any time. As a consequence, just to track the current published prices of drugs utilized by a state's citizens requires resources and expertise that most states do not have.

40. Defendants have further exacerbated the inherent complexities of the drug market by utilizing marketing schemes that conceal the true price of their drugs in the following different ways.

41. First, defendants sell their drugs in a unique manner that hides the true prices. This scheme works as follows. Upon agreeing on a quantity and price of a drug with a provider or group of providers, a defendant purports to sell the agreed-upon drugs at the WAC price to a wholesaler with whom the defendant has a contractual arrangement. The wholesaler then ships the product to the provider, charging the provider the price originally agreed upon by the drug manufacturer and the provider, which price is lower than the WAC. When the wholesaler receives payment from the provider, it sends a bill to the defendant, called a "charge back," for the difference between the WAC and the lower price actually paid by the provider. These charge backs (or "shelf adjustments" or economic inducements with varying names) are kept secret from the payers, including the State of Idaho, so that it appears that the wholesaler actually purchased the drug at the higher WAC price. The effect of this practice is to create the impression of a higher than actual wholesale price paid by the wholesaler and passed on to the provider.

Defendants hide other actual price reductions by directly paying providers market share rebates and other off-invoice rebates and discounts that are calculated long after the actual purchase date of the drugs.

42. Second, defendants further inhibit the ability of Idaho and other payers and ultimate purchasers to learn the true cost of their drugs by wrapping the sales agreements they negotiate with providers in absolute secrecy, terming them trade secrets and proprietary, to preclude providers from telling others the actual price they paid.

43. Third, defendants further obscure the true prices for their drugs through their policy of treating so-called classes of trade differently. Thus, for the same drug, pharmacies are given one price, hospitals another, and doctors yet another.

44. Fourth, some defendants have hidden their real drug prices by providing free drugs and phony grants to providers as a further means of discounting the overall price of their drugs. For example, defendant AstraZeneca paid \$355 million to settle federal fraud charges that it induced doctors to falsely bill Medicare and Medicaid through these practices.

45. Defendants have further concealed their conduct by making sure that all of the entities that purchase drugs directly from the defendants (and thus know the true price of their drugs) have had an incentive to keep defendants' scheme secret. Defendants' scheme permits all providers – pharmacies, physicians, and hospitals/clinics – to make some profit off defendants' inflated spread, because all of them are reimbursed in some manner on the basis of the AWP for at least some of the drugs they sell or administer. For providers, therefore, the greater the difference between the actual price and the published AWP, the more money they make. Thus, providers willingly sign drug sales contracts requiring them to keep secret the prices they pay for drugs.

46. Defendants themselves have continuously concealed the true price of their drugs and have continued to report and cause to be published false and inflated AWPs and WACs as if they were real, representative prices. Indeed, in the 2000 edition of pharmaceutical manufacturer Novartis' Pharmacy Benefit Report, an industry trade publication, the glossary defines AWP as follows:

Average wholesale price (AWP) -- A published suggested wholesale price for a drug, based on the average cost of the drug to a pharmacy from representative sample of drug wholesalers. There are many AWPs available within the industry, AWP is often used by pharmacies to price prescriptions. Health plans also use AWP -- usually discounted -- as the basis for reimbursement of covered medications.

Novartis Pharmacy Benefit Report: Facts and Figures, 2000 edition, East Hanover, NJ, Novartis Pharmaceuticals Corporation, p. 43.

47. Defendants' unlawful scheme has completely corrupted the market for prescription drugs. Instead of competing on price and medicinal value alone, defendants have deliberately sought to create a powerful financial incentive for providers to prescribe drugs based primarily on the spread between the true price of a drug and its published AWP or WAC. Creating incentives for providers to prescribe drugs based on such a spread is inconsistent with Idaho law and public policy. Large price spreads on higher priced drugs encourage providers to prescribe more expensive drugs instead of their lower priced substitutes, thereby increasing the cost of healthcare. Competition on the basis of such spreads also has the potential to influence providers (consciously or unconsciously) to prescribe less efficacious drugs over ones with greater medicinal value. Because of defendants' concealment of their scheme, Idaho has unknowingly underwritten this perversion of competition in the drug market. In sum, defendants have been, and continue to be, engaged in an insidious, deceptive scheme that is causing Idaho to

pay millions of dollars a year more than it should for its prescription drugs, and may well be inducing some providers to prescribe less efficacious drugs.

THE GOVERNMENTAL INVESTIGATIONS OF DEFENDANTS' CONDUCT

48. In 2000, Congress began its investigation of the pricing practices of some of the defendants in connection with the Medicare program based on documents Congress had subpoenaed from these defendants in connection with a confidential *qui tam* filing. On September 28, 2000, as part of this investigation, U.S. representative Pete Stark wrote to the president of the Pharmaceutical Research and Manufacturers of America (the main pharmaceutical trade association of which most of the defendants are members) as follows:

Drug company deception costs federal and state governments, private insurers and others billions of dollars per year in excessive drug costs. This corruptive scheme is perverting the financial integrity of the Medicare program and harming beneficiaries who are required to pay 20% of Medicare's current limited drug benefit. Furthermore, these deceptive, unlawful practices have a devastating financial impact upon the states' Medicaid Program....

The evidence I have obtained indicates that at least some of your members have knowingly and deliberately falsely inflated their representations of the average wholesale price ("AWP"), wholesaler acquisition cost ("WAC") and direct price ("DP") which are utilized by the Medicare and Medicaid programs in establishing drug reimbursements to providers. The evidence clearly establishes and exposes the drug manufacturers themselves that were the direct and sometimes indirect sources of the fraudulent misrepresentation of prices. Moreover, this unscrupulous "cartel" of companies has gone to extreme lengths to "mask" their drugs' true prices and their fraudulent conduct from federal and state authorities. I have learned that the difference between the falsely inflated representations of AWP and WAC versus the true prices providers are paying is regularly referred to in your industry as "the spread"...

The evidence is overwhelming that this "spread" did not occur accidentally but is the product of conscious and fully informed business decisions by certain PhRMA members....

146 Cong. Rec. E1622 (daily ed. September 28, 2000) (September 28, 2000 letter from House Committee on Ways and Means, Subcommittee on Health, to Alan F. Holmer, President, Pharmaceutical Research and Manufacturers of America, Washington, D.C.).

49. On December 21, 2000, Congress passed the Medicare, Medicaid and SCHIP Benefits Improvement and Protection Act of 2000 ("BIPA"), Pub. L. No. 106-554, § 429(c) (2000), which required a comprehensive study of drug pricing.

50. In 2003, the House Committee on Energy and Commerce expanded Congress' Medicare investigation into pricing practices in the state Medicaid program. On June 26, 2003, Chairman Billy Tauzin (R-La.) and Oversight and Investigations Subcommittee Chairman James Greenwood (R-Pa.) wrote as follows to 26 drug companies, including many of the defendants here:

The Committee on Energy and Commerce is conducting an investigation into pharmaceutical reimbursements and rebates under Medicaid. This inquiry builds upon the earlier work by this Committee on the relationship between the drug pricing practices of certain pharmaceutical companies and reimbursements rates under the Medicare program. In that investigation, the Committee uncovered significant discrepancies between what some pharmaceutical companies charged providers for certain drugs and what Medicare then reimbursed those providers for dispensing those drugs. This price difference resulted in profit incentives for providers to use the drugs of specific companies as well as higher costs to the Medicare system and the patients it serves. For example, we learned that one manufacturer sold a chemotherapy drug to a health care provider for \$7.50, when the reported price for Medicare was \$740. The taxpayer therefore reimbursed the doctor almost \$600 for dispensing the drug and the cancer patient had a \$148 co-payment. Such practices are unacceptable in the view of the Committee, which is why we are in the process of moving legislation to address these abuses.

The Committee has similar concerns regarding drug prices in Medicaid, which has a substantially larger pharmaceutical benefit than Medicare.

House Committee on Energy and Commerce Press Release, Tauzin, Greenwood Expand Medicaid Fraud Investigation (June 26, 2003), available at <http://energycommerce.house.gov/108/News/06262003_1002.htm>.

51. The Congressional investigation is continuing. On December 7, 2004, the House Subcommittee of Oversight and Investigation of the Commerce and Energy Committee

conducted a hearing on "Medicaid Prescription Drug Reimbursement: Why the Government Pays Too Much." In his opening remarks, Chairman Joe Barton (R-TX) stated:

Data obtained by the Committee from five of the largest retail pharmacy chains reveals that during the period July 1, 2002 to June 20, 2003, the average acquisition costs for seven widely prescribed generic drugs was \$0.22, while the average Medicaid reimbursement, just for those drugs alone, was \$0.56-more than double the cost...

"Medicaid Prescription Drug Reimbursement: Why the Government Pays Too Much," Hearing Before the House Subcomm. on Oversight and Investigations, No. 108-126, at 5 (2004), available at <http://frwebgate.access.gpo.gov/cgi-bin/useftp.cgi?IPaddress=162.140.64.52&filename=97275.pdf&directory=/disk2/wais/data/108_house_hearings>.

52. The importance to Idaho and the other states of the information being sought by this investigation was explained by Henry Waxman during the December, 2004 House Committee on Energy and Commerce hearings on Medicaid pricing practices. Congressman Waxman explained that even though the federal government had access to the manufacturers' actual average manufacturers prices ("AMPs"), the states did not:

the drug industry was powerful, and they succeeded in securing a provision in the basic legislation that kept the best price and the AMP information a secret.

Can you imagine that? The Federal Government knew this information, but we kept it a secret from the States. This has proved to be a costly error. Without this crucial piece of information, States who are, after all, responsible for establishing the reimbursement rates for prescription drugs could not set their reimbursement rates appropriately.

As a result, [the states] continued to rely on the average wholesale price minus some arbitrary amount simply because they did not have the information they needed to set a more appropriate reimbursement rate.

Id., at 74.

53. As a result of all these investigations, many states began to investigate defendants' drug pricing practices on their own, leading to lawsuits by more than 20 separate states,

including Idaho. Notwithstanding these investigations and lawsuits, defendants continue to publish, or participate in the publication of, inflated wholesale prices, and continue to hide the true prices of their drugs.

**THE INJURY TO THE MEDICAID PROGRAM
CAUSED BY DEFENDANTS' FALSE WHOLESALE PRICES**

54. Medicaid is a joint federal and state health-care entitlement program authorized by federal law, with mandatory and optional provisions for eligibility and benefits covered, including pharmacy. Idaho's Medicaid program is administered by the Idaho Department of Health and Welfare.

55. Idaho Medicaid drug expenditures have increased dramatically. In fiscal year 1999 (covering the period July 1, 1998 to June 30, 1999), Idaho Medicaid drug expenditures totaled over \$64 million. In fiscal year 2005 (covering the period July 1, 2004 to June 30, 2005), Idaho Medicaid drug expenditures totaled over \$166 million, which constitutes approximately 15.5% of the overall Medicaid budget. As of December, 2004, the number of Idaho citizens enrolled in Medicaid is approximately 171,000, which represents approximately 12.5% of the state population.

56. During the relevant time period, with some exceptions, reimbursement to pharmacies, physicians, and hospitals for drugs covered by the Idaho Medicaid program has been made at defendants' published AWP minus a percentage (currently 12%), plus a dispensing fee.

57. For a minority of the drugs purchased by Idaho, the state sets its reimbursement rate at the lesser of the published AWP minus a percentage (currently 12%), the federal upper limit ("FUL"), or at a rate established by the state maximum allowable cost ("MAC") program. For multi-source drugs that have at least three suppliers, the Center for Medicaid Services ("CMS") generally establishes FULs, defined as 150% of the least costly therapeutic equivalent

(using all national compendia) that can be purchased by pharmacies in quantities of 100 tablets or capsule or, in the case of liquids, the commonly listed size. 42 C.F.R. § 447.332. As a practical matter, CMS has relied on the defendants' inflated prices to set most of its FULs. The states also may set reimbursement rates for these drugs at rates lower than the FUL pursuant to the state MAC program and Idaho has done so in a number of instances. Had defendants reported truthful prices, the FULs and state MACs would have been lower.

58. At all relevant times, each defendant was aware of the reimbursement formula used in the Idaho Medicaid program and the dependence of the Medicaid program on defendants' reported AWPs.

59. By reporting false and inflated wholesale prices, and by keeping their true wholesale prices secret, defendants have knowingly created a situation that enabled providers of drugs to Medicaid recipients to receive reimbursements from Idaho that are higher than they would be if the true wholesale prices were reported, and interfered with Idaho's ability to set reasonable reimbursement rates for these drugs.

60. As a consequence, the Idaho Medicaid program has paid more for prescription drugs than it would have if defendants had reported their true wholesale prices.

DEFENDANTS' CONDUCT WAS INTENTIONALLY IN DISREGARD OF ESTABLISHED LAW

61. Defendants had a duty to deal truthfully and honestly with the State of Idaho and they so knew.

62. Moreover, it has uniformly been the law for over 60 years that it is unlawful for a seller to cause to be circulated a price at which no, or few, sales are actually expected, whether it is called a list price, suggested price, or benchmark price. *E.g., F.T.C. v. Colgate-Palmolive Co.*,

380 U.S. 374 (1965). Defendants either knew of this law or acted in reckless and willful disregard of it.

63. Defendants purposefully took advantage of a system designed to assist Idaho's neediest citizens with medical care and established a system designed to plunder it.

64. Defendants have willfully ignored, and continue to ignore: (a) their duty to Idaho to behave with scrupulous honesty; (b) case law uniformly holding that their pricing practices are unlawful; and (c) the reprimands of Congress.

65. As a result, civil penalties, consistent with Idaho's statutory scheme, are mandated in this case.

HARM TO IDAHO

66. Defendants' unlawful activities have significantly and adversely impacted Idaho. Idaho has paid more for the drugs it purchases through its Medicaid program than it would have if defendants had reported the true wholesale prices of their drugs.

67. Defendants' conduct materially affected the ability of Idaho to provide medical care to its neediest citizens by forcing Idaho to pay higher costs thereby reducing the availability of medical assistance to Idaho's neediest citizens.

COUNT I

Violations of the Idaho Consumer Protection Act

68. Plaintiff hereby realleges all previous paragraphs.

69. Idaho Code § 48-603(17) declares that it is unlawful to engage "in any act or practice which is otherwise misleading, false, or deceptive to the consumer."

70. Moreover, the Idaho Administrative Code, IDAPA 04.02.01.066.04 states that it is an unfair and deceptive act or practice for a seller to "state or imply that any goods or services are being offered at 'wholesale' prices or to use a term of similar meaning unless the prices are in

fact at or below the current prices which most retailers in the trade area usually and customarily pay when they buy such goods or services for resale.”

71. Finally, IDAPA 04.02.01.031 places the burden on the defendants “to substantiate all claims or offers made before such claims or offers are advertised. Sellers must maintain sufficient records to substantiate all representations made in their advertisements.”

72. By committing the acts alleged above, defendants have violated the above statute and administrative rules.

73. Idaho has been harmed by defendants’ unfair and deceptive conduct in that it has paid far more for defendants’ drugs than it would have paid had defendants truthfully reported the AWPs of their drugs.

COUNT II

Unjust Enrichment

74. Plaintiff hereby realleges all previous paragraphs.

75. As a result of defendants’ misleading pricing information, Idaho purchased drugs at prices greater than they would have had defendants not engaged in unlawful conduct.

76. Each defendant knew that Idaho was being overcharged by pharmacy providers and physicians as a direct result of defendants’ misleading pricing information.

77. As a result of defendants’ unlawful conduct, defendants obtained increased sales, market share and profits at the expense of Idaho.

78. Each defendant knew that it was not entitled to the profits it realized from the increased sales and market share that resulted from the excessive payments made by Idaho.

WHEREFORE, plaintiff prays that this Court:

- A. declare that defendants' conduct as described above constitutes unfair and/or deceptive acts or practices within the meaning of Idaho Code § 48-603 and the Idaho Administrative Code;

- B. grant judgment for plaintiff;
- C. permanently enjoin defendants and their employees, officers, directors, agents, successors, assigns, affiliates, merged or acquired predecessors, parent or controlling entities, subsidiaries, and any and all persons acting in concert or participation with defendants, from continuing the unlawful conduct, acts, and practices described above;
- D. award plaintiff State of Idaho actual damages for all excessive prescription-drug payments paid as a result of defendants' unlawful conduct;
- E. award penalties for each violation found by the Court to have been committed by a defendant in the amount of \$5,000.00 pursuant to Idaho Code § 48-606(1)(e);
- F. require the defendants to disgorge all profits they realized as a result of their unlawful conduct;
- G. award plaintiff its costs and attorneys' fees; and
- H. award any other relief to which plaintiff is entitled or the Court deems appropriate and just.

PLAINTIFF DEMANDS TRIAL BY JURY OF 12.

Dated this 26th day of January, 2007.

LAWRENCE G. WASDEN
ATTORNEY GENERAL
STATE OF IDAHO

By:


JANE E. HOCHBERG
Deputy Attorney General

Charles Barnhill (pro hac vice application pending)
Miner, Barnhill & Galland, PC
44 East Mifflin Street, Suite 803
Madison WI 53703
(608) 255-5200/(608) 255-5380 (fax)

/ / /
/ / /

Robert S. Libman (pro hac vice application pending)
Miner, Barnhill & Galland, PC
14 West Erie Street
Chicago IL 60610
(312) 751-1170/(312) 751-0438 (fax)

P. Jeffrey Archibald (pro hac vice application pending)
1914 Monroe Street
Madison WI 53711
(608) 661-8855/(608) 661-8855 fax

Michael Winget-Hernandez (pro hac vice application pending)
Winget-Hernandez, LLC
3112 Windsor Road #228
Austin TX 78703
(512) 474-4095/(512) 697-0080 (fax)

Attorneys for Plaintiff

Program Memorandum Intermediaries/Carriers

Transmittal AB-00-86

Department of Health and
Human Services (DHHS)
HEALTH CARE FINANCING
ADMINISTRATION (HCFA)

Date: SEPTEMBER 8, 2000

CHANGE REQUEST 1232

SUBJECT: An Additional Source of Average Wholesale Price Data in Pricing Drugs and Biologicals Covered by the Medicare Program

The purpose of this Program Memorandum (PM) is to provide you with an alternative source of average wholesale price data (attached) for some drugs and biologicals covered by the Medicare program. The first attachment includes data for 32 drugs that you are to consider in determining the Medicare payment allowances for your January 2001 quarterly update. The second attachment includes data for 14 oncology drugs and 3 clotting factors that are not to be implemented in that same quarterly update.

The payment allowance for drugs and biologicals covered by the Medicare program is described in PM AB-99-63. That PM states that drugs and biologicals not paid on a cost or prospective payment basis are paid based on the lower of the billed charge or 95 percent of the average wholesale price reflected in sources such as the Red Book, Blue Book, or Medispan. Examples of drugs that are paid on this basis are drugs furnished incident to a physician's service, drugs furnished by pharmacies under the durable medical equipment benefit, covered oral anti-cancer drugs, and drugs furnished by independent dialysis facilities that are not included in the end stage renal disease composite rate payment. While the Blue Book is no longer available, another publication, Price Alert, is available. Also, there are electronic versions of the same data.

The data in the attachments have come from the United States Department of Justice (DOJ) and the National Association of Medicaid Fraud Control Units (NAMFCU). They are an alternative source of average wholesale price data for certain drugs, which has recently become available to HCFA. These data have been compiled for about 400 national drug codes (NDC) representing about 50 different chemical compounds. These data are from wholesalers' catalogs that list the prices at which the wholesaler sells the respective products. The DOJ has indicated that these are more accurate wholesale prices for these drugs. Furthermore, the DOJ has indicated that because purchasers often receive further discounts below the advertised wholesale catalog price, either from a wholesaler or from the drug manufacturer directly, actual acquisition costs may be lower. The DOJ indicates that some physicians and suppliers obtain drugs at prices lower than the wholesale catalog prices through Group Purchasing Organizations (GPO). For example, the DOJ data from wholesale catalogs indicates an average wholesale price of \$22 for one albuterol sulfate NDC which is substantially less than the \$73 average wholesale price in the Redbook and compares to \$15 from a GPO. These data are generally consistent with findings from OIG reports.

There has been correspondence with some members of congress on this subject. Under separate cover, we will send you a letter from the Administrator to Members of Congress, which places in context the issue of pricing drugs covered under the existing Medicare drug benefit and this new source.

DOJ and NAMFCU have provided these data to First Data Bank, a company that compiles average wholesale prices for most State Medicaid programs. On May 1, 2000, First Data Bank provided these new average wholesale prices to State Medicaid programs. Some States have already implemented these new average wholesale prices while others have not.

HCFA-Pub. 60AB

EXHIBIT

"A"

tables

You are to consider these alternative wholesale prices as another source in determining your January, 2001 quarterly update for the 32 drugs (Attachment 1), as per PM AB-99-63. These drugs account for 75 percent of Medicare spending and 70 percent of savings (based on DOJ data) for the drugs on the complete DOJ list. However, we have some concern about access to care related to the DOJ's wholesale prices for 14 chemotherapy drugs and 3 clotting factors (Attachment 2), due to other Medicare payment policies associated with the provision of these drugs for the treatment of cancer and hemophilia. Therefore, you are not to consider at this time using the DOJ data for these drugs (Attachment 2) to establish your Medicare allowances while we further review these concerns and develop alternative policies. For the drugs shown in Attachment 2, use your usual source of average wholesale prices in your next quarterly update.

The data in these attachments may not represent all of the NDCs for a drug or biological in applying the pricing rules described in PM AB-99-63; if you decide to use these data, then you must use solely these data as the source of average wholesale prices in establishing your Medicare payment allowances for the drugs in Attachment 1.

You are to report by October 15, 2000, your usual source as well as the source you intend to use for the January 2001 updates. Also, you are to provide a list of what the updates would be for the source(s) you identify as usual and for January 2001 updates, and the percentage difference, if any, for all the drugs listed in Attachment 1 and 2 (source for drugs in Attachment 2 can not be DOJ data). You are to submit these reports electronically to a special mailbox being established for this purpose. The e-mail address for this mailbox is DOJAWP@hcfa.gov.

For the drugs in Attachment 1, we may provide additional guidance by the end of October, which could affect your January 2001 updates. We will provide guidance in subsequent correspondence that concerns your future drug updates, and on Medicare allowances for the drugs listed in Attachment 2 as any necessary adjustments to other payments related to the provision of these drugs are being carried out. We will also convey how we plan to adjust Medicare allowances under the outpatient prospective system for drugs that are both subject to the AWP rules and paid on a passthrough basis.

The enclosed data show a price for each NDC that is an average of the wholesale prices in the catalogs of the various wholesale companies that are also shown. The DOJ indicates that these wholesalers have toll-free numbers (included in Attachment 1) and the capacity to supply drugs via overnight delivery to any place in the country. If you decide to use these data and if a physician or supplier indicates that they cannot obtain one of these products for the average wholesale price in this new source, you may explain to the physician or supplier that one or more of the wholesale companies in the attachment have indicated to the DOJ that they supply these drugs at or below these prices. You may give the physician or supplier the name and toll-free number of the wholesaler(s). You may also give the name and telephone number of the manufacturer of the drug (available in the Red Book) as DOJ has indicated that manufacturers often supply the drugs directly. Some of the manufacturers also have web pages on the Internet. Physicians or suppliers who are members of a GPO might also obtain these drugs through that organization at or below these average wholesale prices. However, you should not imply in any way that the physician or supplier is required to change their procedure for obtaining drugs. Further, you should indicate that you are not advocating the use of these sources and do not assume any liability for the choice of source by the physician or supplier.

Sections 1842(o) and 1833(a)(1)(S) of the Social Security Act (the Act) require the Medicare program to set payment allowances for drugs and biologicals at the lower of the actual amount billed or 95 percent of the average wholesale price. The attached data represent another source of average wholesale prices for the products on the attached list. Therefore, use of this new source of average wholesale prices in Attachment 1 is not an inherent reasonableness adjustment under paragraphs (8) and (9) of section 1842(b) of the Act.

The procedure for processing intermediary claims has not changed. As described in PM AB-97-25, all carriers will continue to furnish free of charge their drug payment allowance updates for all drugs and biologicals directly to the fiscal intermediaries in their jurisdiction. Carriers should contact the fiscal intermediaries to determine the preferred method of transmission. Carriers are to send this information to all fiscal intermediaries with whom they routinely deal. To further clarify, fiscal intermediaries must use each carrier's drug payment allowances for claims submitted under that carrier's jurisdiction.

Attachments (3)

The effective date for this (PM) is September 8, 2000.

The implementation date for this PM is September 8, 2000.

These instructions should be implemented within your current operating budget.

This PM may be discarded September 1, 2001.

If you have any questions contact Robert Niemann at 410-786-4531.

Attachment 1 – If you decide to use these data, use solely these data to update the HCPCS billing codes that correspond to the drugs on this list.

<u>Drug Name</u>	<u>Prod/Mfr</u>	<u>Measurements</u>	<u>NDC</u>	<u>Wholesaler</u>	<u>Average Wholesale (AWP)</u>
Acetylcysteine	(Abbott Hosp.)/SOL, IH	10%, 30 ml, 3s	00074-3307-03	MK	\$21.90
Acetylcysteine	(Abbott Hosp.)/SOL, IH	20%, 4 ml, 30 ml, 3s	00074-3308-03	MK, BB	\$18.75
Acetylcysteine	(Dey)/SOL, IH	10%, 4ml, 12s	49502-0181-04	MK	\$25.80
Acetylcysteine	(Dey)/SOL, IH	10%, 10 ml, 3s	49502-0181-10	MK	\$15.27
Acetylcysteine	(Dey)/SOL, IH	10%, 30 ml, 3s	49502-0181-30	MK	\$41.97
Acetylcysteine	(Dey)/SOL, IH	20%, 100 ml, ea	49502-0182-00	MK	\$75.90
Acetylcysteine	(Dey)/SOL, IH	20%, 4 ml, 12s	49502-0182-04	MK	\$31.08
Acetylcysteine	(Dey)/SOL, IH	20%, 10 ml, 3s	49502-0182-10	MK	\$18.57
Acetylcysteine	(Dey)/SOL, IH	20%, 30 ml, 3s	49502-0182-30	MK	\$50.64
Acetylcysteine	(Faulding)/SOL, IH (VIAL)	10%, 4 ml, 10s	61703-0203-04	MK,BB	\$13.50
Acetylcysteine	(Faulding)/SOL, IH (VIAL)	10%, 30 ml, 10s	61703-0203-31	BB	\$91.00
Acetylcysteine	(Faulding)/SOL, IH (VIAL)	10%, 4 ml, 10s	61703-0204-04	MK, BB	\$19.50
Acetylcysteine	(Faulding)/SOL, IH (VIAL)	10%, 30 ml, 10s	61703-0204-31	MK	\$91.00
Acyclovir Sodium	(Abbott Hosp.)/(Vial, Fliptop)	500 mg, 10s	00074-4427-01	BB, MK	\$349.05
Acyclovir Sodium	(Abbott Hosp.)/(Vial, Fliptop)	1000 mg, 10s	00074-4452-01	BB, MK	\$700.10
Acyclovir Sodium	(App)/INJ, IJ (Vial)	50 mg/ml, 10 ml	63323-0325-10	MK	\$15.00
Acyclovir Sodium	(App)/INJ, IJ (Vial)	50 mg/ml, 20 ml	63323-0325-20	MK	\$28.00
Acyclovir Sodium	(App)/PDI	15s, 500 mg, ea	63323-0105-10	MK	\$37.15
Acyclovir Sodium	(App)/PDI	15s, 1000 mg, ea	63323-0105-20	MK	\$75.13
Acyclovir Sodium	(Bedford)/PDI, IJ (S.D.V.)	500 mg, 10s	55390-0612-10	BB, ASD, FI	\$207.00
Acyclovir Sodium	(Bedford)/PDI, IJ (S.D.V.)	1000 mg, 10s	55390-0613-20	BB, ASD, FI, OS	\$401.75
Acyclovir Sodium	(Faulding)/PDI, IJ	500 mg, 10s	61703-0311-20	FI	\$89.00
Acyclovir Sodium	(Faulding)/PDI, IJ	1000 mg, 10s	61703-0311-43	FI	\$179.50
Acyclovir Sodium	(Fujisawa/APP)/PDI, IJ (VIAL)	500 mg, 10s	63323-0105-10	BB, MK	\$371.50
Acyclovir Sodium	(Fujisawa/APP)/PDI, IJ (VIAL)	1000 mg, 10s	63323-0110-20	BB, MK	\$751.80
Acyclovir Sodium	(Fujisawa/APP)/PDI, IJ (VIAL)	500 mg, 10s	63323-0325-10	BB	\$150.00
Acyclovir Sodium	(Fujisawa/APP)/PDI, IJ (VIAL)	1000 mg, 10s	63323-0325-20	BB, MK	\$280.00
Acyclovir Sodium	(Gensia)/PDI, IJ (VIAL)	500 mg, 10s	00703-8104-03	BB	\$100.00
Acyclovir Sodium	(Gensia)/PDI, IJ (VIAL)	1000 mg, 10s	00703-8105-03	BB	\$186.00
Albuterol Sulfate	(Dey)/SOL, IH	0.5%, 20 ml	49502-0196-20	BB, MK	\$5.91
Albuterol Sulfate	(Dey)/SOL, IH	0.083%, 3 ml, 25s, UD	49502-0697-03	BB, MK	\$9.17
Albuterol Sulfate	(Dey)/SOL, IH	0.083%, 3ml, 30s, UD	49502-0697-33	BB, MK	\$11.01
Albuterol Sulfate	(Dey)/SOL, IH	0.083%, 3ml, 60s, UD	49502-0697-60	BB, MK	\$22.01
Albuterol Sulfate	(Schein)/SOL, IH	0.5%, 20 ml	00364-2530-55	BB, MK	\$7.62
Albuterol Sulfate	(Warrick)/SOL, IH	0.083%, 3ml, 60s	59930-1500-06	BB, MK, AND	\$21.92
Albuterol Sulfate	(Warrick)/SOL, IH	0.083%, 3ml, 25s, UD	59930-1500-08	BB, MK, AND	\$9.16
Albuterol Sulfate	(Warrick)/SOL, IH	0.5%, 20 ml	59930-1515-04	BB, MK	\$5.65
Amikacin Sulfate	(Abbott Hosp.)/(Vial, Fliptop)	50 mg/ml, 2 ml, 10s	00074-1955-01	BB	\$125.00
Amikacin Sulfate	(Abbott Hosp.)/(Vial, Fliptop)	250 mg/ml, 2 ml, 10s	00074-1956-01	BB, MK	\$150.00

<i>Amikacin Sulfate</i>	(Abbott Hosp.)/(Vial, Fliptop)	250 mg/ml, 4 ml, 10s	00074-1957-01	BB, MK	\$320.00
<i>Amikacin Sulfate</i>	(Apothecon) Amikin/INJ, IJ (Vial)	250 mg/ml, 2 ml	00015-3020-20	FI, MK	\$17.31
<i>Amikacin Sulfate</i>	(Apothecon) Amikin/INJ, IJ (Vial)	250 mg/ml, 4 ml	00015-3023-20	FI, MK	\$34.49
<i>Amikacin Sulfate</i>	(Bedford)/INJ, IJ (S.D.V., P.F.)	250 mg/ml, 2 ml, 10s	55390-0226-02	BB, MK, FI	\$65.33
<i>Amikacin Sulfate</i>	(Bedford)/INJ, IJ (S.D.V., P.F.)	250 mg/ml, 4 ml, 10s	55390-0226-04	BB, MK, FI	\$125.33
<i>Amikacin Sulfate</i>	(Faulding Pharm.)/INJ, IJ (VIAL)	50 mg/ml, 2 ml, 10s	61703-0201-07	MK	\$295.00
<i>Amikacin Sulfate</i>	(Faulding Pharm.)/INJ, IJ (VIAL)	250 mg/ml, 4 ml, 10s	61703-0202-04	BB, MK	\$890.00
<i>Amikacin Sulfate</i>	(Faulding Pharm.)/INJ, IJ (VIAL)	250 mg/ml, 2 ml, 10s	61703-0202-07	BB, MK	\$450.00
<i>Amikacin Sulfate</i>	(Faulding Pharm.)/INJ, IJ (VIAL)	250 mg/ml, 3 ml, 10s	61703-0202-08	MK	\$600.00
<i>Amikacin Sulfate</i>	(Gensia)/INJ, IJ (S.D.V.)	50 mg/ml, 2 ml, 10s	00703-9022-03	BB, OS	\$72.68
<i>Amikacin Sulfate</i>	(Gensia)/INJ, IJ (S.D.V.)	250 mg/ml, 2 ml, 10s	00703-9032-03	BB, MK	\$70.00
<i>Amikacin Sulfate</i>	(Gensia)/INJ, IJ (Vial)	250 mg/ml, 4 ml, 10s	00703-9040-03	BB	\$140.00
<i>Amphotericin B</i>	(Apothecon) Fungizone/PDI, IJ	50 mg, ea	00003-0437-30	FI	\$6.20
<i>Amphotericin B</i>	(Gensia)/PDI, IJ (S.D.V.)	50 mg, ea	00703-9785-01	BB	\$9.80
<i>Amphotericin B</i>	(Pharmacia/Upjohn) Amphocin/PDI, IJ	50 mg, ea	00013-1405-44	ASD	\$16.00
<i>Calcitriol</i>	(Abbott Hosp) Calcijex/INJ, IJ (AMP)	1mcg/ml, 1ml, 100s	00074-1200-01	FI	\$1,079.00
<i>Calcitriol</i>	(Abbott Hosp) Calcijex/INJ, IJ (AMP)	2 msg/ml, 1 ml, 100s	00074-1210-01	FI	\$2,009.35
<i>Cimetidine Hydrochloride</i>	(Abbott Hosp.)/INJ, IJ	300 mg/50 ml, 50 ml, 48s	00074-7447-16	MK	\$120.00
<i>Cimetidine Hydrochloride</i>	(Abbott Hosp.)/INJ, IJ (ADD-VANTAGE)	150 mg/ml, 2 ml, 25s	00074-7446-02	MK, BB	\$35.00
<i>Cimetidine Hydrochloride</i>	(Abbott Hosp.)/INJ, IJ (VIAL, FLIPTOP)	150 mg/ml, 2 mg/ml, 2 ml, 10s	00074-7444-01	ASD, BB, MK, OTN, FI	\$11.72
<i>Cimetidine Hydrochloride</i>	(Abbott Hosp.)/INJ, IJ (VAIL, FLIPTOP)	150 mg/ml, 8 ml, 10s	00074-7445-01	ASD, BB, MK, OS	\$30.00
<i>Clindamycin Phosphate</i>	(Abbott Hosp.)/(Vial, Fliptop)	150 mg/ml, 2 ml, 25s	00074-4050-01	FI	\$75.35
<i>Clindamycin Phosphate</i>	(Abbott Hosp.)/(Vial, Fliptop)	150 mg/ml, 4 ml, 25s	00074-4051-01	BB	\$174.00
<i>Clindamycin Phosphate</i>	(Pharmacia/Upjohn) Cleocin/INJ, IJ	150 mg/ml, 2 ml, 25s	00009-0870-26	BB, MK	\$61.20
<i>Clindamycin Phosphate</i>	(Pharmacia/Upjohn) Cleocin/INJ, IJ	150 mg/ml, 4 ml, 25s	00009-0775-26	BB, MK	\$126.00
<i>Clindamycin Phosphate</i>	(Add-Vantage)	150 mg/ml, 4 ml, 25s	00009-3124-03	BB, MK	\$126.00
<i>Clindamycin Phosphate</i>	(Add-Vantage)	150 mg/ml, 6 ml, 25s	00009-0902-18	BB, MK	\$162.00
<i>Clindamycin Phosphate</i>	(Add-Vantage)	150 mg/ml, 6 ml, 25s	00009-3447-03	BB, MK	\$162.00
<i>Clindamycin Phosphate</i>	(Add-Vantage)	150 mg/ml, 4 ml, 25s	00009-0728-09	BB, MK	\$259.20
<i>Cromolyn Sodium</i>	(Dey)/SOL, IH	10 mg/ml, 2ml, 60s,	49502-0689-02	BB, MK	\$23.01

		UD			
Cromolyn Sodium	(Dey)/SOL, IH	10 mg/ml, 2ml, 120s, UD	49502-0689-12	BB, MK	\$45.71
Dexamethasone Acetate	(Schein)/INJ, IJ (M.D.V.)	8 mg/ml, 5 ml	00364-6699-53	FI	\$11.50
Dexamethasone Sodium Phosphate	(Elkins-Sin)/(M.D.V.)	10 mg/ml, 10 ml	00641-2277-41	FI, OS	\$2.65
Dexamethasone Sodium Phosphate	(Fujisawa/APP)/INJ, IJ (VIAL)	4 mg/ml, 1 ml ea	00469-1650-00	BB	\$0.66
Dexamethasone Sodium Phosphate	(Fujisawa/APP)/INJ, IJ (VIAL)	4 mg/ml, 5 ml	00469-1650-20	BB	\$1.67
Dexamethasone Sodium Phosphate	(Fujisawa/APP)/INJ, IJ (VIAL)	30 ml	00469-1650-50	BB	\$10.00
Dexamethasone Sodium Phosphate	(Fujisawa/APP)/INJ, IJ (VIAL)	4 mg/ml, 5 ml	63323-0165-05	OTN	\$0.90
Dexamethasone Sodium Phosphate	(Fujisawa/APP)/INJ, IJ (VIAL)	30 ml	63323-0165-30	FI	\$10.00
Dexamethasone Sodium Phosphate	(Fujisawa/APP)/INJ, IJ (VIAL), (M.D.V.)	30 ml	63323-0165-01	BB	\$0.66
Dexamethasone Sodium Phosphate	(Schein)/INJ, IJ (M.D.V.)	4 mg/ml, 5 ml ea	00364-6681-32	BB	\$1.08
Dextrose	(Abbott Hosp.)/(ADD-VANTAGE, LIFECARE)	5%, 50 ml	00074-7100-13	BB, TRI	\$3.22
Dextrose	(Abbott Hosp.)/(ADD-VANTAGE)	5%, 250 ml	00074-7100-02	TRI	\$4.12
Dextrose	(Abbott Hosp.)/(ADD-VANTAGE, LIFECARE)	5%, 100 ml	00074-7100-23	TRI	\$3.22
Dextrose	(Abbott Hosp.)/(LIFECARE)	250 ml	00074-1522-02	TRI, FI	\$3.63
Dextrose	(Abbott Hosp.)/(LIFECARE)	5%, 150 ml	00074-7922-61	BB, TRI	\$1.46
Dextrose	(Abbott Hosp.)/(LIFECARE)	5%, 50 ml	00074-7923-36	BB, TRI	\$1.45
Dextrose	(Abbott Hosp.)/(LIFECARE)	5%, 100 ml	00074-7923-37	ASD	\$1.45
Dextrose	(Abbott Hosp.)/(LIFECARE/PLASTIC)	(1000 ml container), 1000 ml	00074-1518-05	BB, FI, OTN, TRI, OS	\$14.54
Dextrose	(Abbott Hosp.) (LIFECARE/PLASTIC)	(1000 ml container), 1000 ml	00074-1519-05	ASD, OS, FI, OTN, TRI	\$13.71
Dextrose	(Abbott Hosp.) (LIFECARE/PLASTIC)	5%, 500 ml	00074-1522-03	ASD, OS, FI, OTN, TRI	\$3.87
Dextrose	(Abbott Hosp.) (LIFECARE/PLASTIC)	(1000 ml container), 500 ml	00074-1536-03	BB	\$9.19
Dextrose	(Abbott Hosp.) (LIFECARE/PLASTIC)	(1000 ml container), 50%, 500 ml	00074-5645-25	BB, AHT	\$3.69
Dextrose	(Abbott Hosp.) (LIFECARE/PLASTIC)	(1000 ml container), 70%, 500 ml	00074-5647-25	BB, OS, FI	\$4.26
Dextrose	(Abbott Hosp.) (LIFECARE/PLASTIC)	(Bulk Package), 70%, 2000 ml	00074-7120-07	BB	\$13.60
Dextrose	(Abbott Hosp.) (LIFECARE/PLASTIC)	(1000 ml container), 500 ml	00074-7918-19	BB	\$8.81
Dextrose	(Abbott Hosp.) (LIFECARE/PLASTIC)	5%, 250 ml	00074-7922-02	BB	\$1.54
Dextrose	(Abbott Hosp.) (LIFECARE/PLASTIC)	5%, 500 ml	00074-7922-03	BB, TRI	\$1.61

Dextrose	(Abbott Hosp.) / (LIFECARE/PLASTIC)	5%, 1000 ml	00074-7922-09	BB, TRI	\$2.34
Dextrose	(Abbott Hosp.) / (LIFECARE/PLASTIC)	(2000 ml container), 50%, 1000 ml	00074-7936-17	BB, FI, OTN, TRI, OS	\$11.24
Dextrose	(Abbott Hosp.) / (LIFECARE/PLASTIC)	(1000 ml container), 50%, 500 ml	00074-7936-19	ASD, OTN, FI, TRI, OS	\$7.09
Dextrose	(Abbott Hosp.)/INJ, IJ, (50/150 ML PART FILL)	5%, 50 ml	00074-1523-01	BB, OTN, FI, TRI, OS	\$3.91
Dextrose	(Baxter)/(QUAD PACK, MINI-BAG)	5%, 100ml	00338-0017-18	BB, TRI	\$1.55
Dextrose	(Baxter)/(BULK PACKAGE)	50%, 2000 ml	00338-0031-06	BB, TRI	\$21.60
Dextrose	(Baxter)/(BULK PACKAGE)	70%, 2000 ml	00338-0719-06	ASD, OS	\$13.31
Dextrose	(Baxter)/(GLASS FULL FILL)	70%, 1000 ml	00338-0348-04	TRI, FI	\$6.20
Dextrose	(Baxter)/(GLASS UNDERFILL)	70%, 500 ml	00338-0032-13	TRI	\$8.16
Dextrose	(Baxter)/(MINI-BAG PLUS)	5%, 50 ml	00338-0551-11	TRI	\$3.17
Dextrose	(Baxter)/(MULTI-PACK, MINI-BAG)	5%, 50 ml	00338-0017-31	TRI	\$1.80
Dextrose	(Baxter)/(MULTI-PACK, MINI-BAG)	5%, 100ml	00338-0017-38	TRI	\$1.55
Dextrose	(Baxter)/(QUAD PACK, MINI-BAG)	5%, 25 ml	00338-0017-10	TRI	\$1.80
Dextrose	(Baxter)/(QUAD PACK, MINI-BAG)	5%, 50 ml	00338-0017-11	TRI, FI	\$1.55
Dextrose	(Baxter)/(SINGLE PACK MINI-BAG)	250 ml	00338-0016-02	TRI	\$3.39
Dextrose	(Baxter)/(SINGLE PACK MINI-BAG)	150 ml	00338-0017-01	FI, TRI	\$1.50
Dextrose	(Baxter)/(SINGLE PACK MINI-BAG)	250 ml	00338-0017-02	FI, TRI	\$1.50
Dextrose	(Baxter)/(SINGLE PACK MINI-BAG)	500ml	00338-0017-03	BB, TRI	\$1.47
Dextrose	(Baxter)/(SINGLE PACK MINI-BAG)	1000 ml	00338-0017-04	FI, TRI	\$2.11
Dextrose	(Baxter)/(SINGLE PACK MINI-BAG)	5%, 100ml	00338-0017-48	FI, TRI	\$1.55
Dextrose	(Baxter)/(SINGLE PACK MINI-BAG)	10%, 250 ml	00338-0023-02	BB	\$1.69
Dextrose	(Baxter)/(SINGLE PACK MINI-BAG)	5%, 50 ml	00338-0017-41	TRI, FI	\$2.25
Dextrose	(McGaw)/(1000 ML GLASS W/ STOPPER)	50%, 500 ml	00264-1280-55	TRI	\$4.07
Dextrose	(McGaw)/(EXCEL)	5%, 1000 ml	00264-7510-00	TRI, OTN, ASD, OS	\$2.20
Dextrose	(McGaw)/(EXCEL)	500 ml	00264-7510-10	TRI, OTN, ASD, OS	\$1.69
Dextrose	(McGaw)/(EXCEL)	5%, 250 ml	00264-7510-20	TRI, OTN, ASD, OS	\$1.59
Dextrose	(McGaw)/(EXCEL)	10%, 1000 ml	00264-7520-00	TRI	\$1.99
Dextrose	(McGaw)/(GLASS CONTAINER, 1000 ML)	500 ml	00264-1290-50	TRI	\$7.15
Dextrose	(McGaw)/(GLASS CONTAINER, 1000 ML)	70%, 500 ml	00264-1292-55	TRI	\$5.28

Dextrose	(McGaw)/(GLASS W/ AIR TUBE)	70%, 2000 ml	00264-1129-50	TRI	\$18.35
Dextrose	(McGaw)/(GLASS W/SOLID STOPPER)	70%, 1000 ml	00264-1290-55	TRI	\$6.62
Dextrose	(McGaw)/(GLASS W/SOLID STOPPER)	50%, 500 ml	00264-1281-55	TRI	\$2.76
Dextrose	(McGaw)/(W/SOLID STOPPER, GLASS)	50%, 2000 ml	00264-1285-55	TRI	\$11.32
Dextrose	(McGaw)/INJ, IJ (100 ML PAB)	50 ml	00264-1510-31	TRI, OTN	\$1.61
Dextrose	(McGaw)/INJ, IJ (150 ML PAB)	5%, 100 ml	00264-1510-32	TRI, OTN	\$1.62
Dextrose with Sodium Chloride	(Abbott Hosp.)	5%-0.45%, 250 ml	00074-7926-02	TRI, FI, OS	\$1.80
Dextrose with Sodium Chloride	(Abbott Hosp.)	500 ml	00074-7926-03	TRI, OTN, ASD, FI, OS	\$1.96
Dextrose with Sodium Chloride	(Abbott Hosp.)	1000 ml	00074-7926-09	TRI, OTN, ASD, FI, OS	\$2.66
Dextrose with Sodium Chloride	(Abbott Hosp.)	5%-0.9%, 250 ml	00074-7941-02	TRI	\$1.93
Dextrose with Sodium Chloride	(Abbott Hosp.)	500 ml	00074-7941-03	TRI, OTN, ASD, FI, OS	\$1.85
Dextrose with Sodium Chloride	(Abbott Hosp.)	1000 ml	00074-7941-09	BB, OTN, ASD, FI, OS	\$2.24
Dextrose with Sodium Chloride	(Baxter)	5%-0.45%, 250 ml	00338-0085-02	TRI, FI	\$2.47
Dextrose with Sodium Chloride	(Baxter)	500 ml	00338-0085-03	TRI, FI	\$1.90
Dextrose with Sodium Chloride	(Baxter)	1000 ml	00338-0085-04	FI	\$2.25
Dextrose with Sodium Chloride	(Baxter)	5%-0.9%, 250 ml	00338-0089-02	TRI	\$2.93
Dextrose with Sodium Chloride	(Baxter)	500 ml	00338-0089-03	FI	\$2.00
Dextrose with Sodium Chloride	(Baxter)	1000 ml	00338-0089-04	FI	\$2.25
Dextrose with Sodium Chloride	(McGaw)	1000 ml	00264-7610-00	TRI, FI	\$2.10
Dextrose with Sodium Chloride	(McGaw)	500 ml	00264-7610-10	TRI, FI	\$1.81
Dextrose with Sodium Chloride	(McGaw)	5%-0.9%, 250 ml	00264-7610-20	TRI	\$1.78
Dextrose with Sodium Chloride	(McGaw)	1000 ml	00264-7612-00	TRI, FI, ASD	\$1.85
Dextrose with Sodium Chloride	(McGaw)	500 ml	00264-7612-10	TRI, FI	\$1.85
Dextrose with Sodium Chloride	(McGaw)	5%-0.45%, 250 ml	00264-7612-20	TRI, FI	\$1.89
Diazepam	(Abbott Hosp.)/(CARPUJECT LUER LOCK)	5 mg/ml, 2 ml; ea C-IV	00074-1273-32	BB	\$2.03
Diazepam	(Abbott Hosp.)/(CARPUJECT, 22GX1-1/4")	5 mg/ml, 2ml; ea C-IV	00074-1273-02	BB, FI	\$2.12

Diazepam	(Abbott Hosp.)/(VIAL, FLIPTOP)	5 mg/ml, 10 ml, ea, C-IV	00074-3213-01	OTN, MK	\$2.50
Diazepam	(Abbott Hosp.)/INJ, IJ (AMP)	5 mg/ml, 2ml, EA C-IV	00074-3210-32	BB	\$1.49
Diazepam	(Schein)/INJ, IJ (S.D.V.) (M.D.V.)	5 mg/ml, 10 ml, ea, C-IV	00364-0825-54	ASD	\$2.50
Furosemide	(Abbott Hosp.)/INJ, IJ (VIAL, PF, FLIPTOP)	10 mg/ml, 2 ml 25s	00074-6102-02	ASD, BB, MK	\$14.38
Furosemide	(Abbott Hosp.)/INJ, IJ (VIAL, PF, FLIPTOP)	10 mg/ml, 4 ml 25s	00074-6102-04	OS, ASD, OTN, BB, MK	\$20.28
Gentamicin Sulfate	(Abbott Hosp.)/(Vial, Fliptop)	40 mg/ml, 2 ml	00074-1207-03	OTN, BB, OS, FI	\$0.51
Gentamicin Sulfate	(Fujisawa)/(Bulk Package)	40 mg/ml, 50 ml	00469-1000-60	MK, BB	\$7.00
Gentamicin Sulfate	(Fujisawa)/(Bulk Package)	40 mg/ml, 50 ml	63323-0010-50	MK, BB	\$7.00
Gentamicin Sulfate	(Fujisawa)/INJ, IJ (M.D.V.)	40 mg/ml, 20 ml	00469-1000-40	OTN	\$5.40
Gentamicin Sulfate	(Fujisawa)/INJ, IJ (M.D.V.)	40 mg/ml, 20 ml	63323-0010-20	BB, MK	\$3.50
Gentamicin Sulfate	(Schein)/(M.D.V.)	40 mg/ml, 20 ml	00364-6739-55	BB	\$2.63
Gentamicin Sulfate	(Schein)/INJ, IJ (S.D.V.)	40 mg/ml, 2 ml	00364-6739-48	BB	\$1.18
Heparin Lock Flush	(Abbott Hosp.)/INJ, IJ (VIAL, FLIPTOP)	10 u/ml, 10 ml 25s	00074-1151-70	OS, OTN	\$13.60
Heparin Lock Flush	(Abbott Hosp.)/INJ, IJ (VIAL, FLIPTOP)	100 u/ml, 10 ml 25s	00074-1152-70	ASD, OS, FI, OTN	\$13.43
Heparin Lock Flush	(Abbott Hosp.)/INJ, IJ (VIAL, FLIPTOP)	30 ml, 25s	00074-1152-78	ASD, OS, OTN	\$21.07
Hydrocortisone Sodium Succinate	(Pharmacia/Upjohn) Solu-Cortef/ (ACT-O-VIAL)	100 mg, ea	00009-0900-13	BB, MK, ASD, BB, FI, OS	\$1.55
Hydrocortisone Sodium Succinate	(Pharmacia/Upjohn) Solu-Cortef/ (ACT-O-VIAL)	250 mg, ea	00009-0909-08	ASD, FI, BB, MK	\$2.65
Hydrocortisone Sodium Succinate	(Pharmacia/Upjohn) Solu-Cortef/ (ACT-O-VIAL)	500 mg, ea	00009-0912-05	ASD, MK, BB, OS, FI	\$5.89
Hydrocortisone Sodium Succinate	(Pharmacia/Upjohn) Solu-Cortef/ (ACT-O-VIAL)	1000 mg, ea	0009-0920-03	FI, MK	\$11.57
Immune Globulin	(Alpha Therapeutics) Venoglobulin-S 10%/INJ, IJ (10 gm/Vial, w/Admin. Set)	100 mg/ml, 100 ml	49669-1623-01	FI	\$780.00
Immune Globulin	(Alpha Therapeutics) Venoglobulin-S 10%/INJ, IJ (20 gm/Vial, w/Admin. Set)	100 mg/ml, 200 ml	49669-1624-01	FI	\$1,560.00
Immune Globulin	(Alpha Therapeutics) Venoglobulin-S 10%/INJ, IJ (5 gm/Vial, w/Admin. Set)	100 mg/ml, 50 ml	49669-1622-01	FI	\$390.00
Immune Globulin	Baxter Hyland/Immuno) Gammagard S/D/PDI, IJ	2.5 gm, ea	00944-2620-02	FI	\$175.00
Immune Globulin	Baxter Hyland/Immuno) Gammagard S/D/PDI, IJ	5.0 gm, ea	00944-2620-03	FI	\$350.00
Immune Globulin	Baxter Hyland/Immuno) Gammagard S/D/PDI, IJ	10.0 gm, ea	00944-2620-04	FI	\$700.00
Immune Globulin	(Bayer) Gammimune N10%/INJ, KJ (10 gm/Vial)	100 mg/ml, 100 ml	00026-0648-71	FI, ASD, OS, Bayer Wholesale	\$727.50
Immune Globulin	(Bayer) Gammimune N10%/INJ, KJ (20 gm/Vial)	100 mg/ml, 200 ml	00026-0648-24	FI, OS, Bayer Wholesale	\$1,503.33
Immune Globulin	(Bayer) Gammimune N10%/INJ, KJ (5 gm/Vial)	100 mg/ml, 50 ml	00026-0648-20	FI, ASD, OS, Bayer Wholesale	\$362.50

<i>Immune Globulin</i>	(Centeon) Gammaglobin P.I.V./PDI, IJ (w/diluent)	5 gm, ea	00053-7486-05	Health Coalition, ASD, OS	\$296.67
<i>Immune Globulin</i>	(Centeon) Gammaglobin P.I.V./PDI, IJ (w/diluent)	10 gm, ea	00053-7486-10	Health Coalition, ASD, OS	\$593.33
<i>Iron Dextran</i>	(Schein)/INJ, IJ (S.D.V.)	50 mg/ml, 2 ml	00364-3012-47	ASD, OS, FI, OTN	\$24.69
<i>Lorazepam</i>	(Abbott Hosp.)/(HYPAK SYRINGE)	2 mg/ml, 1ml, C-IV	00074-6776-01	BB	\$3.60
<i>Lorazepam</i>	(Abbott Hosp.)/(VIAL)	4 mg/ml, 1ml, C-IV	00074-1539-01	MK	\$3.80
<i>Lorazepam</i>	(Abbott Hosp.)/(VIAL)	4 mg/ml, 10ml, C-IV	00074-1539-10	MK	\$30.00
<i>Lorazepam</i>	(Abbott Hosp.)/(VIAL)	2 mg/ml, 10ml, C-IV	00074-1985-10	BB	\$25.83
<i>Lorazepam</i>	(Abbott Hosp.)/(VIAL, FLIPTOP)	2 mg/ml, 1ml, C-IV	00074-6778-01	BB, FI	\$2.98
<i>Lorazepam</i>	(Abbott Hosp.)/(VIAL, FLIPTOP)	4 mg/ml, 1ml, C-IV	00074-6779-01	BB	\$3.80
<i>Lorazepam</i>	(Abbott Hosp.)/(VIAL, FLIPTOP)	2 mg/ml, 10ml, C-IV	00074-6780-01	ASD, OTN, FI	\$24.42
<i>Lorazepam</i>	(Abbott Hosp.)/(VIAL, FLIPTOP)	4 mg/ml, 10ml, C-IV	00074-6781-01	BB, FI	\$28.75
<i>Lorazepam</i>	(Abbott Hosp.)/INJ, IJ (VIAL)	2 mg/ml, 1ml, C-IV	00074-1985-01	MK	\$3.00
<i>Lorazepam</i>	(Wyeth-Ayerst) Ativan/(M.D.V.)	4 mg/ml, 10ml, C-IV	00008-0570-01	FI	\$48.00
<i>Lorazepam</i>	(Wyeth-Ayerst) Ativan/(M.D.V.)	2 mg/ml, 10ml, C-IV	00008-0581-01	FI	\$29.50
<i>Lorazepam</i>	(Wyeth-Ayerst) Ativan/(S.D.V.)	2 mg/ml, 1ml, C-IV	00008-0581-04	FI	\$8.85
<i>Lupron</i>	(Tap) Lupron Depot/(3 Month Formulation)	22.5 mg, ea	00300-3336-01	ASD, FI, OTN, OS	\$1,447.60
<i>Lupron</i>	(Tap) Lupron Depot/(3 Month Formulation)	11.25 mg, ea	00300-3343-01	FI	\$1,149.00
<i>Lupron</i>	(Tap) Lupron Depot/(4 Month Formulation)	30 mg, ea	00300-3673-01	FI, ASD, OS	\$1,902.80
<i>Lupron</i>	(Tap) Lupron Depot/PDI, IJ (S.D.V.)	7.5 mg, ea	00300-3629-01	ASD, OS, FI, OTN	\$482.52
<i>Lupron</i>	(Tap) Lupron Depot/PDI, IJ (S.D.V.)	3.75 mg, ea	00300-3639-01	FI, OS	\$406.00
<i>Metaproterenol Sulfate</i>	(Dey)/SOL, IH (SULFATE FREE)	0.6%, 2500 ml, 25s, UD	49502-0676-03	BB, MK	\$11.29
<i>Metaproterenol Sulfate</i>	(Dey)/SOL, IH (SULFATE FREE)	0.4%, 2500 ml, 25s, UD	49502-0678-03	BB, MK	\$11.29
<i>Methylprednisolone Sodium Succinate</i>	(Abbott Hosp.) A-Methapred/PDI, IJ (UNIVIAL)	1 gm, ea	00074-5631-08	OTN	\$16.75
<i>Methylprednisolone Sodium Succinate</i>	(Abbott Hosp.) A-Methapred/PDI, IJ (UNIVIAL)	40 mg, ea	00074-5684-01	OTN	\$2.30
<i>Methylprednisolone Sodium Succinate</i>	(Abbott Hosp.) A-Methapred/PDI, IJ (UNIVIAL)	125 mg, ea	00074-5685-02	OTN	\$3.35
<i>Methylprednisolone Sodium Succinate</i>	(Abbott Hosp.) A-Methapred/PDI, IJ (ADD-VANTAGE)	500 mg, ea	00074-5601-44	OTN	\$9.40
<i>Methylprednisolone Sodium Succinate</i>	(Pharmacia/Upjohn) Solu-Medrol/(ACT-O-VIAL)	125 mg, ea	00009-0190-09	BB, OS	\$2.52
<i>Methylprednisolone Sodium Succinate</i>	(Pharmacia/Upjohn) Solu-Medrol/(ACT-O-VIAL)	500 mg, ea	00009-0765-02	BB	\$5.51

<i>Methylprednisolone Sodium Succinate</i>	(Pharmacia/Upjohn) Solu-Medrol/(ACT-O-VIAL)	1 gm, ea	00009-3389-01	BB, ASD, FI, OS	\$11.39
<i>Methylprednisolone Sodium Succinate</i>	(Pharmacia/Upjohn) Solu-Medrol/(VIAL)	1 gm, ea	00009-0698-01	BB, FI, OS	\$11.69
<i>Methylprednisolone Sodium Succinate</i>	(Pharmacia/Upjohn) Solu-Medrol/(VIAL)	500 mg, ea	00009-0758-01	BB, FI, OS	\$6.37
<i>Methylprednisolone Sodium Succinate</i>	(Pharmacia/Upjohn) Solu-Medrol/(W/DILUENT)	2 gm, ea	00009-0796-01	BB, FI	\$14.41
<i>Methylprednisolone Sodium Succinate</i>	(Pharmacia/Upjohn) Solu-Medrol/(W/DILUENT)	500 mg, ea	00009-0887-01	ASD	\$6.17
<i>Methylprednisolone Sodium Succinate</i>	(Pharmacia/Upjohn) Solu-Medrol/PDI, IJ (ACT-O-VIAL)	40 mg, ea	00009-0113-12	ASD, BB, OS	\$1.45
<i>Mitomycin</i>	(Bedford)/PDI, IJ (S.D.V.)	5 mg, ea	55390-0251-01	FI, OS, ASD	\$51.83
<i>Mitomycin</i>	(Bedford)/PDI, IJ (S.D.V.)	20 mg, ea	55390-0252-01	FI, ASD, OS	\$146.67
<i>Mitomycin</i>	(Faulding)/DI, IJ	20 mg, ea	61703-0306-50	ASD, OS	\$134.00
<i>Pentamidine Isethionate</i>	(Fujisawa) Nebupent/PDR, IH (S.D.V., P.F.)	300 mg, ea	57317-0210-06	FI	\$36.00
<i>Pentamidine Isethionate</i>	(Fujisawa) Nebupent/PDR, IH (S.D.V., P.F.)	300 mg, ea	63323-0877-15	FI	\$36.00
<i>Pentamidine Isethionate</i>	(Gensia)/PDI, IJ (S.D.V.)	300 mg, ea	00053-1000-05	FI	\$29.00
<i>Sodium Chloride</i>	(Abbott Hosp.)/(ADD-VANT, LIFECARE P.F.)	0.9%, 50 ml	00074-7101-13	TRI, BB	\$3.22
<i>Sodium Chloride</i>	(Abbott Hosp.)/(ADD-VANT, LIFECARE P.F.)	0.9%, 100 ml	00074-7101-23	TRI, BB	\$3.22
<i>Sodium Chloride</i>	(Abbott Hosp.)/(ADD-VANT, LIFECARE)	0.9%, 250 ml	00074-7101-02	TRI, BB	\$4.19
<i>Sodium Chloride</i>	(Abbott Hosp.)/(LIFECARE)	0.9%, 50 ml	00074-7984-36	TRI, ASD, OS, OTN, FI	\$1.45
<i>Sodium Chloride</i>	(Abbott Hosp.)/(LIFECARE)	0.9%, 100 ml	00074-7984-37	TRI, ASD, OS, OTN, FI	\$1.45
<i>Sodium Chloride</i>	(Abbott Hosp.)/(LIFECARE, PLASTIC CONT)	0.9%, 500 ml	00074-7983-03	FI, ASD, BB, OS	\$1.69
<i>Sodium Chloride</i>	(Abbott Hosp.)/(LIFECARE, PLASTIC CONT)	0.9%, 1000 ml	00074-7983-09	FI, ASD, BB, OS	\$2.17
<i>Sodium Chloride</i>	(Abbott Hosp.)/(LIFECARE, PLASTIC)	0.9%, 250 ml	00074-1583-02	TRI, OTN, FI, OS	\$1.94
<i>Sodium Chloride</i>	(Abbott Hosp.)/(LIFECARE, PLASTIC)	0.9%, 250 ml	00074-7983-02	FI, ASD, BB	\$1.41
<i>Sodium Chloride</i>	(Abbott Hosp.)/(LIFECARE, PLASTIC)	0.9%, 150 ml	00074-7983-61	FI, ASD, OS, OTN	\$1.43
<i>Sodium Chloride</i>	(Baxter)/(MINI-BAG PLUS)	0.9%, 50 ml	00338-0553-11	TRI	\$3.32
<i>Sodium Chloride</i>	(Baxter)/(MINI-BAG PLUS)	0.9%, 100 ml	00338-0553-18	TRI	\$3.17
<i>Sodium Chloride</i>	(Baxter)/(MULTI PACK, MINI-BAG)	0.9%, 50 ml	00338-0049-31	TRI, FI	\$1.55
<i>Sodium Chloride</i>	(Baxter)/(MULTI PACK, MINI-BAG)	0.9%, 100 ml	00338-0049-38	TRI, FI	\$1.55
<i>Sodium Chloride</i>	(Baxter)/(QUAD PACK, MINI-PACK)	0.9%, 50 ml	00338-0049-11	TRI	\$1.80
<i>Sodium Chloride</i>	(Baxter)/(QUAD PACK, MINI-PACK)	0.9%, 100 ml	00338-0049-18	TRI	\$1.80
<i>Sodium Chloride</i>	(Baxter)/(SINGLE PACK, MINI-BAG)	0.9%, 150 ml	00338-0049-01	TRI, FI	\$1.51

Sodium Chloride	(Baxter)/(SINGLE PACK, MINI-BAG)	0.9%, 250 ml	00338-0049-02	TRI, FI	\$1.49
Sodium Chloride	(Baxter)/(SINGLE PACK, MINI-BAG)	0.9%, 500 ml	00338-0049-03	TRI, FI	\$1.58
Sodium Chloride	(Baxter)/(SINGLE PACK, MINI-BAG)	0.9%, 1000 ml	00338-0049-04	TRI, FI	\$2.03
Sodium Chloride	(Baxter)/(SINGLE PACK, MINI-BAG)	0.9%, 50 ml	00338-0049-41	TRI	\$1.71
Sodium Chloride	(Baxter)/(SINGLE PACK, MINI-BAG)	0.9%, 100 ml	00338-0049-48	TRI, FI	\$1.55
Sodium Chloride	(McGaw)	50 ml	00264-1800-31	TRI, FI	\$1.49
Sodium Chloride	(McGaw)/(150 ML PAB)	0.9%, 100 ml	00264-1800-32	TRI, FI	\$1.49
Sodium Chloride	(McGaw)/(EXCEL)	0.9%, 1000 ml	00264-7800-00	TRI, OTN, FI, ASD	\$2.19
Sodium Chloride	(McGaw)/(EXCEL)	0.9%, 500 ml	00264-7800-10	TRI, OTN, FI, ASD	\$1.53
Sodium Chloride	(McGaw)/(EXCEL)	0.9%, 250 ml	00264-7800-20	TRI, OTN, FI, ASD	\$1.51
Testosterone Cypionate	(Pharmacia/Upjohn) Depo-Testosterone	200 mg/ml, 1 ml, C-III	00009-0417-01	BB, OTN	\$11.79
Testosterone Cypionate	(Pharmacia/Upjohn) Depo-Testosterone	200 mg/ml, 10 ml, C-III	00009-0417-02	BB, OTN	\$24.78
Testosterone Enanthate	(Schein)/INJ, IJ (M.D.V.)	200 mg/ml, 10 ml, C-II	00364-6617-54	ASD, MK, FI	\$13.39
Tobramycin Sulfate	(Abbott Hosp.)/(SRN)	40 mg/ml, 2 ml	00074-3583-01	BB	\$5.84
Tobramycin Sulfate	(Abbott Hosp.)/(Vial, Bulk)	40 mg/ml, 50 ml	00074-3590-02	BB, MK	\$103.64
Tobramycin Sulfate	(Abbott Hosp.)/(Vial, Flaptop)	40 mg/ml, 2 ml	00074-3578-01	BB, MK	\$4.99
Tobramycin Sulfate	(Abbott Hosp.)/INJ, IJ (Vial Flaptop)	10 mg/ml, 2 ml	00074-3577-01	BB, MK	\$2.94
Tobramycin Sulfate	(Gensia)/INJ, IJ (M.D.V.)	40 mg/ml, 2ml	00703-9402-04	FI, MK	\$6.98
Tobramycin Sulfate	(Gensia)/INJ, IJ (M.D.V.)	40 mg/ml, 30 ml	00703-9416-01	FI	\$36.90
Vancomycin Hydrochloride	(Abbott Hosp.)/(BULK VIAL)	5 gm, ea	00074-6509-01	FI, MK, BB	\$41.24
Vancomycin Hydrochloride	(Abbott Hosp.)/(VIAL, FLIPTOP)	500 mg, 10s, ea	00074-4332-01	FI, OTN, MK, BB, OS	\$4.98
Vancomycin Hydrochloride	(Abbott Hosp.)/(VIAL, FLIPTOP)	1 gm, 10s, ea	00074-6533-01	FI, ASD, OS, MK, BB	\$9.05
Vancomycin Hydrochloride	(Abbott Hosp.)/(VIAL, FLIPTOP)	1 gm, 10s, ea	00074-6535-01	FI, OTN, MK, BB	\$12.17
Vancomycin Hydrochloride	(Abbott Hosp.)/PDI, IJ (ADD-VANTAGE)	500 mg, 10s, ea	00074-6534-01	FI, MK, BB	\$5.09
Vancomycin Hydrochloride	(Fujisawa) Lyphocin/PDI IJ (VIAL)	500 mg, ea	00469-2210-30	BB, MK	\$7.00
Vancomycin Hydrochloride	(Fujisawa) Lyphocin/PDI IJ (VIAL)	1 gm, ea	00469-2840-40	BB, MK	\$13.00
Vancomycin Hydrochloride	(Fujisawa) Lyphocin/PDI IJ (VIAL)	5 gm, ea	00469-2951-00	BB	\$71.50
Vancomycin Hydrochloride	(Fujisawa) Lyphocin/PDI IJ (VIAL)	1 gm, ea	63323-0284-20	BB, MK	\$13.00
Vancomycin Hydrochloride	(Fujisawa) Lyphocin/PDI IJ (VIAL)	5 gm, ea	63323-0295-41	BB	\$71.50
Vancomycin Hydrochloride	(Fujisawa) Lyphocin/PDI IJ (VIAL)	10 gm, ea	63323-0314-61	MK	\$143.00

<i>Vancomycin Hydrochloride</i>	(Fujisawa) Lyphocin/PDI IJ (VIAL)	500 mg, ea	63323-2210-30	BB, MK	\$7.00
<i>Vancomycin Hydrochloride</i>	(Lederle Std. Prod.) Vancoled/PDI INJ, IJ	5 gm, ea	00205-3154-05	MK, BB	\$45.09
<i>Vancomycin Hydrochloride</i>	(Lederle Std. Prod.) Vancoled/PDI INJ, IJ	1 gm, 10s, ea	00205-3154-15	MK, BB	\$9.02
<i>Vancomycin Hydrochloride</i>	(Lederle Std. Prod.) Vancoled/PDI INJ, IJ	500 mg, 10s, ea	00205-3154-88	MK, BB	\$4.51
<i>Vancomycin Hydrochloride</i>	(Schein)/PDI, IJ (M.D.V.)	1 gm, 10s, ea	00364-2473-91	OTN	\$12.90
<i>Vancomycin Hydrochloride</i>	(Schein)/PDI, IJ (S.D.V.)	500 mg, 10s, ea	00364-2472-33	MK	\$3.84
<i>Winrho SDF</i>	(Nabi) rho (d) immune globulin/ (VIAL)	5000 iu, ea	60492-0024-01	ASD, FI, OTN, OS	\$505.56
<i>Winrho SDF</i>	(Nabi) rho (d) immune globulin/PDI, IJ (S.D.V.)	600 iu, ea	60492-0021-01	ASD, FI, OS	\$64.96
<i>Winrho SDF</i>	(Nabi) rho (d) immune globulin/PDI, IJ (S.D.V.)	1500 iu, ea	60492-0023-01	ASD, FI, OTN, OS	\$152.30

Wholesaler Information

ASD = ASD Specialty Healthcare (1-800-746-6273)
BB = Bergen Brunswig (1-800-746-6273)
FI = Florida Infusion (1-800-624-0152)
MK = McKesson (1-888-782-6156)
OS = Oncology Supply (1-800-633-7555)
OTN = Oncology Therapeutics Network (1-800-482-6700)
TRI = Triad Medical (1-800-999-8633)
ANDA = ANDA (1-800-331-2632)
Biomed Plus 3/99 = Biomed Plus, Inc. (1-800-809-2308)
FFF = FFF Enterprises (1-800-843-7477)
Bayer Wholesale = Bayer Wholesale (1-203-812-2000)
Health Coalition = Health Coalition (1-800-456-7283)

Attachment 2 - Do not use these data to update the HCPCS billing codes that correspond to the drugs on this list. Instead, use your usual source for average wholesale prices.

<u>Drug Name</u>	<u>Prod/Mfr</u>	<u>Measurements</u>	<u>NDC</u>	<u>Wholesaler</u>	<u>Average Wholesale (AWP)</u>
Anti-Inhibitor Coagulant Complex	(NABI) AutoPlex T/PDI, IJ (390-1050 FECU)	ea	59730-6059-07	Biomed Plus 3/99	1.06
Anzemet/Dolasetron Mesylate	(Hoechst Marion)/INJ, IJ (VIAL)	20 mg/ml, 5 ml	00088-1206-32	OS	\$74.08
Bleomycin Sulfate	(Bristol-Myer Onc/Imm) Blexonane/PDI, IJ (VL)	15 u, ea	00015-3010-20	FI, OS, ASD	\$255.39
Bleomycin Sulfate	(Bristol-Myer Onc/Imm) Blexonane/PDI, IJ (VL)	30 u, ea	00015-3063-01	FI, OS	\$509.29
Bleomycin Sulfate	(Pharmacia/Upjohn)/PD I, IJ (VIAL)	15 u, ea	00013-1616-78	ASD, FI, OS	\$158.67
Bleomycin Sulfate	(Pharmacia/Upjohn)/PD I, IJ (VIAL)	30 u, ea	00013-1636-86	ASD, FI, OS	\$322.00
Cisplatin	(APP)/INJ, IJ	1 mg/ml, 50 mg, 50 ml	63323-0103-51	OS, FI	\$150.98
Cisplatin	(APP)/INJ, IJ	1 mg/ml, 200 mg, 200 ml	63323-0103-64	OS, FI	\$603.50
Cisplatin	(APP)/INJ, IJ	1 mg/ml, 100 mg, 100 ml	63323-0103-65	OS, FI	\$301.50
Cyclophosphamide	(Bristol-Myer Onc/Imm) Cytoxan Lyophilized/PDI, IJ (VIAL)	100 mg, ea	00015-0539-41	ASD, OS, OTN	\$4.18
Cyclophosphamide	(Bristol-Myer Onc/Imm) Cytoxan Lyophilized/PDI, IJ (VIAL)	200 mg, ea	00015-0546-41	ASD, OS, OTN	\$7.03
Cyclophosphamide	(Bristol-Myer Onc/Imm) Cytoxan Lyophilized/PDI, IJ (VIAL)	500 mg, ea	00015-0547-41	ASD, OS, OTN	\$11.59
Cyclophosphamide	(Bristol-Myer Onc/Imm) Cytoxan Lyophilized/PDI, IJ (VIAL)	1gm, ea	00015-0548-41	ASD, OS, OTN	\$23.19
Cyclophosphamide	(Bristol-Myer Onc/Imm) Cytoxan Lyophilized/PDI, IJ (VIAL)	2 gm, ea	00015-0549-41	ASD, OS, OTN	\$45.83
Cyclophosphamide	(Pharmacia/Upjohn) Neosar/PDI, IJ, (S.D.V.)	100 mg, ea	00013-5606-93	ASD, OTN, OS, FI	\$3.92
Cyclophosphamide	(Pharmacia/Upjohn) Neosar/PDI, IJ, (S.D.V.)	200 mg, ea	00013-5616-93	ASD, FI, OS, OTN	\$5.06
Cyclophosphamide	(Pharmacia/Upjohn) Neosar/PDI, IJ, (S.D.V.)	500 mg, ea	00013-5626-93	ASD, FI, OS, OTN	\$7.33

<i>Cyclophosphamide</i>	(Pharmacia/Upjohn) Neosar/PDI, IJ, (S.D.V.)	1 gm, ea	00013-5636-70	ASD, Fl, OTN, OS	\$11.24
<i>Cyclophosphamide</i>	(Pharmacia/Upjohn) Neosar/PDI, IJ, (S.D.V.)	2 gm, ea	00013-5646-70	ASD, Fl, OTN, OS	\$21.60
<i>Cytarabine</i>	(Bedford)/PDI, IJ (VIAL)	100 mg, ea	55390-0131-10	ASD, OS, Fl, MK, BB, OTN	\$3.55
<i>Cytarabine</i>	(Bedford)/PDI, IJ (VIAL)	500 mg, ea	55390-0132-10	ASD, OS, Fl, OTN, MK, BB	\$11.46
<i>Cytarabine</i>	(Bedford)/PDI, IJ (VIAL)	1 gm, ea	55390-0133-01	ASD, OS, Fl, OTN, MK, BB	\$23.64
<i>Cytarabine</i>	(Bedford)/PDI, IJ (VIAL)	2 gm, ea	55390-0134-01	ASD, OS, Fl, OTN, BB, MK	\$47.94
<i>Cytarabine</i>	(Bedford)/PDI, IJ (VIAL)	100 mg, ea	55390-0806-10	BB	\$3.50
<i>Cytarabine</i>	(Bedford)/PDI, IJ (VIAL)	500 mg, ea	55390-0807-10	BB	\$10.50
<i>Cytarabine</i>	(Bedford)/PDI, IJ (VIAL)	1 gm, ea	55390-0808-01	BB	\$22.00
<i>Cytarabine</i>	(Bedford)/PDI, IJ (VIAL)	2 gm, ea	55390-0809-01	BB	\$44.00
<i>Cytarabine</i>	(Faulding)/INJ, IJ (S.D.V.,P.F.)	(P.F., BULK PACKAGE) 20 mg/ml, 50 ml	61703-0303-50	BB, MK	\$39.00
<i>Cytarabine</i>	(Faulding)/INJ, IJ (S.D.V.,P.F.)	20 mg/ml, 25 ml	61703-0304-25	ASD, BB, Fl, OS	\$12.63
<i>Cytarabine</i>	(Faulding)/INJ, IJ (S.D.V.,P.F.)	20 mg/ml, 5 ml (M.D.V.)	61703-0305-09	BB, MK, Fl	\$4.62
<i>Cytarabine</i>	(Pharmacia/Upjohn) Cytosar-U/PDI, IJ (M.D.V.)	100 mg, ea	00009-0373-01	ASD, OS, OTN, Fl, MK	\$4.06
<i>Cytarabine</i>	(Pharmacia/Upjohn) Cytosar-U/PDI, IJ (M.D.V.)	500 mg, ea	00009-0473-01	ASD, OS, OTN, Fl, MK	\$13.18
<i>Cytarabine</i>	(Pharmacia/Upjohn) Cytosar-U/PDI, IJ (M.D.V.)	30 ml vial, 1 gm, ea	00009-3295-01	ASD, OS, OTN, Fl, MK	\$25.11
<i>Cytarabine</i>	(Pharmacia/Upjohn) Cytosar-U/PDI, IJ (M.D.V.)	2 gm, ea	00009-3296-01	ASD, OS, OTN, Fl, MK	\$49.82
<i>Cytarabine</i>	(Schein)/PDI, IJ (M.D.V.)	100 mg, ea	00364-2467-53	BB, MK	\$4.16
<i>Cytarabine</i>	(Schein)/PDI, IJ (M.D.V.)	500 mg, ea	00364-2468-54	BB, MK, OTN	\$12.14
<i>Doxorubicin Hydrochloride</i>	(Bedford)/INJ, IJ (M.D.V.)	2 mg/ml, 100 ml	55390-0238-01	Fl, OTN	\$139.75
<i>Doxorubicin Hydrochloride</i>	(Bedford)/INJ, IJ (S.D.V.)	2 mg/ml, 5 ml	55390-0235-10	Fl, OTN	\$10.35
<i>Doxorubicin Hydrochloride</i>	(Bedford)/INJ, IJ (S.D.V.)	10 ml	55390-0236-10	Fl, OTN	\$20.20
<i>Doxorubicin Hydrochloride</i>	(Bedford)/INJ, IJ (S.D.V.)	25 ml	55390-0237-01	Fl, OTN, OS	\$37.97
<i>Doxorubicin Hydrochloride</i>	(Bedford)/PDI, IJ (S.D.V.)	10 mg	55390-0231-10	Fl, OTN	\$9.68
<i>Doxorubicin Hydrochloride</i>	(Bedford)/PDI, IJ (S.D.V.)	20 mg	55390-0232-10	Fl, OTN	\$18.48
<i>Doxorubicin Hydrochloride</i>	(Bedford)/PDI, IJ (S.D.V.)	50 mg, ea	55390-0233-01	Fl, OTN, OS	\$35.92
<i>Doxorubicin Hydrochloride</i>	(Fujisawa/APP)/(VIAL)	2 mg/ml, 100 ml	00469-1001-61	ASD	\$140.00

<i>Doxorubicin Hydrochloride</i>	(Fujisawa/APP)/(VIAL)	2 mg/ml, 100 ml	63323-0101-61	OS	\$117.17
<i>Doxorubicin Hydrochloride</i>	(Fujisawa/APP)/INJ, IJ (S.D.V., P.F.)	2 mg/ml, 5 ml	00469-8830-20	OS	\$7.35
<i>Doxorubicin Hydrochloride</i>	(Fujisawa/APP)/INJ, IJ (S.D.V., P.F.)	10 ml	00469-8831-30	OS	\$14.70
<i>Doxorubicin Hydrochloride</i>	(Fujisawa/APP)/INJ, IJ (S.D.V., P.F.)	25 ml	00469-8832-50	ASD	\$35.00
<i>Doxorubicin Hydrochloride</i>	(Fujisawa/APP)/INJ, IJ (S.D.V., P.F.)	2 mg/ml, 5 ml	63323-0883-05	OS	\$7.35
<i>Doxorubicin Hydrochloride</i>	(Fujisawa/APP)/INJ, IJ (S.D.V., P.F.)	10 ml	63323-0883-10	OS	\$14.70
<i>Doxorubicin Hydrochloride</i>	(Fujisawa/APP)/INJ, IJ (S.D.V., P.F.)	25 ml	63323-0883-30	ASD	\$34.00
<i>Doxorubicin Hydrochloride</i>	(Gensia)/(M.D.V. POLYMER)	2 mg/ml, 100 ml	00703-5040-01	ASD, OS	\$142.00
<i>Doxorubicin Hydrochloride</i>	(Gensia)/INJ, IJ (S.D.V. POLYMER)	2 mg/ml, 5 ml	00703-5043-03	ASD, OS, BB	\$12.63
<i>Doxorubicin Hydrochloride</i>	(Gensia)/INJ, IJ (S.D.V. POLYMER)	25 ml	00703-5046-01	ASD, OS	\$35.50
<i>Doxorubicin Hydrochloride</i>	(Pharmacia/Upjohn) Adriamycin/(M.D.V. P.F.)	2 mg/ml, 100 ml	00013-1166-83	ASD, OS, FI, OTN	\$150.86
<i>Doxorubicin Hydrochloride</i>	(Pharmacia/Upjohn) Adriamycin/(M.D.V.)	150 mg, ea	00013-1116-83	ASD, OS, FI, OTN	\$113.75
<i>Doxorubicin Hydrochloride</i>	(Pharmacia/Upjohn) Adriamycin/PFS INJ, IJ (VIAL, P.F.)	2 mg/ml, 5 ml	00013-1136-91	ASD, OS, FI, OTN	\$8.49
<i>Doxorubicin Hydrochloride</i>	(Pharmacia/Upjohn) Adriamycin/PFS INJ, IJ (VIAL, P.F.)	10 ml	00013-1146-91	ASD, OS, FI, OTN	\$16.74
<i>Doxorubicin Hydrochloride</i>	(Pharmacia/Upjohn) Adriamycin/PFS INJ, IJ (VIAL, P.F.)	25 ml	00013-1156-79	ASD, FI, OTN	\$37.80
<i>Doxorubicin Hydrochloride</i>	(Pharmacia/Upjohn) Adriamycin/PFS INJ, IJ (VIAL, P.F.)	37.500 ml	00013-1176-87	ASD, FI, OTN, OS	\$59.59
<i>Doxorubicin Hydrochloride</i>	(Pharmacia/Upjohn) Adriamycin/RDF PDI, IJ	10 mg, ea	00013-1086-91	ASD, FI, OTN, OS	\$8.24
<i>Doxorubicin Hydrochloride</i>	(Pharmacia/Upjohn) Adriamycin/RDF PDI, IJ	50 mg, ea	00013-1106-79	ASD, OS, FI, OTN	\$37.15
<i>Etoposide</i>	(Bedford)/INJ, IJ (M.D.V.)	20 mg/ml, 5 ml	55390-0291-01	FI, OS	\$8.45
<i>Etoposide</i>	(Bedford)/INJ, IJ (M.D.V.)	25 ml	55390-0292-01	FI, OS	\$45.13
<i>Etoposide</i>	(Bedford)/INJ, IJ (M.D.V.)	50 ml	55390-0293-01	OS, FI	\$87.43
<i>Etoposide</i>	(Bristol-Myer Onc/Imm) Vepesid/INJ, IJ (M.D.V.)	7.5 ml	00015-3084-20	OS	\$51.45
<i>Etoposide</i>	(Bristol-Myer Onc/Imm) Vepesid/INJ, IJ (M.D.V.)	20 mg/ml, 5 ml	00015-3095-20	OS	\$34.30
<i>Etoposide</i>	(Gensia)/(BULK PACKAGE)	20 mg/ml, 50 ml	00703-5668-01	ASD, OS	\$78.63
<i>Etoposide</i>	(Gensia)/(M.D.V.)	20 mg/ml, 25 ml	00703-5646-01	ASD, OS	\$40.00

<i>Etoposide</i>	(Gensia)/INJ, IJ (M.D.V., POLYMER)	20 mg/ml, 5 ml	00703-5653-01	ASD, OS	\$7.00
<i>Etoposide</i>	(Pharmacia/Upjohn) Toposar/INJ, IJ (M.D.V.)	20 mg/ml, 5 ml	00013-7336-91	ASD, OS, FI	\$9.47
<i>Etoposide</i>	(Pharmacia/Upjohn) Toposar/INJ, IJ (M.D.V.)	10 ml	00013-7346-94	ASD, OS, FI	\$19.00
<i>Etoposide</i>	(Pharmacia/Upjohn) Toposar/INJ, IJ (M.D.V.)	25 ml	00013-7356-88	ASD, OS, FI	\$44.00
<i>Factor IX</i>	(Centeon) Mononine/Factor IX Coagulation Factor PDI, IJ	1 iu, ea	00053-7668-01	ASD 3/99	\$0.79
<i>Factor IX</i>	(Centeon) Mononine/Factor IX Coagulation Factor PDI, IJ	1 iu, ea	00053-7668-02	ASD 3/99	\$0.79
<i>Factor IX</i>	(Centeon) Mononine/Factor IX Coagulation Factor PDI, IJ	1 iu, ea	00053-7668-04	ASD 3/99	\$0.79
<i>Factor IX</i>	(Genetics Inst.) Benefix/Factor IX Coagulation Factor PDI, IJ (S.D.V. w/diluent, 1000 iu)	1 iu, ea	58394-0001-01	ASD 2/00	\$0.81
<i>Factor IX</i>	(Genetics Inst.) Benefix/Factor IX Coagulation Factor PDI, IJ (S.D.V. w/diluent, 1000 iu)	1 iu, ea	58394-0002-01	ASD 2/00	\$0.81
<i>Factor IX</i>	(Genetics Inst.) Benefix/Factor IX Coagulation Factor PDI, IJ (S.D.V. w/diluent, 1000 iu)	1 iu, ea	58394-0003-01	ASD 2/00	\$0.81
<i>Factor VIII</i>	(Baxter Hyland/Immuno) Recombinant/anti-hemophilic factor, human PDI, IJ (approx. 1000 iu/Vial)	1 iu, ea	00944-2938-01	Biomed Plus, all sizes, 3/99	\$0.92
<i>Factor VIII</i>	(Baxter Hyland/Immuno) Recombinant/anti-hemophilic factor, human PDI, IJ (approx. 1000 iu/Vial)	1 iu, ea	00944-2938-02	Biomed Plus, all sizes, 3/99	\$0.92
<i>Factor VIII</i>	(Baxter Hyland/Immuno) Recombinant/anti-hemophilic factor, human PDI, IJ (approx. 1000 iu/Vial)	1 iu, ea	00944-2938-03	ASD, all sizes 3/99	\$0.78
<i>Factor VIII</i>	(Bayef Pharm) Koate HP/anti-Hemophilic factor, human PDI, IJ (approx 1000 u/Vial)	1 iu, ea	00026-0664-50	ASD all sizes 3/99	\$0.42

<i>Factor VIII</i>	(Bayer Pharm) Koate HP/anti-hemophilic factor, human PDI, IJ (approx 1500 u/Vial)	1 iu, ea	00026-0664-60	ASD all sizes 3/99	\$0.42
<i>Factor VIII</i>	(Bayer Pharm) Koate HP/anti-hemophilic factor, human PDI, IJ (approx 250 u/Vial)	1 iu, ea	00026-0664-20	ASD all sizes 3/99	\$0.42
<i>Factor VIII</i>	(Bayer Pharm) Koate HP/anti-hemophilic factor, human PDI, IJ (approx 500 u/Vial)	1 iu, ea	00026-0664-30	ASD all sizes 3/99	\$0.42
<i>Factor VIII</i>	(Bayer Pharm) Kogenate/anti-hemophilic factor, recombinant PDI, IJ	1 iu, ea	00026-0670-20	Biomed Plus, all sizes, 3/99	\$0.92
<i>Factor VIII</i>	(Bayer Pharm) Kogenate/anti-hemophilic factor, recombinant PDI, IJ	1 iu, ea	00026-0670-30	Biomed Plus, all sizes, 3/99	\$0.92
<i>Factor VIII</i>	(Bayer Pharm) Kogenate/anti-hemophilic factor, recombinant PDI, IJ	1 iu, ea	00026-0670-50	Biomed Plus, all sizes, 3/99	\$0.92
<i>Factor VIII</i>	(Centeon) Bioclate/anti-hemophilic factor, recombinant PDI, IJ	1 iu, ea	00053-8110-01	Biomed Plus, all sizes 3/99	\$0.91
<i>Factor VIII</i>	(Centeon) Bioclate/anti-hemophilic factor, recombinant PDI, IJ	1 iu, ea	00053-8110-02	(unit) FFF, 8/99	\$0.86
<i>Factor VIII</i>	(Centeon) Bioclate/anti-hemophilic factor, recombinant PDI, IJ	1 iu, ea	00053-8110-04	ASD, all sizes 3/99	\$0.78
<i>Factor VIII</i>	(Centeon) Helixate/anti-hemophilic factor, recombinant PDI, IJ	1 iu, ea	00053-8120-01	ASD, all sizes 3/99	\$0.78
<i>Factor VIII</i>	(Centeon) Helixate/anti-hemophilic factor, recombinant PDI, IJ	1 iu, ea	00053-8120-02	(unit) FFF, 8/99	\$0.86
<i>Factor VIII</i>	(Centeon) Helixate/anti-hemophilic factor, recombinant PDI, IJ	1 iu, ea	00053-8120-04	Biomed Plus, all sizes 3/99	\$0.91
<i>Factor VIII</i>	(Centeon) Monoclate-P/anti-hemophilic factor, human PDI, IJ	1 iu, ea	00053-7656-01	ASD all sizes 2/00	\$0.70
<i>Factor VIII</i>	(Centeon) Monoclate-P/anti-hemophilic factor, human PDI, IJ	1 iu, ea	00053-7656-02	ASD all sizes 2/00	\$0.70
<i>Factor VIII</i>	(Centeon) Monoclate-P/anti-hemophilic factor, human PDI, IJ	1 iu, ea	00053-7656-04	ASD all sizes 2/00	\$0.70
<i>Fluorouracil</i>	(Fujisawa/APP)/INJ, IJ (VIAL)	50 mg/ml, 10 ml	63323-0117-10	OS, FI	\$1.20
<i>Fluorouracil</i>	(Fujisawa/APP)/INJ, IJ (VIAL)	1grn, 20 ml	63323-0117-20	OS, FI	\$2.60

<i>Fluorouracil</i>	(Fujisawa/APP)/INJ, IJ (VIAL)	2.5 gm, 50 ml	63323-0117-51	OS, FI	\$6.00
<i>Fluorouracil</i>	(Fujisawa/APP)/INJ, IJ (VIAL)	5 gm, 100 ml	63323-0117-61	OS, FI	\$11.00
<i>Fluorouracil</i>	(Pharmacia/Upjohn) Adrucil/INJ, IJ (VIAL)	50 mg/ml, 10 ml	00013-1036-91	ASD, OS, OTN, FI	\$1.47
<i>Fluorouracil</i>	(Pharmacia/Upjohn) Adrucil/INJ, IJ (VIAL)	50 ml	00013-1046-94	ASD, OTN, FI	\$8.15
<i>Fluorouracil</i>	(Pharmacia/Upjohn) Adrucil/INJ, IJ (VIAL)	100 ml	00013-1056-94	ASD, OTN, FI, OS	\$14.44
<i>Kytril</i>	(SK Beecham Pharm.)/INJ, IJ (S.D.V.)	1 mg/ml, 1 ml	00029-4149-01	FI, OS, OTN, ASD	\$139.04
<i>Kytril</i>	(SK Beecham Pharm.)/INJ, IJ (S.D.V.)	1 mg/ml, 4 ml	00029-4152-01	FI, OTN, ASD, OS	\$555.67
<i>Leucovorin Calcium</i>	(Abbott Hosp.)/(VIAL, FLIPTOP 30 ML)	10 mg/ml, 25 ml	00074-4541-04	FI, OTN, ASD, OS	\$8.56
<i>Leucovorin Calcium</i>	(Abbott Hosp.)/INJ, IJ (VIAL, FLIPTOP)	10mg/ml, 10ml	00074-4541-02	FI, OTN, OS	\$3.85
<i>Leucovorin Calcium</i>	(Bedford)/PDI, IJ (VIAL)	50 mg, 10s ea	55390-0051-10	FI, OTN, ASD, OS	\$2.76
<i>Leucovorin Calcium</i>	(Bedford)/PDI, IJ (VIAL)	100 mg, 10s ea	55390-0052-10	FI, OTN, ASD, OS	\$3.24
<i>Leucovorin Calcium</i>	(Bedford)/PDI, IJ (VIAL)	200 mg, ea	55390-0053-01	FI, OTN, ASD, OS	\$8.19
<i>Leucovorin Calcium</i>	(Gensia)/PDI, IJ (P.F. VIAL)	100 mg, ea	00703-5140-01	OTN, ASD, OS	\$3.49
<i>Leucovorin Calcium</i>	(Gensia)/PDI, IJ (P.F. VIAL)	350 mg, ea	00703-5145-01	OTN, ASD, OS	\$15.83
<i>Leucovorin Calcium</i>	(Immunex)/PDI, IJ (P.F.)	350 mg, ea	58406-0623-07	OTN, FI, OS	\$14.58
<i>Methotrexate Sodium</i>	(Bedford)/INJ, IJ (S.D.V.)	25 mg/ml, 2 ml, ea	55390-0031-10	ASD, OTN, FI	\$2.63
<i>Methotrexate Sodium</i>	(Bedford)/INJ, IJ (S.D.V.)	25 mg/ml, 4 ml, ea	55390-0032-10	ASD, OTN, FI	\$3.65
<i>Methotrexate Sodium</i>	(Bedford)/INJ, IJ (S.D.V.)	25 mg/ml, 8 ml, ea	55390-0033-10	ASD, OTN, FI	\$5.03
<i>Methotrexate Sodium</i>	(Bedford)/INJ, IJ (S.D.V.)	25 mg/ml, 10 ml, ea	55390-0034-10	ASD, OTN, FI	\$5.70
<i>Methotrexate Sodium</i>	(Immunex) LPF/INJ, IJ (S.D.V., P.F.)	25 mg/ml, 8 ml	58406-0683-12	ASD, OS, OTN, FI	\$5.84
<i>Methotrexate Sodium</i>	(Immunex) LPF/INJ, IJ (S.D.V., P.F.)	25 mg/ml, 2 ml	58406-0683-15	ASD, ASD, OS, FI	\$2.91
<i>Methotrexate Sodium</i>	(Immunex) LPF/INJ, IJ (S.D.V., P.F.)	25 mg/ml, 10 ml	58406-0683-16	ASD, OTN, FI, OS	\$7.10
<i>Methotrexate Sodium</i>	(Immunex) LPF/INJ, IJ (S.D.V., P.E.)	25 mg/ml, 4 ml	58406-0683-18	FI, MK, OTN, OS	\$4.32
<i>Methotrexate Sodium</i>	(Immunex)/INJ, IJ (VIAL, L.P.P.)	25 mg/ml, 2 ml	58406-0681-14	ASD, OS, OTN, FI	\$3.43
<i>Methotrexate Sodium</i>	(Immunex)/PDI, IJ (S.D.V.)	1 gm, ea	58406-0671-05	OS, OTN, MK	\$45.97
<i>Vinblastine Sulfate</i>	(Bedford)/PDI, IJ (VIAL)	10 mg, ea	55390-0091-10	ASD, OS, OTN, FI	\$8.19
<i>Vinblastine Sulfate</i>	(Faulding)/INJ, IJ (VIAL)	10 mg, ea	61703-0310-18	ASD	\$7.95

<i>Vinblastine Sulfate</i>	(Fujisawa/APP)	1 mg/ml, 10 ml	00469-2780-30	ASD, OS	\$9.00
<i>Vinblastine Sulfate</i>	(Fujisawa/APP)	1 mg/ml, 10 ml	63323-0278-10	OTN, FI	\$10.93
<i>Vincristine Sulfate</i>	(Faulding)/INJ, IJ (S.D.V., P.F.)	1 mg/ml, 1 ml	61703-0309-06	ASD, OS, OTN, FI	\$4.34
<i>Vincristine Sulfate</i>	(Faulding)/INJ, IJ (S.D.V., P.F.)	1 mg/ml, 2 ml	61703-0309-16	ASD, OS, OTN, FI	\$7.60
<i>Vincristine Sulfate</i>	(Pharmacia/Upjohn) Vincasar/INJ, IJ (VIAL)	1 mg/ml, 1 ml	00013-7456-86	ASD, OTN, FI, OS	\$5.10
<i>Vincristine Sulfate</i>	(Pharmacia/Upjohn) Vincasar/INJ, IJ (VIAL)	1 mg/ml, 2 ml	00013-7466-86	ASD, OTN, FI, OS	\$8.35
<i>Zofran</i>	(Cerenex)/INJ, IJ (M.D.V.)	2 mg/ml, 20 ml	000173-0442-00	FI, OTN, ASD, OS	\$169.06
<i>Zofran</i>	(Cerenex)/INJ, IJ (PREMIXED BAG)	30 mg/50ml, 50 ml	000173-0461-00	FI, OTN, FI, OS	\$128.09
<i>Zofran</i>	(Cerenex)/INJ, IJ (S.D.V.)	2 mg/ml, 2 ml	000173-0442-02	FI, OTN, OS	\$22.61

REPORTED AWP's, MARKET PRICES AND SPREADS - 2001-2003 - NDCs WITH \$10,000+ IDAHO MEDICAID REIMBURSEMENTS 2001-2003

Defendant	NDC	Drug	Year-end	Avg	Avg	Year-end	Avg	Avg	Year-end	Avg	Avg	Year-end	Avg	Avg	
			Reported	Reported	Market	Mkt Price	Reported	Reported	Market	Mkt Price	Spread	FDB AWP	FDB AWP	AWP	
			FDB AWP	FDB AWP	Price	Mkt Price	FDB AWP	FDB AWP	Price	Mkt Price	Spread	FDB AWP	FDB AWP	AWP	
ALPHARMA	00228260611	ACYCLOVIR	2.170	2.170	0.181	1097%	2.170	2.170	0.455	376%	2.170	2.170	0.159	1252%	
	00228233996	CARB/LEV0	0.760	0.760	0.744	0.254	192%	0.760	0.760	0.258	194%	0.760	0.760	0.259	193%
	00228214396	CARBAMAZEPIN	0.221	0.221	0.221	0.067	231%	0.221	0.221	0.068	226%	0.221	0.221	0.071	211%
	00228300311	CLONAZEPAM	0.749	0.749	0.660	1141%	0.749	0.749	0.056	1231%	0.749	0.749	0.040	1759%	
	00228300350	CLONAZEPAM	0.711	0.711	0.652	1257%	0.711	0.711	0.039	1730%	0.711	0.711	0.032	2122%	
	00228300411	CLONAZEPAM	0.855	0.855	0.855	0.064	129%	0.855	0.051	1565%	0.855	0.855	0.045	1810%	
	00228300450	CLONAZEPAM	0.813	0.813	0.813	0.058	1290%	0.813	0.054	1400%	0.813	0.813	0.039	1286%	
	00228300511	CLONAZEPAM	1.184	1.184	1.184	0.082	1346%	1.184	1.184	0.082	1343%	1.184	1.184	0.088	1251%

tabbies®

EXHIBIT

B

REPORTED AWP'S, MARKET PRICES AND SPREADS - 2001-2003 - NDCs WITH \$10,000+ IDAHO MEDICAID REIMBURSEMENTS 2001-2003

Defendant	NDC	Drug	Year-end	Avg	Avg	AWP	Year-end	Avg	Avg	Mkt. Price	Market												
			Reported FDB AWP	Reported FDB AWP	Market Price	Mkt. Price	Reported FDB AWP	Reported FDB AWP	Market Price	Mkt. Price	Reported FDB AWP	Reported FDB AWP	Market Price	Mkt. Price	Reported FDB AWP	Reported FDB AWP	Market Price	Mkt. Price	Reported FDB AWP	Reported FDB AWP	Market Price	Mkt. Price	Spread 2003
ALPHARMA	00228258809	DILTIAZEM	1.198	1.189	0.653	82%	1.198	1.198	0.631	90%	1.198	1.198	0.628	91%	1.198	1.198	0.628	91%	1.198	1.198	0.628	91%	91%
	00228257709	DILTIAZEM	1.446	1.434	0.788	82%	1.446	1.446	0.764	89%	1.446	1.446	0.756	91%	1.446	1.446	0.756	91%	1.446	1.446	0.756	91%	95%
	00228257309	DILTIAZEM	2.051	2.035	1.114	83%	2.051	2.051	1.074	91%	2.051	2.051	1.051	95%	2.051	2.051	1.051	95%	2.051	2.051	1.051	95%	96%
	00228257909	DILTIAZEM	2.658	2.637	1.446	82%	2.658	2.658	1.379	93%	2.658	2.658	1.358	96%	2.658	2.658	1.358	96%	2.658	2.658	1.358	96%	232%
	00228263211	ETODOLAC	1.465	1.465	0.589	149%	1.465	1.465	0.673	118%	1.465	1.465	0.442	232%	1.465	1.465	0.442	232%	1.465	1.465	0.442	232%	232%
	00228267111	ETODOLAC CR	1.402	1.402	0.974	44%	1.402	1.402	1.402	46%	1.402	1.402	1.003	40%	1.402	1.402	1.003	40%	1.402	1.402	1.003	40%	40%
	00228271311	ISOSORB MONO	1.291	1.291	0.285	352%	1.291	1.291	1.360	573%	1.291	1.291	1.448	429%	1.291	1.291	1.448	429%	1.291	1.291	1.448	429%	429%
	00228271350	ISOSORB MONO	1.093	1.093	0.213	413%	1.093	1.093	1.448	1448	1.093	1.093	1.448	1383%	1.093	1.093	1.448	1383%	1.093	1.093	1.448	1383%	1383%
	00228271150	ISOSORB MONO	1.151	1.151	0.122	842%	1.151	1.151	1.524	1.524	1.151	1.151	1.524	1.524	1.081	1.081	1.524	1.524	1.081	1.081	1.524	1.524	1775%
	00228205750	LORAZEPAM	0.662	0.662	0.109	509%	0.662	0.662	0.662	595%	0.662	0.662	0.662	589%	0.662	0.662	0.662	589%	0.662	0.662	0.662	589%	589%
	00228205910	LORAZEPAM	0.883	0.883	0.137	545%	0.883	0.883	0.146	503%	0.883	0.883	0.150	487%	0.883	0.883	0.150	487%	0.883	0.883	0.150	487%	487%
	00228205950	LORAZEPAM	0.862	0.862	0.127	581%	0.862	0.862	0.122	506%	0.862	0.862	0.101	755%	0.862	0.862	0.101	755%	0.862	0.862	0.101	755%	755%
	00228206310	LORAZEPAM	1.285	1.285	0.194	563%	1.285	1.285	1.195	559%	1.285	1.285	1.231	456%	1.285	1.285	1.231	456%	1.285	1.285	1.231	456%	456%
	00228271811	METFORMIN																					
	00228265711	METFORMIN																					
	00228208550	PROPO-N/APAP	0.535	0.535	0.130	310%	0.535	0.535	0.102	426%	0.535	0.535	0.110	386%	0.535	0.535	0.110	386%	0.535	0.535	0.110	386%	386%
	00228267311	SPRINOLACT	1.424	1.424	0.865	65%	1.424	1.424	0.862	65%	1.424	1.424	0.782	82%	1.424	1.424	0.782	82%	1.424	1.424	0.782	82%	82%
	00228267211	SPRINOLACT	0.816	0.816	0.487	67%	0.816	0.816	0.499	64%	0.816	0.816	0.455	79%	0.816	0.816	0.455	79%	0.816	0.816	0.455	79%	79%
	00228274115	TIZANIDINE																					
	00472008216	ACYCLOVIR	0.212	0.212	0.152	39%	0.231	0.228	0.173	32%	0.251	0.241	0.183	31%	0.251	0.241	0.183	31%	0.251	0.241	0.183	31%	31%
	00472008216	ALBUTEROL	0.412	0.412	0.066	524%	0.412	0.412	0.062	568%	0.412	0.412	0.060	586%	0.412	0.412	0.060	586%	0.412	0.412	0.060	586%	586%
	00472083160	ALBUTEROL	0.412	0.412	0.063	553%	0.412	0.412	0.072	468%	0.412	0.412	0.069	497%	0.412	0.412	0.069	497%	0.412	0.412	0.069	497%	497%
	00472082516	ALBUTEROL	0.065	0.065	0.014	360%	0.085	0.085	0.020	302%	0.085	0.085	0.019	338%	0.085	0.085	0.019	338%	0.085	0.085	0.019	338%	338%
	00472141916	APAP/CODEINE	0.039	0.039	0.039	33%	0.039	0.039	0.039	31%	0.039	0.039	0.039	228%	0.039	0.039	0.039	228%	0.039	0.039	0.039	228%	228%
	00472135832	CONSTULOSE	0.064	0.064	0.008	737%	0.064	0.068	0.067	405%	0.068	0.068	0.015	360%	0.068	0.068	0.015	360%	0.068	0.068	0.015	360%	360%
	00472136016	ENULOSE	0.072	0.072	0.007	924%	0.072	0.076	0.076	565%	0.076	0.076	0.011	601%	0.076	0.076	0.011	601%	0.076	0.076	0.011	601%	601%
	00472075123	IPRATROPIUM	0.904	0.904	0.256	253%	0.904	0.904	0.904	488%	0.904	0.904	0.163	455%	0.904	0.904	0.163	455%	0.904	0.904	0.163	455%	455%
	00472075160	IPRATROPIUM	0.792	0.792	0.211	274%	0.792	0.792	0.792	292%	0.792	0.792	0.792	250%	0.792	0.792	0.792	250%	0.792	0.792	0.792	250%	250%
	00472132002	NYSTATIN	0.250	0.185	0.036	409%	0.273	0.269	0.059	353%	0.273	0.273	0.067	306%	0.273	0.273	0.067	306%	0.273	0.273	0.067	306%	306%
	00472132016	NYSTATIN	0.183	0.168	0.023	644%	0.206	0.202	0.040	405%	0.206	0.206	0.069	197%	0.206	0.206	0.069	197%	0.206	0.206	0.069	197%	197%
	00472006708	PHENYTOIN	0.130	0.130	0.092	41%	0.139	0.139	0.097	41%	0.139	0.139	0.095	46%	0.139	0.139	0.095	46%	0.139	0.139	0.095	46%	46%
	00472162916	PROMETH W/C	0.044	0.044	0.012	280%	0.091	0.091	0.036	155%	0.091	0.091	0.101	107%	0.091	0.091	0.101	107%	0.091	0.091	0.101	107%	107%
	00472162715	PROMETH/GD	0.045	0.045	0.011	305%	0.068	0.064	0.022	185%	0.068	0.068	0.023	192%	0.068	0.068	0.023	192%	0.068	0.068	0.023	192%	192%
	00472163016	PROMETHAZINE	0.031	0.029	0.009	232%	0.045	0.043	0.013	220%	0.045	0.045	0.016	182%	0.045	0.045	0.016	182%	0.045	0.045	0.016	182%	182%
	00472128516	SULFATHI	0.036	0.036	0.009	288%	0.123	0.074	0.028	164%	0.123	0.123	0.051	138%	0.123	0.123	0.051	138%	0.123	0.123	0.051	138%	138%
ASTRAZENECA	00186001631	ATACAND	1.342	1.319	1.097	20%	1.447	1.408	1.138	24%	1.543	1.502	1.190	26%	1.543	1.502	1.190	26%	1.543	1.502	1.190	26%	26%
	00186001654	ATACAND	1.342	1.319	1.103	20%	1.447	1.408	1.143	23%	1.504	1.504	1.194	26%	1.504	1.504	1.194	26%	1.504	1.504	1.194	26%	26%
	00186003231	ATACAND	1.815	1.784	1.486	20%	1.957	1.905	1.540	24%	2.088	2.088	2.033	26%	2.088	2.088	2.033	26%	2.088	2.088	2.033	26%	26%
	00186003254	ATACAND	1.815	1.785	1.494	19%	1.957	1.905	1.547	23%	2.088	2.088	2.033	26%	2.088	2.088	2.033	26%	2.088	2.088	2.033	26%	26%
	00186032254	ATACAND HCT	1.852	1.828	1.528	19%	1.996	1.943	1.576	23%	2.130	2.130	2.073	26%	2.130	2.130	2.073	26%	2.130	2.130	2.073	26%	26%
	00186151601	EMLA	1.562	1.562	1.199	30%	1.773	1.717	1.329	29%	1.749	1.749	1.754	28%	1.749	1.749	1.754	28%	1.749	1.749	1.754	28%	28%
	00186070210	ENTOCORT EC	2.167	2.167	1.802	20%	2.334	2.246	1.831	23%	2.473	2.473	2.411	26%	2.473	2.473	2.411	26%	2.473	2.473	2.411	26%	26%
	00186502031	NEXIUM	3.997	3.997	3.297	21%	4.421	4.364	3.477	25%	4.685	4.685	4.568	26%	4.685	4.685	4.568	26%	4.685	4.685	4.568	26%	26%
	00186504031	NEXIUM	3.997	3.997	3.319	20%	4.421	4.364	3.479	25%	4.685	4.685	4.568	26%	4.685	4.685	4.568	26%	4.685	4.685	4.568	26%	26%
	00186504054	NEXIUM	3.997	3.997	3.315	21%	4.421	4.364	3.482	25%	4.685	4.685	4.568	26%	4.685	4.685	4.568	26%	4.685	4.685	4.568	26%	26%

REPORTED AWP'S, MARKET PRICES AND SPREADS - 2001-2003 - MDCs WITH \$10,000+ IDAHO MEDICAID REIMBURSEMENTS 2001-2003

Defendant	NDC	Drug	Year-end	Avg	Avg	Year-end	Avg	Avg	Year-end	Avg	Avg	Year-end	Avg	Avg
			Reported FDB AWP	Reported FDB AWP	Market Price	Mkt Price	Reported FDB AWP	Reported FDB AWP	Market Price	Mkt Price	Reported FDB AWP	Reported FDB AWP	Market Price	Mkt Price
ASTRAZENECA	00186045258	PLENDIL	1.929	1.921	1.599	20%	2.189	2.120	1.695	25%	2.321	2.262	1.796	26%
	00186045158	PLENDIL	1.073	1.069	0.891	20%	1.219	1.180	0.942	25%	1.291	1.259	1.000	26%
	00186060531	PRLOSEC	3.853	3.788	3.137	21%	4.134	4.132	3.297	25%	4.134	4.134	3.290	26%
	00186060568	PRLOSEC	3.853	3.788	3.143	20%	4.134	4.132	3.298	25%	4.134	4.134	3.294	25%
	00186074228	PRLOSEC	4.301	4.228	3.465	22%	4.614	4.612	3.653	26%	4.614	4.614	3.618	26%
	00186074231	PRLOSEC	4.301	4.228	3.512	20%	4.612	3.576	25%	4.615	4.615	3.668	26%	
	00186074282	PRLOSEC	4.301	4.228	3.492	21%	4.614	4.612	3.672	26%	4.614	4.614	3.668	26%
	00186074331	PRLOSEC	6.172	6.067	5.044	20%	6.622	6.618	5.278	25%	6.622	6.622	5.269	26%
	00186074368	PRLOSEC	6.172	6.067	5.050	20%	6.622	6.618	5.278	25%	6.622	6.622	5.258	26%
	00186091542	PULMICORT	129.430	126.912	105.328	20%	146.390	137.601	111.113	24%	151.000	148.247	117.567	26%
	00186198804	PULMICORT	2.100	1.754	2.035	20%	2.375	2.234	1.809	24%	2.375	2.375	1.890	26%
	00186198804	PULMICORT	2.100	1.752	2.010	20%	2.375	2.234	1.813	23%	2.375	2.375	1.888	26%
	00186107008	RHINOCORT	6.857	6.857	5.573	23%	7.824	7.479	5.954	26%	8.292	8.084	6.418	26%
	00186109205	TOPROL XL	0.980	0.951	0.790	20%	1.106	1.057	0.855	24%	1.176	1.154	0.916	26%
	00186109405	TOPROL XL	1.959	1.902	1.572	21%	1.959	1.630	1.959	20%	1.959	1.959	1.620	21%
	00186109805	TOPROL XL	0.652	0.638	0.535	19%	0.736	0.704	0.573	23%	0.783	0.768	0.610	26%
	00186109905	TOPROL XL	0.652	0.633	0.526	20%	0.736	0.704	0.569	24%	0.783	0.768	0.610	26%
	00310040260	ACCOLATE	1.126	1.104	0.915	21%	1.260	1.243	0.987	26%	1.335	1.302	1.030	26%
	00310020130	ARIMIDEX	6.794	6.651	5.522	20%	7.574	7.335	5.838	26%	7.813	7.670	6.090	26%
	00310070530	CASODEX	12.408	12.359	10.255	21%	14.034	13.589	10.799	26%	14.476	14.212	11.250	26%
	00310048230	IRESSA											5.768	26%
	00310060060	NOLVADEX	1.899	1.892	1.466	29%	2.107	2.080	1.606	29%	2.233	2.177	1.695	28%
	00310027110	SEROQUEL	2.680	2.635	2.180	21%	2.906	2.823	2.277	24%	2.301	2.301	2.387	26%
	00310027139	SEROQUEL	2.680	2.635	2.155	22%	2.906	2.823	2.252	25%	3.101	3.018	2.343	29%
	00310027710	SEROQUEL	5.056	4.970	4.120	21%	5.483	5.325	4.305	24%	5.850	5.694	4.511	26%
	00310027710	SEROQUEL	5.056	4.970	4.148	21%	5.483	5.325	4.305	24%	5.850	5.694	4.511	26%
	00310027510	SEROQUEL	1.473	1.448	1.196	21%	1.597	1.551	1.251	24%	1.704	1.658	1.308	27%
	00310027759	SEROQUEL	1.473	1.448	1.180	23%	1.597	1.551	1.238	25%	1.704	1.658	1.283	29%
	00310027439	SEROQUEL	7.219	7.096	5.930	20%	7.219	7.05	6.05	20%	7.219	7.219	5.924	22%
	00310027460	SEROQUEL	7.219	7.096	5.952	19%	7.219	7.04	6.004	20%	7.219	7.219	5.981	21%
	00310089110	SULAR	1.002	1.002	0.834	20%	1.157	1.145	0.933	23%	1.328	1.266	1.002	26%
	00310089210	SULAR	1.002	1.002	0.834	20%	1.157	1.145	0.935	22%	1.328	1.266	1.006	26%
	00310014110	ZESTORETIC	1.129	1.105	0.906	22%	1.281	1.241	0.979	27%	1.322	1.298	1.029	26%
	00310014210	ZESTORETIC	1.222	1.196	0.983	22%	1.387	1.343	1.061	27%	1.431	1.405	1.114	26%
	00310014510	ZESTORETIC	1.236	1.210	0.994	22%	1.404	1.359	1.075	27%	1.448	1.422	1.127	26%
	00310013110	ZESTRIL	1.011	0.990	0.817	21%	1.148	1.112	0.881	26%	1.185	1.163	0.914	27%
	00310013210	ZESTRIL	1.083	1.050	0.875	21%	1.229	1.190	0.943	26%	1.268	1.245	0.974	28%
	00310013310	ZESTRIL	1.533	1.501	1.240	21%	1.741	1.685	1.334	26%	1.795	1.763	1.394	26%
	00310013410	ZESTRIL	1.584	1.550	1.275	22%	1.798	1.741	1.375	27%	1.855	1.821	1.434	27%
	00310013010	ZESTRIL	0.980	0.959	0.790	21%	1.112	1.077	0.851	27%	1.147	1.126	0.890	27%
	00310013034	ZESTRIL	0.969	0.949	0.775	22%	1.100	1.065	0.837	27%	1.135	1.114	0.813	27%
	00310021020	ZOMIG	14.448	12.009	20%	15.938	15.480	12.461	21%	17.007	16.552	13.036	27%	
	00310021125	ZOMIG	16.716	16.432	13.660	20%	18.127	17.605	14.184	24%	19.337	18.822	14.842	27%
BARR	00555097202	AMPHETAMINE	1.372	1.342	0.886	51%	1.372	1.372	0.882	56%	1.372	1.372	0.882	56%
	00555097302	AMPHETAMINE	1.372	1.342	0.888	51%	1.372	1.372	0.882	56%	1.372	1.372	0.881	56%
	00555097742	AMPHETAMINE	1.372	1.342	0.887	51%	1.372	1.372	0.882	56%	1.372	1.372	0.881	56%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - NDCs WITH \$10,000+ IDAHO MEDICAID REIMBURSEMENTS 2001-2003

Defendant	NDC	Drug	Year-end	Avg	AWP	Year-end	Avg	AWP	Year-end	Avg	AWP	Year-end	Avg	AWP	Year-end	Avg	AWP	
			Reported FDB AWP	Reported FDB AWP	Market Price	Mkt Price	Reported FDB AWP	Reported FDB AWP	Market Price	Mkt Price	Reported FDB AWP	Reported FDB AWP	Market Price	Mkt Price	Reported FDB AWP	Reported FDB AWP	Market Price	
BARR	00555097102	AMPHETAMINE	2001	0.582	0.970	1.372	1.342	0.879	53%	1.372	1.372	0.883	55%	2001	0.685	55%		
	0055504358	APRI		0.650	1.143	0.970	0.970	0.653	49%	1.043	1.041	0.685	56%					
	0055504558	AVIANE				1.076	1.076	1.166	1.181	1.166	0.791		47%					
	00555071558	CAMILA				1.076	1.076	1.319	1.319	1.319	0.883		49%					
	00555081402	CIPROFLOXACN				1.076	1.076	4.956	4.956	4.956	3.634		36%					
	00555081502	CIPROFLOXACN				1.076	1.076	5.801	5.801	5.801	4.258		36%					
	00555095602	DEXTROAMPHET				1.296	1.296	0.887	0.887	0.887	4.2%		44%					
	00555034458	ERRIN				1.296	1.296	1.319	1.319	1.319	0.903		44%					
	00555087702	FLUOXETINE		2.668	2.668	1.832	1.832	46%	1.194	1.194	123%	1.319	0.884	49%	1.319	0.884	49%	
	00555096902	FLUOXAMINE		3.034	3.034	3.034	3.034	3.034	2.668	2.668	2.668	2.668	0.110	2327%	2.668	0.110	2327%	
	00555096802	FLUVOXAMINE		2.958	2.958	2.958	2.958	2.958	2.668	2.668	2.668	2.668	2.330	25%	2.668	2.330	25%	
	00555095058	KARIVA				1.058	1.058	0.678	0.678	0.678	50%	1.100	0.712	50%	1.100	0.712	50%	
	00555048527	LEUCODOR CA		24.000	24.000	7.205	7.205	233%	24.000	24.000	246%	24.000	24.000	259%	24.000	24.000	259%	
	00555087202	MEDROXYPR AC		0.298	0.298	0.053	0.053	46%	0.298	0.298	376%	0.313	0.313	124%	0.313	0.313	124%	
	00555038102	MEPERIDINE		0.681	0.681	0.265	0.265	157%	0.681	0.681	106%	0.681	0.681	79%	0.681	0.681	79%	
	00555057202	METHOTREXATE		4.050	3.921	0.278	0.278	1308%	3.564	3.564	1361%	3.564	3.564	1257%	3.564	3.564	1257%	
	00555090201	NALTREXONE		4.275	4.275	2.128	2.128	101%	4.275	4.275	124%	4.275	4.275	127%	4.275	4.275	127%	
	00555090168	SPRINTEC 28				1.151	1.151	0.781	0.781	0.781	47%	1.151	1.151	49%	1.151	1.151	49%	
	00555044609	TAMOXIFEN		1.899	1.892	1.474	1.474	28%	2.027	1.999	1.568	1.894	1.894	1.272%	1.912	1.912	1.272%	
	00555044663	TAMOXIFEN		1.899	1.892	1.486	1.486	27%	2.027	1.999	1.573	1.894	1.894	175%	1.912	1.912	175%	
	00555090401	TAMOXIFEN		3.798	3.783	2.965	2.965	28%	4.053	3.998	3.137	3.788	3.788	283%	3.824	3.824	283%	
	00555090414	TAMOXIFEN		3.798	3.783	2.990	2.990	27%	4.053	3.998	3.151	3.788	3.788	341%	3.824	3.824	341%	
	00555073202	TRAZODONE		1.469	1.469	0.215	0.215	563%	1.469	1.469	0.202	1.469	1.469	73%	1.469	1.469	73%	
	00555083102	WARFARIN		0.583	0.583	0.256	0.256	128%	0.583	0.583	0.215	0.583	0.583	191%	0.583	0.583	191%	
	00555083202	WARFARIN		0.628	0.628	0.260	0.260	141%	0.628	0.628	0.215	0.628	0.628	230%	0.628	0.628	230%	
	00555086902	WARFARIN		0.609	0.609	0.257	0.257	137%	0.609	0.609	0.218	0.609	0.609	203%	0.609	0.609	203%	
	00555092502	WARFARIN		0.631	0.631	0.345	0.345	83%	0.631	0.631	0.237	0.631	0.631	215%	0.631	0.631	215%	
	00555087402	WARFARIN		0.633	0.633	0.277	0.277	128%	0.633	0.633	0.227	0.633	0.633	215%	0.633	0.633	215%	
	00555083302	WARFARIN		0.637	0.637	0.275	0.275	132%	0.637	0.637	0.214	0.637	0.637	226%	0.637	0.637	226%	
	00555083305	WARFARIN		0.637	0.637	0.279	0.279	129%	0.637	0.637	0.211	0.637	0.637	240%	0.637	0.637	240%	
	00555092602	WARFARIN		0.903	0.903	0.495	0.495	82%	0.903	0.903	0.359	151%	0.903	228%	0.903	0.903	228%	
	00555083402	WARFARIN		0.934	0.934	0.413	0.413	126%	0.934	0.934	0.294	0.934	0.934	241%	0.934	0.934	241%	
IVAX	00172426760	ACYLOVIR	2.169	2.169	0.108	1905%	2.169	2.169	0.092	2259%	2.169	2.169	0.096	2150%	2.169	0.096	2150%	
	00172426660	ACYLOVIR	4.216	4.216	0.232	1720%	4.216	4.216	0.195	2062%	4.216	4.216	0.208	1923%	4.216	0.208	1923%	
	00172439018	ALBUTEROL	1.752	1.730	0.547	216%	1.752	1.752	0.368	316%	1.752	1.752	0.247	610%	1.752	0.247	610%	
	00172640549	ALBUTEROL	0.412	0.412	0.054	656%	0.412	0.412	0.051	701%	0.412	0.412	0.045	813%	0.412	0.045	813%	
	00172409660	BACLOFEN	0.371	0.371	0.028	1216%	0.610	0.441	0.057	681%	0.610	0.610	0.175	248%	0.610	0.175	248%	
	00172409680	BACLOFEN	0.331	0.331	0.027	1119%	0.559	0.398	0.063	535%	0.559	0.559	0.167	234%	0.559	0.167	234%	
	00172409780	BACLOFEN	0.646	0.646	0.058	1012%	1.096	0.779	0.124	530%	1.096	1.096	0.327	236%	1.096	0.327	236%	
	00172423360	BUMETANIDE	0.425	0.425	0.088	384%	0.457	0.440	0.075	483%	0.520	0.520	0.084	520%	0.520	0.084	520%	

REPORTED AWP'S, MARKET PRICES AND SPREADS - 2001-2003 - NDCs WITH \$10,000+ IDAHO MEDICAID REIMBURSEMENTS 2001-2003

Defendant	NDC	Drug	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Market Price 2003	Avg AWP Mkt Price Spread 2003	
			FDB AWP 2001	FDB AWP 2001	Market Price 2001	Mkt Price Spread 2001	FDB AWP 2002	FDB AWP 2002	Market Price 2002	Mkt Price Spread 2002	FDB AWP 2003	FDB AWP 2003	Market Price 2003	Mkt Price Spread 2003	
IVAX	00172423460	BUMETANIDE	0.732	0.732	0.093	685%	0.772	0.750	0.091	726%	0.857	0.891	0.112	693%	
	00172566470	BUSPIRONE			1.376	0.136	915%	1.376	1.376	0.110	1.376	1.376	0.110	1146%	
	00172566560	BUSPIRONE			2.115	0.206	925%	2.115	2.115	0.169	2.115	2.115	0.169	1154%	
	00172477423	CEFACOLOR	0.341	0.341	0.591	454%	0.341	0.341	0.341	0.341	0.341	0.341	0.076	348%	
	00172405660	CEFADROXIL	3.280	3.280	1.087	0.098	1011%	1.348	1.290	0.151	752%	1.348	1.348	0.170	692%
	00172407470	CEPHALEXIN	1.114	1.087	0.98	1011%	1.348	1.290	0.151	752%	3.328	3.328	1.088	206%	
	00172436060	CLOZAPINE	3.328	3.309	1.394	137%	3.328	3.328	1.217	173%	3.328	3.328	1.088	206%	
	00172436070	CLOZAPINE	3.236	3.217	1.318	144%	3.236	3.236	1.160	179%	3.236	3.236	1.080	200%	
	00172435560	CLOZAPINE	1.285	1.277	0.517	147%	1.285	1.285	0.478	169%	1.285	1.285	0.435	196%	
	00172435970	CLOZAPINE	1.249	1.242	0.502	147%	1.249	1.249	0.457	174%	1.249	1.249	0.422	196%	
	00172292960	CYPROHEPTAD	0.427	0.421	0.146	188%	0.427	0.427	0.151	184%	0.427	0.427	0.132	222%	
	00172572860	FAMOTIDINE	1.730	1.730	0.112	1448%	1.730	1.730	0.090	1817%	1.730	1.730	0.067	2496%	
	00172572980	FAMOTIDINE	3.344	3.344	0.262	1178%	3.344	3.344	0.180	1755%	3.344	3.344	0.132	2434%	
	00172435660	FLUoxetine			2.653	0.060	4287%	2.653	2.653	0.060	4287%	2.653	2.653	0.065	3983%
	00172439260	FLUvoxamine	2.627	2.627	2.627	2.627	2.627	2.627	2.627	2.627	2.627	2.627	2.627	334%	
	00172290880	FURSEMIDE	0.138	0.138	0.022	541%	0.159	0.148	0.025	483%	0.159	0.159	0.035	359%	
	00172290780	FURESEMIDE	0.158	0.158	0.025	534%	0.179	0.167	0.030	467%	0.179	0.179	0.036	392%	
	00172208380	HYDROCHLOROT	0.077	0.077	0.010	685%	0.079	0.079	0.026	202%	0.079	0.079	0.027	194%	
	00172436560	LABETALOL	0.691	0.691	0.128	441%	0.691	0.691	0.113	512%	0.780	0.758	0.181	320%	
	00172375960	LISINOPRIL			0.984	0.934	0.122	703%	0.984	0.984	0.984	0.984	0.172	472%	
	00172376050	LISINOPRIL			1.053	1.053	0.184	471%	1.053	1.053	1.053	1.053	0.205	413%	
	00172376160	LISINOPRIL			1.540	1.540	0.342	350%	1.540	1.540	1.540	1.540	0.366	321%	
	00172375860	LISINOPRIL			0.953	0.953	0.092	930%	0.953	0.953	0.953	0.953	0.122	680%	
	00172443260	METFORMIN			1.443	1.443	0.247	484%	1.443	1.443	1.443	1.443	0.185	680%	
	00172433160	METFORMIN			0.700	0.700	0.146	381%	0.700	0.700	0.700	0.700	0.112	525%	
	00172433060	METFORMIN			1.191	1.191	0.203	485%	1.191	1.191	1.191	1.191	0.136	777%	
	00172443160	MISOPROSTOL			1.200	1.200	0.743	61%	1.200	1.200	1.200	1.200	0.667	80%	
	00172213160	NITROFUR MAC	1.198	1.198	0.308	289%	1.859	1.510	0.730	107%	1.859	1.859	1.181	57%	
	00172213060	NITROFUR MAC	0.678	0.678	0.180	276%	1.094	0.844	0.461	92%	1.094	1.094	0.692	58%	
	00172592360	NIZATIDINE			2.383	2.383	1.197	99%	2.383	2.383	2.383	2.383	1.269	88%	
	00172562460	NIZATIDINE			4.672	4.672	4.672	4.672	4.672	4.672	4.672	4.672	1.842	154%	
	00172498670	PROPO-N/APAP	0.572	0.572	0.081	605%	0.572	0.572	0.073	687%	0.572	0.572	0.065	780%	
	00172498680	PROPO-N/APAP	0.460	0.460	0.068	575%	0.460	0.460	0.063	627%	0.460	0.460	0.060	671%	
	00172477260	QUININE SULF	0.160	0.160	0.068	134%	0.775	0.337	0.177	90%	0.775	0.775	0.355	118%	
	00172655560	TRAMADOL HCL			0.834	0.834	0.134	522%	0.834	0.834	0.834	0.834	0.118	605%	
	00172428660	VERAPAMIL	1.073	0.992	0.425	133%	1.073	1.073	0.451	138%	1.073	1.073	0.412	160%	
	00172428660	VERAPAMIL	1.360	1.264	0.152	73%	1.440	1.362	0.185	637%	1.440	1.440	0.277	420%	
	00172428660	VERAPAMIL	1.556	1.446	0.156	824%	1.636	1.557	0.187	734%	1.636	1.636	0.276	492%	
	00172428070	VERAPAMIL	1.541	1.416	0.138	924%	1.689	1.545	0.179	765%	1.689	1.689	0.265	537%	
JANSSEN	50458003605	DURAGESIC	42.646	41.751	34.641	21%	50.282	46.167	37.110	24%	54.002	52.066	41.406	26%	
	50458003305	DURAGESIC	12.814	12.598	10.465	20%	14.548	13.829	11.093	25%	15.146	14.835	11.774	26%	
	50458003405	DURAGESIC	21.365	20.916	17.360	20%	24.722	23.093	18.544	25%	26.676	25.659	20.386	26%	
	50458003505	DURAGESIC	33.905	33.333	27.694	20%	38.862	36.618	29.426	24%	40.690	39.738	31.619	26%	
	50458022304	NIZORAL	0.198	0.194	0.161	20%	0.229	0.214	0.171	25%	0.243	0.236	0.186	26%	
	50458030600	REMYNL	2.160	1.794	2.499	20%	2.335	1.872	2.622	25%	2.558	2.558	2.023	26%	

REPORTED AWP'S, MARKET PRICES AND SPREADS - 2001-2003 - NDCs WITH \$10,000+ IDAHO MEDICAID REIMBURSEMENTS 2001-2003

Defendant	NDC	Drug	Avg	Avg	Avg	Avg	Avg	Avg	Avg	Avg	Avg	Avg	Avg	Avg
			Year-end Reported FDB AWP 2001	Reported FDB AWP 2001	Market Price 2001	Mkt Price 2001	Year-end Reported FDB AWP 2002	Reported FDB AWP 2002	Market Price 2002	Mkt Price 2002	Year-end Reported FDB AWP 2003	Reported FDB AWP 2003	Market Price 2003	Mkt Price 2003
JANSSEN	50458039160	REMNYL	2,160	2,160	1,790	21%	2,499	2,335	1,876	24%	2,622	2,558	2,027	26%
	5045803603	RISPERDAL	3,440	3,368	2,789	21%	3,943	3,715	2,984	25%	4,136	4,036	3,175	27%
	50458030104	RISPERDAL	2,788	2,729	2,269	20%	3,081	2,961	2,372	25%	3,125	3,125	2,477	26%
	50458030150	RISPERDAL	2,788	2,729	2,252	21%	3,081	2,961	2,363	25%	3,173	3,125	2,451	28%
	50458030206	RISPERDAL	2,788	2,729	2,268	20%	3,196	3,011	2,413	25%	3,352	3,271	2,592	26%
	5045803050	RISPERDAL	2,788	2,729	2,244	22%	3,195	3,011	2,390	26%	3,352	3,270	2,556	28%
	50458030001	RISPERDAL	2,787	2,729	2,230	22%	3,302	2,388	2,7%	27%	3,563	3,427	2,642	30%
	5045803006	RISPERDAL	2,788	2,729	2,266	20%	3,303	3,030	2,427	25%	3,564	3,428	2,715	26%
	50458030050	RISPERDAL	2,788	2,729	2,251	21%	3,302	3,030	2,406	26%	3,563	3,427	2,677	28%
	50458032001	RISPERDAL	4,640	4,542	3,713	22%	5,318	5,011	4,017	25%	5,579	5,443	4,237	28%
	50458032006	RISPERDAL	4,640	4,543	3,773	20%	5,319	5,012	3,991	26%	5,579	5,444	4,316	26%
	50458032050	RISPERDAL	4,640	4,543	3,752	21%	5,319	5,012	3,991	26%	5,579	5,444	4,291	27%
	50458033001	RISPERDAL	5,480	5,365	4,403	22%	6,431	5,951	4,714	26%	6,875	6,644	5,143	29%
	50458033006	RISPERDAL	5,480	5,365	4,454	20%	6,431	5,951	4,770	25%	6,875	6,644	5,265	28%
	50458033050	RISPERDAL	5,479	5,364	4,432	21%	6,431	5,951	4,730	26%	6,875	6,644	5,210	28%
	50458033506	RISPERDAL	7,221	7,069	5,856	21%	8,475	7,842	6,259	25%	9,145	8,796	6,935	27%
	50458029004	SPORANOX	7,778	7,615	6,318	21%	8,492	8,403	6,733	25%	9,362	9,143	7,252	26%
	50458029028	SPORANOX	7,782	7,618	6,310	21%	9,175	8,424	6,746	25%	9,845	9,496	7,528	26%
	50458029515	SPORANOX	0,815	0,789	0,659	20%	0,855	0,818	0,681	20%	0,935	0,893	0,726	23%
MCNEIL	00045025414	HALDOL DECAN	66,182	64,794	53,565	21%	76,590	71,536	57,079	25%	81,100	78,752	62,339	26%
	00045025446	HALDOL DECAN	66,182	64,794	53,690	21%	76,586	71,536	57,316	25%	81,102	78,751	62,510	26%
	00045152050	LEVAQUIN	7,599	7,468	6,184	21%	8,627	8,142	6,496	25%	9,223	8,913	7,034	27%
	00045152510	LEVAQUIN	8,929	8,774	7,018	25%	10,137	9,567	7,384	30%	10,634	10,375	7,884	32%
	00045152550	LEVAQUIN	8,875	8,722	7,228	21%	10,076	9,510	7,603	25%	10,570	10,313	8,168	26%
	00045153050	LEVAQUIN	10,820	10,633	8,890	20%	12,284	11,594	9,334	24%	16,903	14,499	11,537	26%
	00045006801	LEVACIN/DSW	0,414	0,406	0,276	47%	0,457	0,430	0,277	55%	0,457	0,457	0,286	59%
	00045009560	PANCREASE	0,462	0,452	0,370	22%	0,534	0,499	0,394	26%	0,586	0,549	0,430	28%
	00045009569	PANCREASE	0,440	0,430	0,347	24%	0,509	0,475	0,363	31%	0,589	0,523	0,414	26%
	00045034260	PANCREASE MT	0,909	0,890	0,727	22%	1,052	1,052	0,982	34%	1,114	1,081	0,858	26%
	00045034360	PANCREASE MT	1,459	1,428	1,168	22%	1,689	1,577	1,202	31%	1,788	1,736	1,375	26%
	00045034660	PANCREASE MT	1,817	1,779	1,431	24%	2,103	1,964	1,479	33%	2,227	2,162	1,720	26%
	00045034160	PANCREASE MT	0,364	0,356	0,288	24%	0,421	0,383	0,304	29%	0,446	0,433	0,344	26%
	00045081015	REGRANEX	30,543	29,902	24,859	20%	35,543	33,029	26,491	25%	35,543	35,543	28,259	26%
	00045064765	TOPAMAX	1,311	1,284	1,072	20%	1,524	1,423	1,144	24%	1,608	1,564	1,247	25%
	00045064565	TOPAMAX	1,585	1,551	1,293	20%	1,843	1,720	1,381	24%	1,943	1,891	1,505	26%
	00045064165	TOPAMAX	3,250	3,182	2,646	20%	3,778	3,527	2,826	25%	4,141	3,952	3,135	26%
	00045064265	TOPAMAX	3,805	3,725	3,059	20%	4,424	4,129	3,308	25%	4,848	4,627	3,669	26%
	00045063965	TOPAMAX	1,386	1,357	1,129	20%	1,612	1,504	1,206	25%	1,700	1,654	1,312	26%
	00045065060	ULTRACET	0,853	0,853	0,711	20%	0,977	0,921	0,742	24%	1,025	1,000	0,795	26%
	00045065960	ULTRAM	0,853	0,835	0,696	20%	1,065	0,927	0,736	26%	1,128	1,095	0,867	26%
	00045065970	ULTRAM	0,853	0,835	0,693	20%	1,065	0,927	0,731	27%	1,128	1,095	0,863	27%
MERCK	00006382210	CANCIDAS	360,000	360,000	285,702	26%	376,910	360,046	283,553	27%	388,210	380,037	295,197	29%
	00006362835	COSOPT	8,770	8,770	7,011	25%	9,380	9,198	7,330	25%	10,076	9,552	7,576	26%
	00006382836	COSOPT	8,771	8,771	7,004	25%	9,384	9,201	7,329	26%	10,080	9,556	7,587	26%

REPORTED AWP'S, MARKET PRICES AND SPREADS - 2001-2003 - NDCs WITH \$10,000+ IDAHO MEDICAID REIMBURSEMENTS 2001-2003

Defendant	NDC	Drug	Year-end	Avg	AWP	Year-end	Avg	AWP	Year-end	Avg	AWP	Year-end	Avg	AWP
			Reported FDB AWP	Reported FDB AWP	Market Price	Mkt Price	Reported FDB AWP	Reported FDB AWP	Market Price	Mkt Price	Reported FDB AWP	Reported FDB AWP	Market Price	Mkt Price
MERCK	00006096631	COZAA	1.948	1.948	1.557	25%	2.063	2.044	1.630	25%	2.253	2.153	1.711	26%
	00006096658	COZAA	1.948	1.948	1.555	25%	2.063	2.044	1.633	25%	2.254	2.153	1.700	27%
	00006095154	COZAA	1.430	1.386	1.108	25%	1.515	1.501	1.197	25%	1.662	1.580	1.258	26%
	00006095158	COZAA	1.430	1.386	1.107	25%	1.515	1.501	1.195	26%	1.662	1.580	1.245	27%
	00006095231	COZAA	1.430	1.385	1.112	25%	1.515	1.501	1.198	25%	1.662	1.581	1.250	26%
	00006095254	COZAA	1.430	1.386	1.110	25%	1.515	1.501	1.199	25%	1.662	1.580	1.253	26%
	00006095258	COZAA	1.430	1.386	1.105	25%	1.515	1.501	1.194	26%	1.662	1.580	1.250	26%
	00006057354	CRIXIVAN	2.908	2.826	2.242	26%	3.035	3.005	2.397	25%	3.035	3.035	2.415	26%
	00006057392	CRIXIVAN	2.908	2.826	2.244	26%	3.035	3.005	2.382	26%	3.035	3.035	2.404	26%
	00006093631	FOSAMAX	2.313	2.269	1.811	25%	2.449	2.416	1.929	25%	2.618	2.552	2.029	26%
	00006093658	FOSAMAX	2.313	2.269	1.797	26%	2.449	2.416	1.916	26%	2.618	2.552	2.020	26%
	0000607744	FOSAMAX	16.191	15.889	12.781	24%	17.144	16.914	13.467	26%	18.328	17.865	14.150	26%
	00006092531	FOSAMAX	2.313	2.269	1.808	25%	2.449	2.416	1.924	26%	2.618	2.552	2.030	26%
	000060603121	FOSAMAX	16.191	15.880	12.768	24%	17.146	16.916	13.489	25%	18.328	17.865	14.122	27%
	000060603144	FOSAMAX	16.191	15.880	12.752	25%	17.144	16.914	13.472	26%	18.328	17.865	14.160	26%
	00006074731	HYZAR	1.948	1.948	1.555	25%	2.063	2.044	1.628	26%	2.263	2.153	1.708	26%
	00006074758	HYZAR	1.948	1.948	1.558	25%	2.063	2.044	1.633	25%	2.264	2.153	1.703	26%
	00006071731	HYZAR	1.430	1.385	1.104	26%	1.515	1.501	1.193	26%	1.662	1.581	1.248	27%
	00006071754	HYZAR	1.430	1.386	1.109	25%	1.515	1.501	1.197	25%	1.662	1.580	1.255	26%
	00006071758	HYZAR	1.430	1.386	1.108	25%	1.515	1.501	1.197	25%	1.662	1.580	1.253	26%
	00006074758	HYZAR	1.948	1.948	1.555	25%	2.063	2.044	1.628	26%	2.263	2.153	1.708	26%
	00006074776	MAXALT	1.948	1.948	1.558	25%	2.063	2.044	1.633	25%	2.264	2.153	1.703	26%
	00006071731	HYZAR	1.430	1.385	1.104	26%	1.515	1.501	1.193	26%	1.662	1.581	1.248	27%
	00006071754	HYZAR	1.430	1.386	1.109	25%	1.515	1.501	1.197	25%	1.662	1.580	1.255	26%
	00006071758	HYZAR	1.430	1.386	1.108	25%	1.515	1.501	1.197	25%	1.662	1.580	1.253	26%
	000060726706	MAXALT	16.165	15.885	12.681	25%	17.117	16.963	13.497	26%	18.798	17.876	14.169	26%
	00006096328	PEPCID	16.165	15.885	12.702	25%	17.117	16.953	13.497	26%	18.798	17.876	14.150	26%
	000060963106	MAXALT-MLT	16.165	15.885	12.683	25%	17.117	16.953	13.500	26%	18.890	17.875	14.180	26%
	00006073161	MEVAJOR	2.636	2.586	2.060	26%	2.636	2.100	2.636	26%	2.636	2.636	2.083	27%
	00006073261	MEVAJOR	4.746	4.655	3.774	25%	4.746	4.746	3.787	25%	4.746	4.746	3.769	26%
	000063533892	PEPCID	2.054	2.054	1.641	25%	2.154	2.154	1.722	25%	2.154	2.154	1.714	26%
	00006096328	PEPCID	1.933	1.933	1.274	52%	2.028	2.028	1.598	27%	2.028	2.028	1.617	25%
	00006096331	PEPCID	1.933	1.933	1.550	25%	2.028	2.028	1.620	25%	2.028	2.028	1.615	26%
	00006096358	PEPCID	1.933	1.933	1.541	25%	2.028	2.028	1.607	26%	2.028	2.028	1.609	26%
	00006096382	PEPCID	1.933	1.933	1.534	26%	2.028	2.028	1.625	25%	2.028	2.028	1.615	26%
	00006096431	PEPCID	3.737	3.737	2.985	25%	3.920	3.920	3.123	26%	3.920	3.920	3.120	26%
	00006096458	PEPCID	3.737	3.737	2.983	25%	3.920	3.920	3.124	25%	3.920	3.920	3.104	26%
	00006096459	PRIMAXIN IV	30.727	23.686	30%	31.434	31.434	23.472	34%	32.690	31.647	23.397	35%	
	00006010658	PRINTIVIL	1.011	0.992	0.810	22%	1.116	1.099	0.866	27%	1.116	1.116	0.887	26%
	00006010682	PRINTIVIL	1.002	0.983	0.749	31%	1.105	1.099	0.791	38%	1.105	1.105	0.708	56%
	00006020758	PRINTIVIL	1.083	1.062	0.869	22%	1.195	1.176	0.928	27%	1.195	1.195	0.948	26%
	00006023758	PRINTIVIL	1.584	1.553	1.257	24%	1.747	1.720	1.350	27%	1.747	1.747	1.377	27%
	00006001958	PRINTIVIL	0.980	0.961	0.779	23%	1.081	1.064	0.835	27%	1.081	1.081	0.856	26%
	00006027554	SINGULAIR	2.752	2.731	2.187	25%	2.914	2.888	2.303	25%	3.130	3.053	2.427	26%
	00006011731	SINGULAIR	2.514	2.499	1.991	25%	2.715	2.663	2.117	26%	2.875	2.183	2.342	26%
	00006011754	SINGULAIR	2.752	2.731	2.184	25%	2.914	2.888	2.299	26%	3.130	3.053	2.426	26%
	00006027531	SINGULAIR	2.752	2.731	2.194	24%	2.914	2.888	2.307	25%	3.130	3.053	2.428	26%
	00006011028	VTOXX	2.752	2.666	2.088	28%	2.914	2.888	2.296	26%	3.130	3.053	2.424	26%
	00006011031	VTOXX	2.752	2.666	2.144	24%	2.914	2.888	2.211	26%	3.014	2.948	2.228	32%
	00006011068	VTOXX	2.752	2.666	2.144	24%	2.914	2.888	2.220	25%	3.014	2.948	2.342	26%
	00006011082	VTOXX	2.752	2.666	2.124	24%	2.914	2.888	2.214	26%	3.014	2.948	2.336	26%
			2.752	2.666	2.125	24%	2.914	2.888	2.209	25%	3.014	2.948	2.338	26%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - NDOS WITH \$10,000+ IDAHO MEDICAID REIMBURSEMENTS 2001-2003

Defendant	NDC	Drug	Year-end	Avg	Avg	Avg	Year-end	Avg	Avg	Avg	Year-end	Avg	Avg	Year-end	Avg	Market	Mkt Price	AWP	Year-end	Avg	Avg	Market	Mkt Price	AWP	Year-end	Avg	Market	Mkt Price	AWP
			Reported FDB AWP	Reported FDB AWP	Market Price	Reported FDB AWP	Reported FDB AWP	Mkt Price	Reported FDB AWP	Mkt Price	Reported FDB AWP	Reported FDB AWP	Mkt Price	Reported FDB AWP	Reported FDB AWP	Mkt Price	Reported FDB AWP	Reported FDB AWP	Mkt Price	Reported FDB AWP	Reported FDB AWP	Mkt Price	Reported FDB AWP	Reported FDB AWP	Mkt Price	Reported FDB AWP	Reported FDB AWP	Mkt Price	
MERCK	00006011468	VIOXX	4.019	3.894	3.111	25%	4.200	4.066	3.235	26%	4.401	4.305	3.411	26%	4.744	2.648	2.105	26%	5.27	2.527	2.012	26%	5.744	2.527	2.009	26%	6.248	2.527	2.093
	00006073531	ZOCOR	2.387	2.387	1.905	25%	2.628	2.527	2.012	26%	2.648	2.105	2.093	26%	2.744	2.527	2.009	26%	2.744	2.527	2.009	26%	2.744	2.527	2.009	26%	2.744	2.527	2.009
	00006073554	ZOCOR	2.387	2.387	1.903	26%	2.628	2.527	2.000	26%	2.648	2.105	2.093	26%	2.744	2.527	2.000	26%	2.744	2.527	2.000	26%	2.744	2.527	2.000	26%	2.744	2.527	2.000
	00006073561	ZOCOR	2.387	2.387	1.900	26%	2.628	2.528	2.000	26%	2.648	2.105	2.093	26%	2.744	2.528	2.000	26%	2.744	2.528	2.000	26%	2.744	2.528	2.000	26%	2.744	2.528	2.000
	00006074031	ZOCOR	4.163	4.163	3.326	25%	4.585	4.409	3.515	25%	4.787	4.620	3.679	25%	4.787	4.409	3.515	25%	4.787	4.409	3.515	25%	4.787	4.409	3.515	25%	4.787	4.409	3.515
	00006074054	ZOCOR	4.163	4.163	3.316	26%	4.585	4.164	3.313	26%	4.787	4.619	3.674	26%	4.787	4.164	3.313	26%	4.787	4.164	3.313	26%	4.787	4.164	3.313	26%	4.787	4.164	3.313
	00006074061	ZOCOR	4.163	4.163	3.306	26%	4.585	4.409	3.478	27%	4.787	4.619	3.509	32%	4.787	4.409	3.478	27%	4.787	4.409	3.478	32%	4.787	4.409	3.478	32%	4.787	4.409	3.478
	00006074082	ZOCOR	4.163	4.163	3.326	25%	4.585	4.409	3.516	25%	4.787	4.620	3.682	25%	4.787	4.409	3.516	25%	4.787	4.409	3.516	25%	4.787	4.409	3.516	25%	4.787	4.409	3.516
	00006074931	ZOCOR	4.163	4.163	3.309	26%	4.585	4.409	3.499	26%	4.787	4.619	3.647	27%	4.787	4.409	3.499	26%	4.787	4.409	3.499	26%	4.787	4.409	3.499	26%	4.787	4.409	3.499
	00006074954	ZOCOR	4.163	4.163	3.318	25%	4.585	4.164	3.319	25%	4.787	4.619	3.681	25%	4.787	4.164	3.319	25%	4.787	4.164	3.319	25%	4.787	4.164	3.319	25%	4.787	4.164	3.319
	00006074961	ZOCOR	4.163	4.163	3.319	25%	4.585	4.409	3.509	26%	4.787	4.620	3.671	26%	4.787	4.409	3.509	26%	4.787	4.409	3.509	26%	4.787	4.409	3.509	26%	4.787	4.409	3.509
	00006054331	ZOCOR	4.163	4.163	3.319	25%	4.585	4.409	3.506	26%	4.787	4.619	3.643	27%	4.787	4.409	3.506	26%	4.787	4.409	3.506	26%	4.787	4.409	3.506	26%	4.787	4.409	3.506
	00006054354	ZOCOR	4.163	4.163	3.319	25%	4.585	4.409	3.506	26%	4.787	4.619	3.643	27%	4.787	4.409	3.506	26%	4.787	4.409	3.506	26%	4.787	4.409	3.506	26%	4.787	4.409	3.506
ORTHO	00062154002	FLOXIN	4.388	4.247	3.507	21%	4.973	4.685	3.735	25%	5.316	5.137	4.062	26%	5.671	5.447	5.060	27%	6.394	5.880	5.660	26%	6.647	5.880	5.660	26%	6.647	5.880	5.660
	00062154201	FLOXIN	5.444	5.330	4.421	21%	6.241	5.880	4.680	26%	6.647	6.447	5.060	27%	7.088	6.647	6.447	27%	7.353	6.647	6.447	27%	7.647	6.647	6.447	27%	7.647	6.647	6.447
	00062020604	GRIFFLVIN V	0.272	0.266	0.221	20%	0.327	0.300	0.241	25%	0.343	0.335	0.266	26%	0.343	0.335	0.266	26%	0.343	0.335	0.266	26%	0.343	0.335	0.266	26%	0.343	0.335	0.266
	00062192015	ORTHO EVRA			0.185		1.573	1.489	0.606	14%	1.729	1.648	1.296	27%	1.729	1.648	1.296	27%	1.729	1.648	1.296	27%	1.729	1.648	1.296	27%	1.729	1.648	1.296
	00062141116	ORTHO MICRON	1.159	1.138	0.946	20%	1.316	1.242	0.995	25%	1.394	1.353	1.088	24%	1.394	1.353	1.088	24%	1.394	1.353	1.088	24%	1.394	1.353	1.088	24%	1.394	1.353	1.088
	00062190315	ORTHO TRI-					1.316	1.269	1.006	25%	1.394	1.353	1.088	24%	1.394	1.353	1.088	24%	1.394	1.353	1.088	24%	1.394	1.353	1.088	24%	1.394	1.353	1.088
	00062125115	ORTHO TRI-CY					1.355	1.285	1.012	25%	1.489	1.419	1.122	26%	1.489	1.419	1.122	26%	1.489	1.419	1.122	26%	1.489	1.419	1.122	26%	1.489	1.419	1.122
	00062179615	ORTHO-CEPT	1.171	1.149	0.954	20%	1.355	1.285	1.012	25%	1.489	1.419	1.122	26%	1.489	1.419	1.122	26%	1.489	1.419	1.122	26%	1.489	1.419	1.122	26%	1.489	1.419	1.122
	00062190115	ORTHO-CYCLEN	1.171	1.149	0.955	20%	1.355	1.285	1.012	25%	1.489	1.419	1.122	26%	1.489	1.419	1.122	26%	1.489	1.419	1.122	26%	1.489	1.419	1.122	26%	1.489	1.419	1.122
	00062178115	ORTHO-NOWM	1.171	1.149	0.954	20%	1.355	1.285	1.012	25%	1.489	1.419	1.122	26%	1.489	1.419	1.122	26%	1.489	1.419	1.122	26%	1.489	1.419	1.122	26%	1.489	1.419	1.122
	00062446001	SPECTAZOLE	0.957	0.937	0.779	20%	1.152	1.057	0.845	25%	1.232	1.190	0.933	28%	1.232	1.190	0.933	28%	1.232	1.190	0.933	28%	1.232	1.190	0.933	28%	1.232	1.190	0.933
	00062546003	SPECTAZOLE	0.689	0.674	0.563	20%	0.829	0.761	0.610	25%	0.887	0.857	0.673	27%	0.887	0.857	0.673	27%	0.887	0.857	0.673	27%	0.887	0.857	0.673	27%	0.887	0.857	0.673
	00062355601	TERAZOL 3	1.691	1.655	1.379	20%	1.957	1.828	1.467	25%	2.072	2.012	1.593	26%	2.072	2.012	1.593	26%	2.072	2.012	1.593	26%	2.072	2.012	1.593	26%	2.072	2.012	1.593
	00062355101	TERAZOL 7	0.751	0.736	0.612	20%	0.870	0.812	0.652	25%	0.921	0.894	0.710	26%	0.921	0.894	0.710	26%	0.921	0.894	0.710	26%	0.921	0.894	0.710	26%	0.921	0.894	0.710
	59676031001	PROCART	133.560	130.495	106.692	22%	133.560	109.077	107.976	22%	133.560	133.560	107.976	23%	133.560	133.560	107.976	23%	133.560	133.560	107.976	23%	133.560	133.560	107.976	23%	133.560	133.560	107.976
	59676031201	PROCART	133.560	130.490	105.827	23%	133.560	107.976	107.976	24%	133.560	133.560	107.976	24%	133.560	133.560	107.976	24%	133.560	133.560	107.976	24%	133.560	133.560	107.976	24%	133.560	133.560	107.976
	59676032001	PROCART	26.712	26.100	21.295	23%	26.712	21.744	21.744	23%	26.712	26.712	21.744	24%	26.712	26.712	21.744	24%	26.712	26.712	21.744	24%	26.712	26.712	21.744	24%	26.712	26.712	21.744
	59676030301	PROCART	40.068	39.147	31.963	22%	40.068	32.655	23%	23%	40.068	40.068	32.655	24%	40.068	40.068	32.655	24%	40.068	40.068	32.655	24%	40.068	40.068	32.655	24%	40.068	40.068	32.655
	59676030401	PROCART	53.423	52.200	43.072	21%	53.423	53.423	43.920	22%	53.423	53.423	43.920	22%	53.423	53.423	43.920	22%	53.423	53.423	43.920	22%	53.423	53.423	43.920	22%	53.423	53.423	43.920
	59676030401	PROCART	534.240	521.969	429.791	21%	534.240	438.823	438.823	22%	534.240	534.240	438.823	22%	534.240	534.240	438.823	22%	534.240	534.240	438.823	22%	534.240	534.240	438.823	22%	534.240	534.240	438.823
PAR	49884011701	AMILORIDE	0.476	0.476	0.311	53%	0.476	0.476	0.302	53%	0.476	0.476	0.302	53%	0.476	0.476	0.302	53%	0.476	0.476	0.302	53%	0.476	0.476	0.302	53%	0.476	0.476	0.302
	49884016501	BENZTROPINE	0.217	0.199	0.035	46%	0.217	0.217	0.109	99%	0.217	0.217	0.109	100%	0.217	0.217	0.109	100%	0.217	0.217	0.109	100%	0.217	0.217					

REPORTED AWPS, MARKET PRICES AND SPREADS - 2001-2003 - NDCS WITH \$10,000+ IDAHO MEDICAID REIMBURSEMENTS 2001-2003

Defendant	NDC	Drug	Year-end Reported FOB AWP			Avg Reported FDB AWP			Year-end Reported FDB AWP			Avg Reported FDB AWP			Year-end Reported FDB AWP			Avg Reported FDB AWP			Year-end Reported FDB AWP					
			2001	2001	2001	2001	2001	2001	2002	2002	2002	2002	2002	2002	2003	2003	2003	2003	2003	2003	2003	2003	2003			
PAR			49884060810	FAMOTIDINE	1.734	1.734	0.069	2840%	1.734	1.734	0.060	2789%	1.734	1.734	0.058	2878%	1.734	1.734	0.058	2878%	1.734	1.734	0.058	2878%		
			49884060801	FAZOMITIDINE	3.350	3.350	0.179	1770%	3.350	3.350	0.122	2657%	3.350	3.350	0.110	2959%	3.350	3.350	0.110	2959%	3.350	3.350	0.110	2959%		
			49884073301	FLUOXETINE	5.336	5.336	3.623	47%	5.336	5.336	1.319	305%	5.336	5.336	2.668	0.377	607%	5.336	5.336	2.668	0.377	607%	5.336	5.336	2.668	0.377
			49884074301	FLUOXETINE	2.601	2.601	1.692	55%	2.731	2.731	0.191	148%	2.731	2.731	1.700	1.257	324%	2.731	2.731	0.191	148%	2.731	2.731	1.700	1.257	
			49884074311	FLUOXETINE	2.601	2.601	1.772	47%	2.731	2.721	0.250	990%	2.731	2.731	0.081	3292%	2.731	2.731	0.081	3292%	2.731	2.731	0.081	3292%		
			49884073501	FLUOXETINE	2.668	2.668	1.106	141%	2.801	2.790	0.681	310%	2.801	2.801	0.554	406%	2.801	2.801	0.554	406%	2.801	2.801	0.554	406%		
			49884073510	FLUOXETINE	2.667	2.667	1.051	154%	2.800	2.790	0.576	384%	2.800	2.800	0.556	404%	2.800	2.800	0.556	404%	2.800	2.800	0.556	404%		
			49884046805	IBU	0.240	0.240	0.024	901%	0.240	0.240	0.024	886%	0.240	0.240	0.240	0.240	0.240	0.240	0.240	0.240	0.240	0.240	0.240	0.240		
			49884046805	IBU	0.305	0.305	0.037	720%	0.305	0.305	0.037	733%	0.305	0.305	0.305	0.305	0.305	0.305	0.305	0.305	0.305	0.305	0.305	0.305		
			49884077805	IBUPROFEN	0.025	0.025	0.025	0.240	0.240	0.240	0.240	862%	0.240	0.240	0.240	0.240	0.240	0.240	0.240	0.240	0.240	0.240	0.240	0.240		
			49884077905	IBUPROFEN	0.037	0.037	0.037	0.305	0.305	0.305	0.305	714%	0.305	0.305	0.305	0.305	0.305	0.305	0.305	0.305	0.305	0.305	0.305	0.305		
			49884090738	MEGESTROL AC	0.600	0.600	0.409	46%	0.600	0.600	0.399	50%	0.600	0.600	0.399	52%	0.600	0.600	0.399	52%	0.600	0.600	0.399	52%		
			49884029001	MEGESTROL AC	1.230	1.230	0.241	411%	1.230	0.241	0.241	410%	1.230	1.230	0.236	421%	1.230	1.230	0.236	421%	1.230	1.230	0.236	421%		
			49884064101	METHIMAZOLE	0.758	0.739	0.473	56%	0.768	0.768	0.460	67%	0.768	0.768	0.386	99%	0.768	0.768	0.386	99%	0.768	0.768	0.386	99%		
			49884076601	NIZATIDINE	2.754	2.754	1.515	319%	2.754	1.515	0.361	319%	2.754	1.515	1.515	0.264	475%	2.754	1.515	1.515	0.264	475%	2.754	1.515	1.515	0.264
			49884072301	OXAPROZIN	1.515	1.515	0.423	258%	1.515	1.515	0.361	319%	1.515	1.515	1.515	0.264	475%	1.515	1.515	1.515	0.264	475%	1.515	1.515	1.515	0.264
			49884087611	PAROXETINE	2.533	2.533	2.533	2.533	2.533	2.533	2.533	2.533	2.533	2.533	2.533	2.533	2.533	2.533	2.533	2.533	2.533	2.533	2.533	2.533		
			49884087701	PAROXETINE	2.644	2.644	2.644	2.644	2.644	2.644	2.644	2.644	2.644	2.644	2.644	2.644	2.644	2.644	2.644	2.644	2.644	2.644	2.644	2.644		
			49884087711	PAROXETINE	2.643	2.643	2.643	2.643	2.643	2.643	2.643	2.643	2.643	2.643	2.643	2.643	2.643	2.643	2.643	2.643	2.643	2.643	2.643	2.643		
			49884087811	PAROXETINE	2.722	2.722	2.722	2.722	2.722	2.722	2.722	2.722	2.722	2.722	2.722	2.722	2.722	2.722	2.722	2.722	2.722	2.722	2.722	2.722		
			49884087911	PAROXETINE	2.876	2.876	2.876	2.876	2.876	2.876	2.876	2.876	2.876	2.876	2.876	2.876	2.876	2.876	2.876	2.876	2.876	2.876	2.876	2.876		
			49884054401	RANITIDINE	1.562	1.562	0.442	3578%	1.562	1.562	0.063	2393%	1.562	1.562	0.058	2595%	1.562	1.562	0.058	2595%	1.562	1.562	0.058	2595%		
			49884054402	RANITIDINE	1.588	1.588	0.042	365%	1.588	1.588	0.057	2701%	1.588	1.588	0.058	2625%	1.588	1.588	0.058	2625%	1.588	1.588	0.058	2625%		
			49884054405	RANITIDINE	1.560	1.560	0.038	4010%	1.560	1.560	0.054	2783%	1.560	1.560	0.053	2853%	1.560	1.560	0.053	2853%	1.560	1.560	0.053	2853%		
			49884054410	RANITIDINE	1.528	1.528	0.040	3759%	1.528	1.528	0.053	2809%	1.528	1.528	0.051	2905%	1.528	1.528	0.051	2905%	1.528	1.528	0.051	2905%		
			49884054501	RANITIDINE	2.867	2.867	0.082	3383%	2.867	2.867	0.120	2295%	2.867	2.867	0.116	2382%	2.867	2.867	0.116	2382%	2.867	2.867	0.116	2382%		
			49884054504	RANITIDINE	2.788	2.788	0.124	2143%	2.788	2.788	0.118	2358%	2.788	2.788	0.113	2369%	2.788	2.788	0.113	2369%	2.788	2.788	0.113	2369%		
			49884054511	RANITIDINE	2.930	2.930	0.115	2443%	2.930	2.930	0.125	2242%	2.930	2.930	0.118	2374%	2.930	2.930	0.118	2374%	2.930	2.930	0.118	2374%		
			49884058201	SOTALOL HCL	2.347	2.347	0.396	493%	2.347	2.347	0.222	955%	2.347	2.347	0.190	1136%	2.347	2.347	0.190	1136%	2.347	2.347	0.190	1136%		
			49884060040	SSD	0.064	0.064	0.064	0.064	0.064	0.064	0.032	101%	0.088	0.087	0.047	87%	0.088	0.087	0.047	87%	0.088	0.087	0.047	87%		
			49884078253	TIZANIDINE	1.222	1.222	1.485	1.485	1.222	1.222	0.781	88%	1.465	1.465	1.535	127%	1.465	1.465	1.535	127%	1.465	1.465	1.535	127%		
SANDOZ	00781107705	ALPHAZOLAM	0.761	0.701	0.015	4480%	0.761	0.761	0.020	3744%	0.761	0.761	0.840	0.047	1704%	0.761	0.761	0.840	0.047	1704%	0.761	0.761	0.840	0.047		
	00781107710	ALPRAZOLAM	0.665	0.665	0.014	4778%	0.665	0.665	0.019	3377%	0.665	0.665	0.814	0.031	2495%	0.665	0.665	0.814	0.031	2495%	0.665	0.665	0.814	0.031		
	0078120360	AMIDARONE	3.299	3.299	0.469	604%	3.299	3.299	0.472	598%	3.299	3.299	0.492	570%	3.299	3.299	0.492	570%	3.299	3.299	0.492	570%				
	0078149001	AMITRIPTYLIN	1.111	0.643	0.066	874%	1.111	1.111	0.105	954%	1.111	1.111	0.121	817%	1.111	1.111	0.121	817%	1.111	1.111	0.121	817%				
	0078148710	AMITRIPTYLIN	0.339	0.287	0.023	1143%	0.339	0.339	0.043	694%	0.339	0.339	0.060	461%	0.339	0.339	0.060	461%	0.339	0.339	0.060	461%				
	0078164366	AMOX/K CLAV	0.703	0.703	0.018	3823%	0.818	0.818	0.725	0.023	2996%	0.818	0.818	0.846	0.047	1678%	0.818	0.818	0.846	0.047	1678%	0.818	0.818	0.846	0.047	
	00781107801	ATENOLOL	0.685	0.685	0.015	4367%	0.792	0.792	0.023	2991%	0.792	0.792	0.046	1626%	0.792	0.792	0.046	1626%	0.792	0.792	0.046	1626%				
	00781184101	BISOPRIL/HCTZ	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140			
	0078182401	BISOPRIL/HCTZ	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140	1.140			
	00781106401	BUPROPION	0.961	0.961	0.353	172%	0.961	0.961	0.348	176%	0.961	0.961	0.424	127%	0.961	0.961	0.424	127%	0.961	0.961	0.424	127%	0.961	0.961	0.424	127%

REPORTED ANH'S, MARKET PRICES AND SPREADS - 2001-2003 - NDCS WITH \$10,000+ IDAHO MEDICAID REIMBURSEMENTS 2001-2003

Defendant	NDC	Drug	Year-end			Avg			Avg			Year-end			Avg			Avg			Year-end					
			Reported			Reported			Market			Mkt Price			Reported			Market			Mkt Price					
			FDB AWP 2001	Price 2001	Spread 2001	FDB AWP 2002	Price 2002	Spread 2002	FDB AWP 2003	FDB AWP 2003	FDB AWP 2003	FDB AWP 2003	Price 2003	Spread 2003	Mkt Price 2003	AWP 2003										
SANDOZ	00781105501	BUPROPION	0.720	0.720	0.269	167%	0.720	0.720	0.268	169%	0.720	0.720	0.268	169%	0.720	0.720	0.268	169%	0.720	0.720	0.268	169%	0.720	0.720	0.360	160%
	0078150505	CARISOPRODOL	0.736	0.736	0.282	50.573	0.573	0.573	0.290	97%	0.573	0.573	0.290	97%	0.573	0.573	0.290	97%	0.573	0.573	0.290	97%	0.573	0.573	0.291	97%
	00781171801	CHLORPROMAZ	0.861	0.861	0.211	249%	0.861	0.861	0.271	192%	0.861	0.861	0.271	192%	0.861	0.861	0.271	192%	0.861	0.861	0.271	192%	0.861	0.861	0.271	142%
	0078135501	CLEMASTINE	0.861	0.861	0.149	479%	0.861	0.861	0.154	459%	0.861	0.861	0.154	459%	0.861	0.861	0.154	459%	0.861	0.861	0.154	459%	0.861	0.861	0.154	471%
	00781202701	CLONIPRAMINE	0.790	0.790	0.147	439%	0.790	0.790	0.271	191%	0.790	0.790	0.271	191%	0.790	0.790	0.271	191%	0.790	0.790	0.271	191%	0.790	0.790	0.271	171%
	00781203701	CLONOFEN POT	1.562	1.562	0.229	577%	1.552	1.552	0.192	709%	1.552	1.552	0.192	709%	1.552	1.552	0.192	709%	1.552	1.552	0.192	709%	1.552	1.552	0.192	856%
	00781501701	DICLOFENAC	2.814	2.814	1.406	100%	2.814	2.814	1.078	161%	2.814	2.814	1.078	161%	2.814	2.814	1.078	161%	2.814	2.814	1.078	161%	2.814	2.814	1.078	205%
	00781136101	DICLOFENAC	0.907	0.907	0.089	920%	0.907	0.907	0.078	1058%	0.907	0.907	0.078	1058%	0.907	0.907	0.078	1058%	0.907	0.907	0.078	1058%	0.907	0.907	0.078	890%
	00781178701	DICLOFENAC	1.065	1.065	0.096	1005%	1.065	1.065	0.086	1142%	1.065	1.065	0.086	1142%	1.065	1.065	0.086	1142%	1.065	1.065	0.086	1142%	1.065	1.065	0.086	823%
	00781178901	DICLOFENAC	1.071	1.071	0.062	1624%	1.071	1.071	0.118	807%	1.071	1.071	0.118	807%	1.071	1.071	0.118	807%	1.071	1.071	0.118	807%	1.071	1.071	0.118	97%
	00781123501	ENALAPRIL	1.524	1.524	0.091	1581%	1.524	1.524	0.194	683%	1.524	1.524	0.194	683%	1.524	1.524	0.194	683%	1.524	1.524	0.194	683%	1.524	1.524	0.194	127%
	00781123301	ENALAPRIL	1.020	1.020	0.058	161%	1.020	1.020	0.124	723%	1.020	1.020	0.124	723%	1.020	1.020	0.124	723%	1.020	1.020	0.124	723%	1.020	1.020	0.124	55%
	00781282801	FLUOXETINE	2.598	2.598	1.724	51%	2.598	2.598	1.003	159%	2.598	2.598	1.003	159%	2.598	2.598	1.003	159%	2.598	2.598	1.003	159%	2.598	2.598	1.003	1100%
	00781282801	FLUOXETINE	5.331	5.331	2.665	413%	5.331	5.331	0.413	545%	5.331	5.331	0.413	545%	5.331	5.331	0.413	545%	5.331	5.331	0.413	545%	5.331	5.331	0.413	866%
	00781143901	FLUOPHENAZINE	1.148	1.148	0.121	846%	1.148	1.148	0.125	821%	1.148	1.148	0.125	821%	1.148	1.148	0.125	821%	1.148	1.148	0.125	821%	1.148	1.148	0.125	833%
	0078143801	FLUOPHENAZINE	0.900	0.900	0.097	828%	0.900	0.900	0.091	884%	0.900	0.900	0.091	884%	0.900	0.900	0.091	884%	0.900	0.900	0.091	884%	0.900	0.900	0.091	866%
	00781504201	FLUOXAMINE	2.639	2.639	1.134	133%	2.639	2.639	0.683	287%	2.639	2.639	0.683	287%	2.639	2.639	0.683	287%	2.639	2.639	0.683	287%	2.639	2.639	0.683	365%
	00781504101	FLUOXAMINE	2.572	2.572	1.167	132%	2.572	2.572	0.647	297%	2.572	2.572	0.647	297%	2.572	2.572	0.647	297%	2.572	2.572	0.647	297%	2.572	2.572	0.647	370%
	00781181810	FURSEMIDE	0.123	0.123	0.017	618%	0.123	0.123	0.025	391%	0.123	0.123	0.025	391%	0.123	0.123	0.025	391%	0.123	0.123	0.025	391%	0.123	0.123	0.025	290%
	00781196610	HALOPERIDOL	0.140	0.140	0.021	558%	0.140	0.140	0.029	392%	0.140	0.140	0.029	392%	0.140	0.140	0.029	392%	0.140	0.140	0.029	392%	0.140	0.140	0.029	330%
	00781139701	HALOPERIDOL	0.715	0.715	0.074	870%	1.310	0.749	0.089	747%	1.310	0.749	0.089	747%	1.310	0.749	0.089	747%	1.310	0.749	0.089	747%	1.310	0.749	0.089	34%
	00781139601	HALOPERIDOL	0.709	0.709	0.039	1719%	0.780	0.713	0.046	1451%	0.780	0.780	0.046	1451%	0.780	0.780	0.046	1451%	0.780	0.780	0.046	1451%	0.780	0.780	0.046	374%
	00781140701	HYDROXYCHLOR	1.096	1.096	0.215	410%	1.096	1.096	0.218	402%	1.096	1.096	0.218	402%	1.096	1.096	0.218	402%	1.096	1.096	0.218	402%	1.096	1.096	0.218	372%
	00781176201	IMIPRAM HCL	0.284	0.284	0.052	447%	0.430	0.430	0.0312	450%	0.430	0.430	0.0312	450%	0.430	0.430	0.0312	450%	0.430	0.430	0.0312	450%	0.430	0.430	0.0312	175%
	00781176401	IMIPRAM HCL	0.474	0.474	0.061	678%	0.718	0.521	0.080	555%	0.718	0.521	0.080	555%	0.718	0.521	0.080	555%	0.718	0.521	0.080	555%	0.718	0.521	0.080	244%
	00781176410	IMIPRAM HCL	0.454	0.454	0.046	878%	0.682	0.498	0.056	787%	0.682	0.682	0.056	787%	0.682	0.682	0.056	787%	0.682	0.682	0.056	787%	0.682	0.682	0.056	266%
	00781176601	IMIPRAM HCL	0.690	0.690	0.073	851%	1.219	0.793	0.091	769%	1.219	0.793	0.091	769%	1.219	0.793	0.091	769%	1.219	0.793	0.091	769%	1.219	0.793	0.091	304%
	00781176610	IMIPRAM HCL	0.656	0.656	0.055	1066%	1.158	0.753	0.067	1027%	1.158	0.753	0.067	1027%	1.158	0.753	0.067	1027%	1.158	0.753	0.067	1027%	1.158	0.753	0.067	327%
	00781126210	LONDX	0.421	0.421	0.059	512%	0.421	0.421	0.070	504%	0.421	0.421	0.070	504%	0.421	0.421	0.070	504%	0.421	0.421	0.070	504%	0.421	0.421	0.070	220%
	00781140305	LORAZEPAM	0.625	0.625	0.073	762%	0.625	0.625	0.060	943%	0.625	0.625	0.060	943%	0.625	0.625	0.060	943%	0.625	0.625	0.060	943%	0.625	0.625	0.060	1024%
	00781140401	LORAZEPAM	0.838	0.838	0.094	788%	0.838	0.838	0.079	964%	0.838	0.838	0.079	964%	0.838	0.838	0.079	964%	0.838	0.838	0.079	964%	0.838	0.838	0.079	1039%
	00781140405	LORAZEPAM	0.810	0.810	0.081	902%	0.810	0.810	0.086	1120%	0.810	0.810	0.086	1120%	0.810	0.810	0.086	1120%	0.810	0.810	0.086	1120%	0.810	0.810	0.086	1180%
	00781140410	LORAZEPAM	0.797	0.797	0.072	1010%	0.797	0.797	0.061	1202%	0.797	0.797	0.061	1202%	0.797	0.797	0.061	1202%	0.797	0.797	0.061	1202%	0.797	0.797	0.061	1318%
	00781140501	LORAZEPAM	1.221	1.221	0.146	737%	1.221	1.221	0.118	933%	1.221	1.221	0.118	933%	1.221	1.221	0.118	933%	1.221	1.221	0.118	933%	1.221	1.221	0.118	1046%
	00781140505	LORAZEPAM	1.188	1.188	0.129	818%	1.188	1.188	0.108	995%	1.188	1.188	0.108	995%	1.188	1.188	0.108	995%	1.188	1.188	0.108	995%	1.188	1.188	0.108	1070%
	00781121060	LOVASTATIN	2.370	2.370	2.370	2.370	2.370	2.370	0.613	287%	2.370	2.370	0.613	287%	2.370	2.370	0.613	287%	2.370	2.370	0.613	287%	2.370	2.370	0.613	331%
	00781505201	METFORMIN	0.714	0.714	0.248	188%	0.714	0.714	0.354	99%	0.714	0.714	0.354	99%	0.714	0.714	0.354	99%	0.714	0.714	0.354	99%	0.714	0.714	0.354	286%
	00781175301	METHYLPHENID	0.714	0.714	0.248	188%	0.714	0.714	0.354	99%	0.714	0.714	0.354	99%	0.714	0.714	0.354	99%	0.714	0.714	0.354	99%	0.714	0.714	0.354	322%
	00781884201	METHYLPHENID	0.494	0.494	0.278	78%	0.494	0.494	0.225	119%	0.494	0.494	0.225	119%	0.494	0.494	0.225	119%	0.494	0.494	0.225	119%	0.494	0.494	0.225	217%
	00781174901	METHYLPHENID	0.497	0.497	0.176	182%	0.497	0.497	0.192	173%	0.497	0.497	0.192	173%	0.497	0.497	0.192	173%	0.497	0.497	0.192	173%	0.497	0.497	0.192	144%
	00781884101	METHYLPHENID	1.110	1.110	0.471	135%	1.110	1.110	0.510	117%	1.110	1.110	0.510	117%	1.110	1.110	0.510	117%	1.110	1.110	0.510	117%	1.110	1.110	0.510	226%
</																										

REPORTED AWP's, MARKET PRICES AND SPREADS - 2001-2003 - NDCs WITH \$10,000+ IDAHO MEDICAID REIMBURSEMENTS 2001-2003

Defendant	NDC	Drug	Year-end	Avg	Avg	Avg	Year-end	Avg	Avg	Avg	Year-end	Avg	Avg	Avg
			Reported FDB AWP 2001	Reported FDB AWP 2001	Market Price 2001	Mkt Price Reported FDB AWP 2002	Mkt Price Reported FDB AWP 2002	Mkt Price Reported FDB AWP 2002	Mkt Price Reported FDB AWP 2003					
SANDOZ	00781190801	NABUMETONE												
	00781164901	ORPHENADRINE	2.077	2.077	1.544	34%	2.077	0.995	109%	2.077	2.077	1.248	66%	65%
	00781165510	PENICILLIN VK	0.085	0.085	0.103	43%	0.379	0.148	0.379	0.379	0.379	0.175	116%	116%
	00781183001	PROMETHAZINE	0.170	0.140	0.073	92%	0.506	0.364	0.210	73%	0.506	0.362	40%	40%
	00781183010	PROMETHAZINE	0.086	0.073	0.054	34%	0.481	0.331	0.169	96%	0.481	0.336	43%	43%
	00781183201	PROMETHAZINE	0.272	0.233	0.155	44%	0.776	0.549	0.357	54%	0.776	0.584	33%	33%
	00781285505	RANITIDINE	1.475	1.475	0.382	307%	1.475	1.475	0.483	206%	1.475	1.475	0.505	192%
	00781286505	RANITIDINE	2.661	2.661	0.674	295%	2.661	0.948	181%	2.661	2.661	0.999	166%	166%
	00781188305	RANITIDINE	1.480	1.480	0.040	3636%	1.480	1.480	0.072	1954%	1.480	0.180	1036%	1036%
	00781188310	RANITIDINE	1.480	1.480	0.042	3463%	1.480	0.071	1974%	1.480	1.480	0.076	1848%	1848%
	00781188360	RANITIDINE	1.480	1.480	0.048	2971%	1.480	1.480	0.092	1505%	1.480	0.110	1244%	1244%
	00781159901	SPIRONOLACT	0.415	0.410	0.176	132%	0.459	0.450	0.225	100%	0.459	0.255	80%	80%
	007811659910	SPIRONOLACT	0.357	0.356	0.171	109%	0.436	0.420	0.211	99%	0.436	0.233	87%	87%
	00781205401	TERAZOSIN	1.604	1.604	0.177	805%	1.604	1.604	0.157	925%	1.604	0.128	1148%	1148%
	00781205101	TERAZOSIN	1.604	1.604	0.178	800%	1.604	1.604	0.145	1006%	1.604	0.129	1145%	1145%
	00781205201	TERAZOSIN	1.604	1.604	0.177	806%	1.604	1.604	0.144	1011%	1.604	1.604	0.129	1142%
	00781205301	TERAZOSIN	1.604	1.604	0.177	805%	1.604	1.604	0.144	1011%	1.604	0.128	1150%	1150%
	00781167401	THIORDIAZINE	0.950	0.950	0.471	101%	1.101	1.070	0.700	53%	1.101	1.101	0.777	42%
	00781207401	TRIAM/HCTZ	0.375	0.375	0.059	541%	0.375	0.053	605%	0.375	0.375	0.050	648%	648%
	00781207410	TRIAM/HCTZ	0.361	0.361	0.054	574%	0.361	0.049	640%	0.361	0.361	0.046	682%	682%
	00781122301	TRIAM/HCTZ	0.340	0.340	0.053	543%	0.340	0.045	662%	0.340	0.340	0.056	508%	508%
	00781112305	TRIAM/HCTZ	0.323	0.323	0.050	549%	0.323	0.040	703%	0.323	0.323	0.050	543%	543%
	00781103601	TRIFLUOPERAZ	1.522	1.522	0.169	801%	1.522	0.143	965%	1.585	1.574	0.584	110%	110%
	00781103401	TRIFLUOPERAZ	1.010	1.010	0.144	603%	1.010	0.132	665%	1.051	1.044	0.391	167%	167%
TEVA	00993066116	ALBUTEROL	0.065	0.065	0.042	57%	0.065	0.065	0.044	48%	0.065	0.044	47%	47%
	00993913306	AMIDODARONE	3.303	3.303	0.494	568%	3.303	3.303	0.437	655%	3.303	3.303	0.470	603%
	00993227434	AMOX/K CLAV												
	00993227534	AMOXICILLIN	0.369	0.369	0.045	727%	0.369	0.369	0.052	347%	0.369	0.502	51%	51%
	00993310905	AMOXICILLIN	0.228	0.228	0.062	266%	0.450	0.377	0.073	413%	0.450	0.450	168%	168%
	00993226805	AMOXICILLIN	0.202	0.202	0.062	227%	0.437	0.359	0.084	327%	0.437	0.437	0.181	141%
	00993415573	AMOXICILLIN	0.061	0.061	0.013	359%	0.061	0.061	0.018	237%	0.061	0.061	0.018	236%
	00993415580	AMOXICILLIN	0.047	0.047	0.011	347%	0.047	0.047	0.015	212%	0.047	0.047	0.015	208%
	00993416173	AMOXICILLIN	0.872	0.872	0.629	39%	0.872	0.872	0.638	37%	0.872	0.609	43%	43%
	00993226401	APAP/CODEINE	0.284	0.280	0.073	286%	0.284	0.284	0.122	132%	0.284	0.114	149%	149%
	00993038001	APAP/CODEINE	0.639	0.623	0.168	271%	0.639	0.639	0.250	155%	0.639	0.233	174%	174%
	00993038005	APAP/CODEINE	0.552	0.542	0.155	251%	0.552	0.552	0.235	135%	0.552	0.231	139%	139%
	00993026001	BURROPION	0.962	0.962	0.367	162%	0.962	0.962	0.325	196%	0.962	0.962	0.286	236%
	00993026001	BURROPION	0.721	0.721	0.269	168%	0.721	0.721	0.243	196%	0.721	0.721	0.228	216%
	00993065701	CALCITHIOL	1.210	1.210	0.908	33%	1.210	1.210	0.889	36%	1.210	1.210	0.869	39%
	00993065801	CALCITHIOL	1.934	1.934	34%	1.934	1.934	1.427	35%	1.934	1.934	1.392	39%	39%

REPORTED AWPS, MARKET PRICES AND SPREADS - 2001-2003 - NDCs WITH \$10,000+ IDAHO MEDICAID REIMBURSEMENTS 2001-2003

Defendant	NDC	Drug	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	Avg Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	Avg Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	Avg Mkt Price Spread 2003
			TEVA	00093029201	CARB/LEVO	0.709	0.698	0.177	294%	0.709	0.709	0.252	181%	0.709
	00093029301	CARB/LEVO	0.800	0.787	0.191	311%	0.800	0.800	0.297	170%	0.800	0.800	0.291	175%
	00093029305	CARB/LEVO	0.776	0.761	0.198	284%	0.776	0.776	0.274	183%	0.776	0.776	0.256	203%
	00093029310	CARB/LEVO	0.760	0.746	0.208	258%	0.760	0.760	0.255	198%	0.760	0.760	0.259	194%
	00093029401	CARB/LEVO	1.020	1.001	0.221	352%	1.020	1.020	0.326	213%	1.020	1.020	0.316	223%
	00093077801	CARBAZEPIN	0.231	0.231	0.112	107%	0.231	0.231	0.231	99%	0.231	0.231	0.114	103%
	00093010901	CARBAZEPIN	0.302	0.302	0.064	374%	0.302	0.302	0.066	354%	0.302	0.302	0.068	343%
	00093010910	CARBAZEPIN	0.302	0.302	0.057	428%	0.302	0.302	0.058	423%	0.302	0.302	0.063	379%
	00093314501	CEPHALEXIN	0.639	0.639	0.051	1152%	0.694	0.685	0.124	452%	0.694	0.694	0.145	378%
	00093314505	CEPHALEXIN	0.567	0.567	0.047	1109%	0.624	0.615	0.111	454%	0.624	0.624	0.140	345%
	00093314701	CEPHALEXIN	1.260	1.260	0.087	1351%	1.376	1.357	0.210	546%	1.376	1.376	0.246	458%
	00093314705	CEPHALEXIN	1.114	1.114	0.076	1363%	1.226	1.208	0.186	549%	1.226	1.226	0.246	398%
	00093417574	CEPHALEXIN	0.779	0.776	0.030	155%	0.779	0.779	0.052	51%	0.779	0.779	0.054	45%
	00093417773	CEPHALEXIN	0.189	0.170	0.056	206%	0.189	0.189	0.085	122%	0.189	0.189	0.085	122%
	00093417774	CEPHALEXIN	0.158	0.147	0.045	229%	0.158	0.158	0.070	124%	0.158	0.158	0.070	125%
	000930014416	CHLORHEX GLU	0.022	0.022	0.006	272%	0.022	0.022	0.007	208%	0.022	0.022	0.007	221%
	00093317101	CLINDAMYCIN	1.191	1.191	0.305	290%	1.191	1.191	0.290	310%	1.191	1.191	0.356	235%
	00093083201	CLONAZEPAM	0.749	0.749	0.050	1407%	0.749	0.749	0.053	1303%	0.749	0.749	0.051	1372%
	00093083205	CLONAZEPAM	0.749	0.749	0.041	1745%	0.749	0.749	0.042	1668%	0.749	0.749	0.043	1627%
	00093083301	CLONAZEPAM	0.855	0.855	0.063	1265%	0.855	0.855	0.064	1233%	0.855	0.855	0.062	1280%
	00093083305	CLONAZEPAM	0.855	0.855	0.052	1534%	0.855	0.855	0.060	1333%	0.855	0.855	0.053	1516%
	00093083310	CLONAZEPAM	0.855	0.855	0.059	1345%	0.855	0.855	0.061	1307%	0.855	0.855	0.047	1735%
	00093083401	CLONAZEPAM	1.184	1.184	0.104	1033%	1.184	1.184	0.118	900%	1.184	1.184	0.094	1162%
	00093104101	DICLOFENAC	2.812	2.812	1.62%	228%	2.812	2.812	1.646	71%	2.812	2.812	1.526	84%
	00093511258	DILTIAZEM	1.198	1.170	0.656	78%	1.198	1.198	0.622	93%	1.198	1.198	0.614	95%
	00093511798	DILTIAZEM	1.446	1.441	0.793	78%	1.446	1.446	0.752	92%	1.446	1.446	0.742	95%
	00093511898	DILTIAZEM	2.051	2.002	1.126	78%	2.051	2.051	1.094	88%	2.051	2.051	1.058	94%
	00093511998	DILTIAZEM	2.638	2.595	1.459	78%	2.638	2.638	1.389	91%	2.638	2.638	1.364	95%
	00093002801	ENALAPRIL	1.072	1.072	0.245	337%	1.072	1.072	0.570	88%	1.072	1.072	1.072	84%
	00093002901	ENALAPRIL	1.525	1.525	1.110	37%	1.525	1.525	0.808	89%	1.525	1.525	1.525	167%
	00093002701	ENALAPRIL	1.021	1.021	0.866	18%	1.021	1.021	0.546	87%	1.021	1.021	0.382	151%
	00093719856	EPITOL	0.302	0.302	0.080	279%	0.302	0.302	0.119	153%	0.302	0.302	0.120	151%
	00093112201	ETODOLAC ER	1.402	1.402	0.794	77%	1.402	1.402	0.762	84%	1.402	1.402	0.734	91%
	00093717201	ETODOLAC ER	1.465	1.465	1.123	30%	1.465	1.465	1.065	38%	1.465	1.465	1.033	42%
	00093026492	FLUCONONIDE	0.767	0.767	0.196	291%	0.767	0.767	0.203	27%	0.767	0.767	0.218	252%
	000936719856	FLUDOXETINE	0.987	0.987	0.697	697%	0.987	0.987	0.654	51%	0.987	0.987	0.424	133%
	00093610812	FLUDOXETINE	0.987	0.987	0.697	42%	0.987	0.987	0.654	51%	0.987	0.987	0.424	425%
	00093667005	GEMFIBROZIL	1.187	1.187	0.133	790%	1.187	1.187	0.166	616%	1.187	1.187	0.226	425%
	0009383410	GLYBURIDE	0.661	0.661	0.102	549%	0.661	0.661	0.101	552%	0.661	0.661	0.091	627%
	00093836405	GLYBURIDE	0.683	0.683	0.128	433%	0.683	0.683	0.136	404%	0.683	0.683	0.133	415%
	000933636410	GLYBURIDE	0.661	0.661	0.106	526%	0.661	0.661	0.109	507%	0.661	0.661	0.108	514%
	00093516101	HYDROCOD/IBU	1.174	1.174	0.200	485%	1.174	1.174	0.195	502%	1.174	1.174	0.188	524%
	00093977401	HYDROXYCHLOR	1.174	1.174	0.200	485%	1.174	1.174	0.195	502%	1.174	1.174	0.188	524%
	00093804015	KETOCONAZOLE	1.097	1.097	0.745	47%	1.097	1.097	0.728	51%	1.097	1.097	0.713	54%
	00093084030	KETOCONAZOLE	0.923	0.923	0.624	48%	0.923	0.923	0.600	54%	0.923	0.923	0.593	56%
	00093084092	KETOCONAZOLE	0.701	0.701	0.473	48%	0.701	0.701	0.454	58%	0.701	0.701	0.448	57%
	00093111401	LISINAPRIL	1.063	1.063	0.469	48%	1.063	1.063	0.469	48%	1.063	1.063	0.423	514%
	00093057606	LOVASTATIN	2.373	2.373	1.046	127%	2.373	2.373	0.889	167%	2.373	2.373	0.786	202%
	00093092806	LOVASTATIN	4.271	4.271	1.806	137%	4.271	4.271	1.431	198%	4.271	4.271	1.344	218%
	00093910729	MEBERDAZOLE	5.321	5.321	3.583	48%	5.321	5.321	3.611	47%	5.321	5.321	3.582	49%

REPORTED AWP'S, MARKET PRICES AND SPREADS - 2001-2003 - NDCs WITH \$10,000+ IDAHO MEDICAID REIMBURSEMENTS 2001-2003

Defendant	NDC	Drug	Year-end	Avg	Avg	Avg	Year-end	Avg	Avg	Avg	Year-end	Avg	Avg	Year-end	Avg	Market
			Reported FDB AWP	Reported FDB AWP	Market Price	Mkt Price	Reported FDB AWP	Reported FDB AWP	Market Price	Mkt Price	Reported FDB AWP	Reported FDB AWP	Market Price	Mkt Price	Reported FDB AWP	Market Price
TEVA	00093104801	METFORMIN					0.704	0.704	0.423	67%	0.704	0.704	0.137	414%		
	00093104805	METFORMIN					0.704	0.704	0.457	54%	0.704	0.704	0.351	101%		
	00093104901	METFORMIN					1.197	1.197	0.744	61%	1.197	1.197	0.537	123%		
	00093220505	METOCLOPRAM	0.261	0.261	0.051	409%	0.261	0.261	0.068	285%	0.261	0.261	0.065	301%		
	00093220405	METOCLOPRAM	0.330	0.330	0.090	265%	0.330	0.330	0.097	241%	0.330	0.330	0.111	196%		
	00093073310	METOPROLOL	0.544	0.544	0.027	1817%	0.544	0.544	0.035	1447%	0.544	0.544	0.035	1457%		
	00093316753	MINOCYCLINE	2.459	2.459	0.446	451%	2.459	0.490	401%	3.397	3.166	0.715	343%			
	00093720656	MIRTAZAPINE									2.715	2.797	1.744	56%		
	00093720756	MIRTAZAPINE									2.797	2.797	1.836	52%		
	00093515001	MOEXIPRIL									0.879	0.879	0.645	36%		
	00093915601	MULTIVIT/FL	0.090	0.090	0.020	353%	0.090	0.090	0.021	318%	0.151	0.136	0.034	302%		
	00093101601	NABUMETONE	1.297	1.297	0.909	43%	1.297	0.838	55%	1.297	1.297	0.552	135%			
	00093101601	NABUMETONE	1.532	1.532	1.083	41%	1.532	1.003	53%	1.532	1.532	0.658	133%			
	00093014901	NAPROXEN	1.289	1.299	0.993	1294%	1.299	1.299	0.93	1299%	1.299	1.299	0.092	1307%		
	00093014905	NAPROXEN	1.193	1.193	0.090	1221%	1.193	1.193	0.098	1112%	1.193	0.086	1284%			
	00093053701	NAPROXEN SOD	1.294	1.221	0.107	1039%	1.294	0.220	488%	1.294	1.294	1.294	0.241	437%		
	00093117701	NEOMYCIN	1.246	1.184	0.671	76%	1.246	0.841	48%	1.246	1.246	0.813	53%			
	00093102201	NIFERIAC CC	2.032	2.032	1.404	45%	2.168	2.084	1.387	50%	2.168	2.168	1.387	56%		
	00093081901	NIFERICAL XL	1.365	1.350	1.003	35%	1.365	0.958	42%	1.365	1.365	0.916	49%			
	00093517301	NIFEDICAL XL	2.362	2.325	2.084	12%	2.362	1.674	41%	2.362	2.362	1.610	47%			
	00093102101	NIFEDIPINE	1.081	1.081	0.736	47%	1.154	1.109	0.715	55%	1.154	1.154	0.720	60%		
	0009311601	PENTOXIFYLLI	0.595	0.595	0.096	517%	0.595	0.595	0.102	485%	0.595	0.595	0.096	519%		
	00093715901	PERGOLIDE									1.863	1.863	1.302	43%		
	00093611816	PREDISOLONE	0.236	0.236	0.059	297%	0.236	0.091	16%	0.236	0.236	0.079	198%			
	00093611887	PREDISOLONE	0.295	0.295	0.065	356%	0.295	0.295	0.105	181%	0.295	0.295	0.087	238%		
	00093911101	PREGNATAL	0.213	0.213	0.046	365%	0.213	0.213	0.055	287%	0.311	0.287	0.060	377%		
	00093911105	PREGNATAL	0.213	0.213	0.051	319%	0.213	0.213	0.052	310%	0.296	0.296	0.275	0.070	296%	
	0009349005	PROPO-N/APAP	0.535	0.535	0.098	444%	0.535	0.535	0.127	321%	0.535	0.535	0.125	329%		
	00093089005	PROPO-N/APAP	0.535	0.535	0.113	374%	0.535	0.535	0.116	361%	0.535	0.535	0.106	406%		
	00093854401	RANITIDINE	1.480	1.480	0.953	2714%	1.480	1.480	0.207	615%	1.480	1.480	0.329	350%		
	00093854405	RANITIDINE	1.480	1.480	0.152	875%	1.480	1.480	0.149	890%	1.480	1.480	0.189	681%		
	00093854406	RANITIDINE	1.480	1.480	0.078	1796%	1.480	1.480	0.109	1252%	1.480	1.480	0.188	688%		
	00093854410	RANITIDINE	1.480	1.480	0.050	2887%	1.480	1.480	0.120	1128%	1.480	1.480	0.223	564%		
	00093854701	RANITIDINE	2.687	2.687	0.569	372%	2.687	2.687	0.459	485%	2.687	2.687	0.758	254%		
	00093854756	RANITIDINE	2.687	2.687	0.188	1326%	2.687	2.687	0.542	396%	2.687	2.687	0.256	951%		
	00093008905	SMZ/TMP DS	0.903	0.903	0.068	1223%	0.903	0.903	0.080	1032%	0.903	0.903	0.077	1078%		
	00093106101	SOTALOL HCL	2.347	2.347	0.369	536%	2.347	2.347	0.430	446%	2.347	2.347	0.609	286%		
	00093221001	SUCRALFATE	0.730	0.730	0.168	334%	0.730	0.730	0.168	333%	0.730	0.730	0.171	327%		
	00093221005	SUCRALFATE	0.708	0.708	0.150	371%	0.708	0.708	0.150	373%	0.708	0.708	0.154	359%		
	00093154041	TICLOPIDINE	1.860	1.860	0.489	281%	1.860	1.860	0.363	412%	1.860	1.860	0.301	518%		
	00093713001	TORSEMIDE									3.041	2.177	4041	2.114	44%	
	00093712201	TORSEMIDE									0.703	0.505	39%	0.493	43%	
	000937122901	TORSEMIDE	2.578	2.578	1.850	39%	2.578	2.578	1.828	41%	0.821	0.821	0.572	44%		
	000939388001	URSDIOL	0.152	0.152	0.022	579%	0.152	0.029	0.029	432%	0.152	0.029	0.028	436%		

REPORTED AWPS, MARKET PRICES AND SPREADS - 2001-2003 - NDCS WITH \$10,000+ IDAHO MEDICAID REIMBURSEMENTS 2001-2003

Defendant	NDC	Drug	Year-end	Avg.	Year-end	Avg.	Year-end	Avg.	Year-end	Avg.	Year-end	Avg.	Year-end	Avg.	Year-end	Avg.
			Reported FDB AWP	Reported FDB AWP	Market Price	Mkt Price	Reported FDB AWP	Mkt Price								
WATSON	00591573001	BACLOFEN	0.363	0.344	0.036	845%	0.610	0.423	0.042	912%	0.610	0.610	0.198	208%		
	00591573005	BACLOFEN	0.363	0.363	0.034	954%	0.580	0.416	0.036	1088%	0.580	0.580	0.237	145%		
	00591573101	BACLOFEN	0.640	0.597	0.063	841%	1.096	0.751	0.077	872%	1.096	1.096	0.422	160%		
	00591573105	BACLOFEN	0.609	0.615	0.044	1287%	1.041	0.714	0.076	843%	1.041	1.041	0.413	152%		
	00591065801	BUSPIRONE					1.345	1.345	0.209	542%	1.345	1.345	0.089	1413%		
	00591071860	BUSPIRONE					2.115	2.115	0.303	577%	2.115	2.115	0.205	932%		
	00591042501	BUT/ASA/CAF/	1.219	1.219	0.070	391%	1.402	1.071	1.402	1.402	1.057	1.057	33%			
	00591551301	CARISOPRODOL	0.596	0.342	0.066	765%	0.596	0.596	0.060	887%	0.596	0.596	0.055	991%		
	00591551305	CARISOPRODOL	0.573	0.573	0.066	765%	0.573	0.573	0.056	931%	0.573	0.573	0.049	1062%		
	00591551310	CARISOPRODOL	0.525	0.525	0.063	731%	0.525	0.525	0.051	929%	0.525	0.525	0.046	1044%		
	00591570801	CLINDAMYCIN	1.191	1.100	0.244	351%	1.191	0.253	1.191	1.191	1.191	1.191	0.302	294%		
	00591074601	CLONAZEPAM			0.030		0.749	0.749	0.034	2091%	0.749	0.749	0.057	1216%		
	00591074701	CLONAZEPAM			0.039		0.855	0.855	0.041	1968%	0.855	0.855	0.052	1534%		
	00591565801	CYCLOBENZAPR	1.016	0.940	0.034	2658%	1.016	1.016	0.033	3000%	1.149	1.123	0.126	792%		
	00591565805	CYCLOBENZAPR	0.873	0.873	0.031	2755%	0.873	0.873	0.031	2746%	1.114	1.067	0.116	822%		
	00591565810	CYCLOBENZAPR	0.879	0.879	0.027	3110%	0.879	0.879	0.027	3170%	1.091	1.049	0.106	888%		
	00591067001	ENALAPRIL	1.072	1.072	0.061	1655%	1.072	1.072	0.060	1674%	1.072	1.072	0.114	841%		
	00591067101	ENALAPRIL	1.525	1.525	0.080	1818%	1.525	1.525	0.085	1700%	1.525	1.525	0.153	898%		
	00591066901	ENALAPRIL	1.021	1.021	0.053	1810%	1.021	1.021	0.053	1819%	1.021	1.021	0.078	1211%		
	00591021610	FOLIC ACID	0.026	0.026	0.010	157%	0.078	0.031	0.014	120%	0.078	0.078	0.059	32%		
	00591044401	GUANIFACINE	0.872	0.872	0.273	219%	0.872	0.872	0.240	264%	0.872	0.872	0.241	262%		
	00591085301	HYDROCO/APAP	0.675	0.675	0.078	120%	0.675	0.675	0.078	161%	0.699	0.699	0.233	200%		
	00591085305	HYDROCO/APAP	0.533	0.533	0.053	120%	0.533	0.533	0.053	120%	0.675	0.675	0.216	212%		
	00591054401	HYDROCO/APAP	0.533	0.533	0.056	120%	0.533	0.533	0.056	120%	0.533	0.533	0.157	239%		
	00591054005	HYDROCO/APAP	0.506	0.506	0.056	120%	0.506	0.506	0.056	120%	0.506	0.506	0.148	242%		
	00591038801	HYDROCO/APAP	0.384	0.334	0.083	301%	0.384	0.334	0.114	193%	0.384	0.334	0.098	239%		
	00591034905	HYDROCO/APAP					0.465	0.465	0.039	1103%	0.465	0.465	0.034	1279%		
	00591038505	HYDROCO/APAP	0.515	0.515	0.091	465%	0.515	0.515	0.054	844%	0.515	0.515	0.052	884%		
	00591038705	HYDROCO/APAP	0.409	0.409	0.056	637%	0.409	0.409	0.055	643%	0.409	0.409	0.045	815%		
	00591069801	HYDROXYCHLOR	1.232	1.232	1.232	1.232	1.232	1.232	0.203	503%	1.232	1.232	0.188	555%		
	00591040801	LISINOPRIL					1.059	1.059	0.234	353%	1.059	1.059	0.273	288%		
	00591040901	LISINOPRIL					1.549	1.549	0.389	298%	1.549	1.549	0.354	337%		
	00591024005	LORAZEPAM					0.662	0.662	0.053	1138%	0.662	0.662	0.049	1239%		
	00591037101	LOXATINE					0.063	0.063	0.640	0.640	0.056	1049%	0.640	0.640	0.051	1159%
	00591024010	LORAZEPAM					0.076	0.061	0.861	0.861	0.064	1235%	0.861	0.861	0.058	1382%
	00591024105	LORAZEPAM					0.071	0.083	0.843	0.058	1357%	0.843	0.843	0.054	1461%	
	00591024110	LORAZEPAM					0.124	1.282	1.282	0.108	108%	1.282	1.282	0.101	1165%	
	00591024201	LORAZEPAM					0.737	1.925	1.925	0.934	105%	1.925	1.925	1.053	83%	
	00591037701	METHOCARBAM					1.443	1.443	0.198	623%	1.443	1.443	0.172	736%		
	00591245501	METFORMIN					0.700	0.700	0.133	427%	0.700	0.700	0.109	541%		
	00591271301	METFORMIN					1.191	1.191	0.155	663%	1.191	1.191	0.131	811%		
	00591277501	METFORMIN					0.494	0.494	0.114	332%	0.494	0.494	0.205	141%		
	00591538201	METHOCARBAM	0.494	0.276	0.151	83%	0.494	0.494	0.114	332%	0.494	0.494	0.205	141%		
	00591538205	METHOCARBAM	0.471	0.471	0.146	223%	0.471	0.471	0.128	269%	0.471	0.471	0.268	75%		
	00591568301	METHYLPHENID	0.477	0.477	0.349	37%	0.477	0.477	0.323	47%	0.477	0.477	0.271	76%		
	00591588401	METHYLPHENID	0.686	0.686	0.568	21%	0.686	0.686	0.507	35%	0.686	0.686	0.394	74%		
	00591569550	MINOCYCLINE	2.460	2.460	0.392	527%	2.460	2.460	0.334	637%	3.397	3.397	0.716	349%		
	00591313760	NIZATIDINE					2.383	2.383	0.978	144%	2.383	2.383	0.964	147%		
	00591039501	PENTAZOCINE/					0.424	0.424	0.412	136%	0.424	0.424	0.405	140%		
	00591332101	PRIMIDONE	0.996	0.996	0.970	0.970	0.412	0.412	0.970	0.970	0.412	0.412	0.996	139%		
	00591530701	PROMETHAZINE	0.033	0.033	0.477	103%	0.477	0.477	0.355	0.355	0.477	0.477	0.501	44%		

REPORTED AWP'S, MARKET PRICES AND SPREADS - 2001-2003 - NDCS WITH \$10,000+ IDAHO MEDICAID REIMBURSEMENTS 2001-2003

Defendant	NDC	Drug	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	Year-end Reported Mkt Price 2001	Avg Reported FDB AWP 2002	Avg Market Price 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	Avg Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	Avg Mkt Price Spread 2003
WATSON	00591058201	PROPafenone	1.636	1.540	0.922	67%	1.636	1.636	0.703	133%	1.636	1.636	0.492	233%
	00591078001	SUGRAfATE			0.323		0.709	0.709	0.122	483%	0.709	0.709	0.114	523%
	00591046501	TRAMADOL HCL					0.834	0.834	0.212	293%	0.834	0.834	0.093	799%
	00591046510	TRAMADOL HCL					0.792	0.792			0.792	0.792	0.216	267%
	00591533701	TRIMEXYPHEN	0.364	0.305	0.172	77%			0.364	0.364	0.160	127%	0.364	0.156
	52544047530	ANDRODERM	4.499	4.246	3.447	23%	5.155	4.973	3.970	25%	5.955	5.504	4.355	26%
	52544083701	CLORAZ DIPOT	2.173	2.173	0.380	472%	2.173	2.173	2.173	253%	2.173	2.173	0.216	906%
	52544083501	CLORAZ DIPOT	1.284	1.284	0.271	373%	1.184	1.184	0.153	723%	1.184	1.184	0.116	920%
	52544083601	CLORAZ DIPOT	1.597	1.597	0.291	450%	1.597	1.597	0.168	850%	1.597	1.597	0.147	990%
	52544027528	LEVORA-28	1.018	1.008	0.669	51%	1.105	1.069	0.815	34%	1.105	1.105	0.828	33%
	52544084728	LOW-GESTREL	1.048	1.038	0.669	55%	1.090	1.082	0.807	34%	1.090	1.090	0.828	32%
	52544055228	NECON	1.007	1.002	0.428	134%	1.052	1.044	0.644	62%	1.052	1.052	0.777	35%
	52544055228	NECON	1.007	1.002	0.433	131%	1.052	1.044	0.714	46%	1.052	1.052	0.786	34%
	52544023528	NOR-QD	1.319	1.192	0.967	23%	1.465	1.369	1.106	24%	1.573	1.566	1.244	26%
	52544029128	TRIVORA-28	0.982	0.972	0.662	47%	0.982	0.973	0.743	32%	0.982	0.982	0.731	34%